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ABSTRACT 
 
Serotonin (5-HT) is a ubiquitous neurotransmitter in the brain that is involved 
in various physiologic functions including the regulation of hypothalamic 
hormones and has been implicated in various mood disorders such as depression. 
Preclinical and clinical data from studies in adults have shown that 
antidepressant drugs produce time-dependent changes in serotonergic and other 
systems and can also normalize dysfunction associated with the hypothalamic-
pituitary-adrenal (HPA) axis.  To date, our understanding of the mechanisms of 
5-HT receptor signaling and the actions of drugs on serotonergic function have 
been derived from extensive preclinical research carried out using cell lines in 
vitro or in adult animal models in vivo. Fewer studies have investigated 
serotonergic signaling mechanisms or the effects of antidepressants (i.e., selective 
serotonin reuptake inhibitors (SSRIs)) in animal models prior to sexual 
maturation.  This is a scientific and clinically relevant issue as (1) SSRIs, the most 
effective pharmacological option for treating mood disorders in children and 
adolescents, are being increasingly prescribed and may be associated with 
suicidal thoughts or behaviors in these age groups and (2) preclinical studies in 
rodents indicate that SSRI-induced modulation of the serotonergic system prior 
xvi 
to sexual maturation produces effects that are distinct and more long-lasting than 
those produced in adults. To date, few if any studies have investigated 
mechanisms of 5-HT receptor signal transduction in peripubertal hypothalamic 
neurons in vivo and their regulation by SSRIs, despite a wealth of existing 
comparative data on serotonin 1A (5-HT1A) receptor signaling in adult 
hypothalamic rat paraventricular nucleus (PVN).  
Given the clinical relevance of potential age-dependent differences in 
serotonergic signaling and regulation of hypothalamic function, the objective of 
the studies in this dissertation was to identify and characterize the mechanisms 
of 5-HT1A receptor signaling in the peripubertal hypothalamic PVN. 
 The data generated by studies in this dissertation project provide the first in 
vivo evidence that 5-HT1A receptors in the peripubertal PVN can activate 
multiple responses: (1) oxytocin and adrenocorticotropic hormone (ACTH) 
plasma hormone responses, (2) activation of extracellular signal-regulated kinase 
(ERK), and (3) activation of protein kinase B (Akt).  The data also demonstrate 
that these pathways may be differentially responsive to different classes of 5-
HT1A receptor agonists.  (+)8-OH-DPAT (an aminotetralin), acted as a “full” 
agonist on each of the respective pathways, while tandospirone (an azapirone) 
exhibited “partial” agonist activity on activation of Akt but exhibited “full” 
agonist activity on neuroendocrine responses and activation of ERK.  5-HT1A 
receptors produce a rapid and prolonged activation of ERK in the peripubertal 
xvii 
PVN, unlike the rapid but more transient response in the adult PVN.  In addition, 
the 5-HT1A activation of ERK may be expressed only in certain populations of 
neuroendocrine cells in the peripubertal PVN.  These studies have also revealed 
some unique aspects that Gα proteins in the peripubertal PVN, since: (1) there 
are age-dependent increases only in Gαo levels, (2) Gαi3 and Gαo are not 
reduced by intra-PVN injection with pertussis toxin, and (3) Gαz proteins are not 
reduced by 7 or 14 days of  fluoxetine treatment. We also have determined that 
chronic fluoxetine treatment desensitizes 5-HT1A receptor-mediated 
phosphorylation of GSK3β in the absence of changes in its canonical upstream 
kinase, Akt.  These data suggest fluoxetine may induce changes in phosphatase 
activity or that there may be a different upstream kinase mediating the 
phosphorylation of GSK3β in the peripubertal PVN. 
In conclusion, the present studies determined the mechanisms of 5-HT1A 
receptor-mediated signaling in peripubertal PVN and identified some aspects of 
5-HT1A receptor signaling that differ from those previously identified in adults. 
These findings may be clinically relevant with respect to facilitating a better 
understanding of mechanisms mediating the therapeutic and/or side effects of 
SSRIs prescribed to young patients or to identify novel drug targets to treat 
mood disorders in children and adolescents. 
 
 1 
CHAPTER 1 
INTRODUCTION 
Serotonin (5-hydroxytryptamine, 5-HT) is primarily found in the 
gastrointestinal tract, platelets, and central nervous system, where it acts as a 
monoamine neurotransmitter.  In the brain, 5-HT can function as a 
“developmental signal” to direct biochemical and morphological differentiation 
of 5-HT-containing cells localized in the raphe nuclei (Lauder 1990; Rubenstein 
1998).  The raphe nuclei are discrete groups of cells located in the brainstem that 
contain perikarya of serotonergic neurons that constitute the ascending and 
descending serotonergic projections to almost every area of the central nervous 
system.  Two prominent ascending projections that innervate various brain 
regions (including the hypothalamus) arise from neurons located in the dorsal 
and median raphe nuclei.   
5-HT plays a prominent role in the regulation of behavior, mood, appetite, 
perception, circadian rhythms, body temperature, and cognitive functions such 
as memory and learning (Berger et al., 2009).  Many studies have linked 
dysfunction of the serotonergic system with psychological disorders such as 
depression and anxiety, and many classes of psychotropic drugs used to treat 
these disorders alter serotonergic signaling.   
2 
 
To date, seven families (5-HT1-7) of receptors encompassing a total of 15 
subtypes have been identified that mediate the various effects of 5-HT.  The 
serotonin 1A (5-HT1A) receptor was one of the first 5-HT receptor subtypes to be 
identified and cloned (Albert et al., 1990), and has been extensively investigated 
with respect to its pharmacology and regional distribution in brain.  5-HT1A 
receptors on serotonergic neurons are localized to the soma and dendrites and 
function as inhibitory autoreceptors to regulate cell firing.  This population of 
somatodendritic autoreceptors has generated a great deal of attention since the 
desensitization of these receptors (i.e., an attenuation of a receptor-mediated 
response despite the presence of agonist) plays a prominent role in the 
therapeutic efficacy of various drugs used to treat mood disorders.  5-HT1A 
receptors also are localized post-synaptically on non-serotonergic cells in various 
brain regions such as the hippocampus, frontal cortex, and hypothalamus, where 
they can initiate a variety of signal transduction cascades (Kia et al., 1996a; Kia et 
al., 1996b; Blier and Ward 2003; Marvin et al., 2010).  5-HT1A receptors in the 
hypothalamus are involved in the serotonergic stimulation of various hormones 
and regulation of the hypothalamic-pituitary-adrenal (HPA) axis, the interface 
between the brain and body in response to stress (reviewed in Sullivan-Hanley 
and Van de Kar, 2003 and Carrasco and Van de Kar et al., 2003).  Dysregulation 
of the HPA axis has been associated with mood disorders, and normalization of 
3 
the HPA axis has been suggested to contribute to some of the therapeutic actions 
of antidepressants (Nemeroff 1996; Holsboer 1999, 2000). 
Selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine (Prozac ®) 
have completely revolutionized the field of adult psychiatry since they are 
comparable in effectiveness to tricyclic antidepressant (TCA) and monoamine 
oxidase inhibitor (MAOI) drug classes in treating several mood disorders but 
exhibit a more favorable side effect profile than the TCAs or MAOIs (Hirschfeld 
1999; Papakostas and Fava, 2006).  It is noteworthy that SSRIs, but not tricyclic 
antidepressants or MAOIs (Ryan 2003; Bostic et al., 2005), have been shown to be 
effective in treating childhood and adolescent clinical disorders such as 
depression, obsessive-compulsive disorders, eating disorders, Tourette’s 
syndrome, autism, and panic disorder (Cohen 2007; Rushton and Whitmire, 2001; 
Wong et al., 2004). Although SSRIs remain one of the only pharmacological 
options for treating childhood and adolescent mood disorders, their use has been 
controversial due to a reported increase in suicidal thoughts or behavior (USFDA, 
2004).  In the United Kingdom, most SSRI use in children and adolescents has 
been banned (European Medicines Agency, 2004), while in the United States, the 
Food and Drug Administration has issued a ‘black box’ warning for SSRI use in 
children and adolescents.  However, in the years since these restrictions were 
enacted, suicide among child and adolescent age groups significantly increased, 
indicating an inverse relationship between SSRI prescription rates and suicide 
4 
(Gibbons et al., 2007).   Therefore, although the use of SSRIs in children and 
adolescents may pose an increased risk of suicidal thoughts or behavior in some 
individuals (Reeves and Ladner 2010), it is likely that these drugs will continue 
to be prescribed with caution to children and adolescents.  These clinical findings 
suggest that some aspects of SSRI effects on the immature brain may be different 
than those demonstrated in the adult brain.    
 Preclinical studies indicate that SSRI-induced modulation of the serotonergic 
system prior to sexual maturation in rodents produces effects that are distinct 
and more long-lasting than those produced in adults.  For example, in contrast 
to adult treatment, administration of SSRIs to young animals results in: (1) 
decreased levels of the serotonin (5-HT) transporter and tryptophan hydroxylase 
that persist into adulthood (Maciag et al., 2006), (2) increased anxiety-like 
behavior that persists into adulthood (Ansorge et al., 2004), (3) altered aggressive 
behavior around the time of sexual maturation (Taravosh-Lahn et al., 2006) and 
(4) paradoxical anxiogenic responses in several behavioral tests (Oh et al., 2009).  
These studies demonstrating differences in the way that antidepressants induce 
neuroadaptations and behavioral effects in the developing brain suggest inherent 
differences in the mechanisms of serotonergic signaling in the immature vs. adult 
brain.  
The objective of this dissertation is to identify the mechanisms of 5-HT1A 
receptor signaling and regulation in the peripubertal brain in order to discern 
5 
any aspects of 5-HT1A receptor signaling that may be unique to this age relative 
to mechanisms operative in the adult brain.  Several studies in the adult brain 
indicate that the time necessary for clinical efficacy of antidepressants (~2-3 
weeks) corresponds to the time necessary to desensitize 5-HT1A autoreceptors on 
serotonergic neurons (Le Poul et al., 2000; Czachura and Rasmussen 2000).  
Desensitization of post-synaptic 5-HT1A receptors on non-serotonergic neurons, 
also a time-dependent response observed with chronic antidepressant treatment, 
may contribute to the long-term therapeutic effects of anxiolytic and 
antidepressant drugs (Borsini 1994).  However, the majority of studies 
investigating the mechanisms of 5-HT1A receptor signaling and desensitization 
have been primarily conducted either in cell cultures or in vivo in the adult brain.  
These studies have revealed that the 5-HT1A receptor has the capacity to couple 
to a variety of signal transduction pathways (e.g., inhibition of adenylyl cyclase, 
activation of potassium channels, and activation of phopholipase C), with the 
specificity of 5-HT1A receptor responses dependent on various factors such as cell 
type, brain region, availability of second messengers, and/or intracellular milieu 
(reviewed in Barnes and Sharp 1999; Raymond et al., 2001; Filip and Bader 2009; 
Polter and Li 2010).  A number of recent reports have demonstrated post-
synaptic 5-HT1A receptors in vivo can also activate mitogenic signaling pathways, 
including activation of the mitogen-activated protein kinase (MAPK) pathway 
6 
(Chen et al., 2002; Sullivan et al., 2005; Crane et al., 2007; Buritova et al., 2009) and 
the protein kinase B (Akt) pathway (Polter et al., 2010). 
 In the adult rat hypothalamic paraventricular nucleus (PVN), 5-HT1A 
receptors can activate independent signaling pathways, utilizing different 
subsets of Gα proteins as shown in figure 1.  Pertussis toxin-insensitive Gαz 
proteins mediate the 5-HT1A receptor-induced increase in plasma levels of 
oxytocin and adrenocorticotropic hormone (ACTH) (Serres et al., 2000a), whereas 
pertussis toxin-sensitive Gαi/o proteins mediate 5-HT1A receptor-induced 
activation of extracellular signal-regulated kinase (ERK) (Crane et al., 2007; 
Garcia et al., 2006; Sullivan et al., 2005).  These responses to acute 5-HT1A 
receptor activation are independent, since complete blockade of ERK signaling 
does not alter 5-HT1A signaling of hormone responses (Jia et al., 2007).  These 
respective 5-HT1A receptor-mediated signaling pathways are also differentially 
responsive to desensitization by SSRIs.  Chronic treatment with SSRIs decreases 
hypothalamic levels of Gαz proteins and desensitizes 5-HT1A receptor-mediated 
oxytocin and ACTH hormone responses (Raap et al., 1999) but does not 
desensitize the 5-HT1A receptor-Gαi/o-mediated increase in activated 
(phosphorylated) ERK (pERK) in the PVN (Jia et al., 2006). However, 
pharmacological blockade of the ERK signaling pathway, either by inactivation 
of Gαi/o proteins or via blockade of MAPK kinase (the activating kinase for ERK) 
during SSRI treatment abolishes both the SSRI-induced desensitization of 5-HT1A 
7 
receptor signaling of hormone responses from oxytocin and corticotrophin 
releasing hormone (CRH)-containing neurons and the reductions in associated 
Gαz proteins (Jia et al., 2007).  These recent novel findings suggesting the 
requirement of MAPK in the desensitization of 5-HT1A receptor-mediated 
hormone responses highlight the complexity of 5-HT1A receptor signaling in 
adult hypothalamic PVN, and indicate the important role of kinases in 
depression and the effects of antidepressant drugs.   
 Multiple lines of evidence have implicated protein kinases/phosphatases in 
the pathology of mood disorders and the effects of antidepressants.  As 
previously mentioned, intact ERK signaling is required for SSRI-induced 
desensitization of 5-HT1A receptor-mediated neuroendocrine responses (Jia et al., 
2007).  Furthermore, in the adult rodent brain, ERK and its regulators have also 
been shown to be involved with stress-induced behavioral responses (Gourley et 
al., 2008) and antidepressant-induced amelioration of depressive behavior 
(Duman et al., 2007; Duric et al., 2010).  Another kinase pathway, the 
phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt)/glycogen synthase 
kinase-3β (GSK3β) pathway, has also been recently implicated in the pathology 
of psychological disorders including chronic stress, depression, and 
schizophrenia.  The Akt pathway also plays a prominent role in the effects of 
lithium, SSRIs, and other classes of psychotropic drugs (Zhang et al., 2003; Li et 
al, 2004; Basta-Kaim et al., 2005; Li et al., 2007; Amar et al., 2008; Reddy et al, 
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2008; Szymanska et al., 2009).  For example, increased levels of activated 
(phosphorylated) Akt (pAkt) have been found in animals subjected to chronic 
stress (Lee et al., 2006), and the activity of PI3K and Akt were significantly 
decreased in the occipital cortex of suicide victims when compared to controls 
(Hsiung et al., 2003).  Furthermore, SSRIs increase levels of inactivated (i.e., 
phosphorylated) GSK3β in the adult mouse frontal cortex, possibly via 5-HT1A 
receptor activation (Li et al., 2004).   
 To date, no studies have elucidated the specific pathways or mechanisms of 
5-HT1A receptor signaling in the immature hypothalamus.  Therefore, the overall 
purpose of this dissertation is to identify and characterize the 5-HT1A receptor-
mediated signaling pathways that are operative in the hypothalamic PVN of 
peripubertal rats (see figure 2).  The determination of hypothalamic 5-HT1A 
receptor signaling mechanisms, and any aspects that may be unique to the 
immature brain, should contribute to a better understanding of differences in 
therapeutic and/or side effects of SSRIs in adult vs. young patients and may 
identify novel drug targets to treat mood disorders in children and adolescents. 
The HYPOTHESIS for this dissertation is that, in the peripubertal rat 
hypothalamic PVN:  (1) 5-HT1A receptors on oxytocin- or CRH-containing 
neurons stimulate oxytocin and ACTH plasma hormone responses and activate 
ERK and Akt via different subsets of Gα proteins; (2) different structural classes 
of agonists may exhibit biased agonism of 5-HT1A receptor-mediated signaling 
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responses; and (3) 5-HT1A receptor-mediated activation of protein kinase 
pathways will be resistant to desensitization by SSRIs (in contrast to 
neuroendocrine responses).  The main objectives of the dissertation studies in the 
peripubertal rat hypothalamic PVN are to determine: (1) if different structural 
classes of 5-HT1A receptor agonists (i.e., an aminotetralin and/or an azapirone) 
that stimulate oxytocin and ACTH responses can concomitantly activate the ERK 
and/or Akt protein kinase pathways; (2) the onset and longevity of the 
respective 5-HT1A receptor-mediated responses activated by two different classes 
of agonists; (3) the efficacy and potency of two agonist classes on each of the 
respective 5-HT1A receptor-mediated responses; (4) potential “agonist-dependent 
selectivity” or targeting of any specific response pathway by either class of 
agonist; (5) levels of the respective Gα protein subtypes at peripubertal versus 
younger (prepubertal) and adult ages, (6) the role of PTX-sensitive and PTX-
insensitive Gα proteins in the respective 5-HT1A receptor-mediated responses; (7) 
the regulation of hypothalamic Gα proteins and 5-HT1A receptor-mediated 
activation of ERK, Akt, and its downstream effector GSK3β in PVN upon chronic 
SSRI treatment paradigms (7 or 14 days); and (8) if 5-HT1A receptors can activate 
ERK in oxytocin- and CRH-containing cells and if the profile of ERK activation is 
qualitatively similar to that in adult PVN.  
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Figure 1.   5-HT1A 
receptor signaling (A) and SSRI-induced desensitization (B) in the adult rat PVN.  In the ADULT 
PVN, 5-HT1A receptor activation results in increases in plasma levels of oxytocin and ACTH and 
increases in pERK levels in PVN.  These pathways are mediated by different subsets of Gα 
proteins and are independent with respect to acute 5-HT1A receptor activation, yet intact ERK 
signaling is required for SSRIs to desensitize 5-HT1A receptor-mediated neuroendocrine 
responses and decrease hypothalamic levels of Gαz proteins (white dashed line). 
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 PERIPUBERTAL PVN 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.   Proposed 5-HT1A receptor signaling mechanisms in the PERIPUBERTAL rat PVN.  5-
HT1A receptors can potentially activate oxytocin and ACTH plasma hormone responses and 
protein kinase (ERK and Akt) activation in peripubertal PVN.  In these dissertation studies, the 
potential agonist specificity to activate these respective responses, the role of Gα proteins, cellular 
localization of ERK responses, and regulation of kinase activity by fluoxetine will be determined. 
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CHAPTER 2 
REVIEW OF RELATED LITERATURE 
The serotonergic system 
Serotonin (5-hydroxytryptamine, 5-HT) is a monoamine neurotransmitter 
that can also function as a “developmental signal” in early postnatal 
development (Lauder 1990; Rubenstein 1998). In the brain, serotonergic cell 
bodies are localized along the midline of the brainstem (medulla, pons, and 
midbrain) and are organized in 9 distinct nuclei designated B1-B9 by Dahlstrom 
and Fuxe in 1964.  These cell groups generally correspond to the raphe nuclei 
defined by Taber et al. in 1960, although not all raphe neurons are serotonergic.   
In the rat, expression of the serotonergic phenotype begins on embryonic day 12 
and continues on until embryonic day 15, when generation of 5-HT neurons in 
the raphe is complete (Lauder 1990; Rubenstein 1998).  Serotonergic cells send 
ascending projections to almost every area of the brain as well as descending 
projections to the spinal cord.  Two prominent and morphologically different 
ascending pathways arise from the dorsal and median raphe nuclei to innervate 
the forebrain.  Although these pathways have distinct patterns of innervation, 
projections from both dorsal and median raphe nuclei innervate the 
hypothalamus (Tork 1990; Hensler 2006).   5-HT mediates its effects via 7
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families of receptors (5-HT1-7) containing at least 15 subtypes to regulate a wide 
variety of functions including behavior, mood, appetite, perception, circadian 
rhythms, body temperature, and cognitive functions such as memory and 
learning (Berger et al., 2009).   
5-HT synthesis, release, and reuptake 
5-HT does not pass the blood brain barrier easily; therefore, most brain 5-HT 
is synthesized within the raphe nuclei.  The amino acid precursor to 5-HT, 
tryptophan, is transported into the central nervous system via a neutral amino 
acid transporter located on brain capillary endothelial cells (Boado et al., 1999).  
Brain levels of tryptophan depend on its total concentration in blood, as well as 
its levels relative to other neutral amino acids.  Tryptophan is converted to 5-
hydroxytryptophan by tryptophan hydroxylase (TPH).  TPH is the rate-limiting 
enzyme in 5-HT synthesis and is synthesized only in 5-HT-containing cells.  TPH 
exists in two isoforms: TPH1 and TPH2.  TPH2 is primarily expressed in 
brainstem while TPH1 is expressed in the gut, pineal gland, spleen, and thymus 
(Walther and Bader, 2003).  5-hydroxytryptophan is converted to 5-
hydroxytryptamine (5-HT) by the enzyme aromatic amino acid decarboxylase 
(AAADC).  AAADC is not specific to 5-HT-containing cells, as this enzyme can 
also convert L-dopa to dopamine.  5-HT is packaged into vesicles by the 
vesicular monoamine transporter 2 (VMAT2) (Hensler in Siegel text, 2006).  After 
synaptic release of 5-HT via exocytosis, the major means of terminating the 
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signal is reuptake back into the cell by the serotonin transporter (SERT).  SERT is 
localized to neurons, although some astrocytes in culture can take up 5-HT.  5-
HT is metabolized to 5-hydroxyindoleacetic acid (5-HIAA) by monoamine 
oxidase (MAO), which is primarily localized in mitochondria.  5-HT can also be 
converted to melatonin in the pineal gland (Hensler in Siegel text, 2006). 
With regards to developmental levels of some of these regulators of 5-HT 
synthesis and reuptake, TPH and SERT immunoreactivity in rat raphe neurons 
are high in early postnatal development but decrease to stable levels by postnatal 
day 21 (Liu and Wong-Riley, 2010).   
Mechanism of action of selective serotonin reuptake inhibitors (SSRIs) 
Selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine (Prozac ®) 
comparable in effectiveness to other antidepressants, such as tricyclic 
antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs), in treating 
several mood disorders but exhibit a more favorable side effect profile than the 
TCAs and MAOIs (Hirschfeld 1999; Papakostas and Fava, 2006).  SSRIs initially 
function to block the reuptake of 5-HT by SERT at the synapse, which increases 
synaptic levels of 5-HT.  Therefore, acute administration of SSRIs increases 5-HT 
and triggers 5-HT1A autoreceptors (located on the soma and dendrites of 5-HT 
cells) to inhibit further cell firing (Newman et al., 2004).  Upon continued 
treatment with an SSRI, increased levels of 5-HT desensitizes (i.e., an attenuation 
of a receptor-mediated response despite the presence of agonist) the inhibitory 
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somatodendritic 5-HT1A autoreceptors, thereby reestablishing or strengthening 5-
HT cell firing.  The time necessary for desensitization of 5-HT1A autoreceptors is 
consistent with the 2-3 week delay in therapeutic response to SSRIs.  
Desensitization of post-synaptic 5-HT1A receptors on non-serotonergic neurons in 
other brain regions is also observed with antidepressant drug treatment and may 
be involved in the long-term therapeutic effect of anxiolytic and antidepressant 
drugs (Borsini 1994).  SSRIs can also attenuate increases in SERT protein levels in 
the raphe nuclei of chronically stressed rats (Abumaria et al., 2007) and in a rat 
model of depression (Saitoh et al., 2007). 
The hypothalamic-pituitary-adrenal (HPA) axis  
The serotonergic system exerts significant control over the hypothalamic-
pituitary-adrenal (HPA) axis, the main interface between the brain and body in 
response to both psychological and physiological stressors (Carrasco and Van de 
Kar, 2003; Sullivan-Hanley and Van de Kar, 2003; Jorgensen 2007; Pompili et al., 
2010).  Alterations in HPA function have been associated with mood disorders 
(Modell and Holsboer, 2005; Papiol et al., 2007; Thomson and Craighead, 2008; 
Bao et al., 2008; Holsboer and Ising, 2010), and antidepressants used to treat these 
disorders produce changes in HPA function in both humans and animal models 
(Conti et al., 2007, Lerer et al., 1999, Li et al., 1997, Li et al., 1996, Serres et al., 
2000b, Young et al., 2004).  The hypothalamus, a major component of the HPA 
axis, is a limbic structure involved in a number of vital functions such as 
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circadian rhythms, body temperature regulation, appetite, and the regulation of 
mood (Adamec 1990, Kruk 1991).  The paraventricular nucleus (PVN) is one of 
several nuclei in the hypothalamus and is a center of control over many 
neuropeptides/hormones. Oxytocin and corticotrophin releasing hormone 
(CRH) are two hormones that are subject to serotonergic regulation via 5-HT1A 
receptors in hypothalamic PVN (Osei-Owusu et al., 2005).  5-HT1A receptors in 
the PVN mediate hormone release via direct (e.g., oxytocin) and sequential (e.g., 
CRH → adrenocorticotropic hormone (ACTH)) pathways (Armstrong 2004).  
Measuring plasma levels of ACTH and oxytocin after in vivo injection of 5-HT1A 
receptor agonists (i.e., “neuroendocrine challenge test”) is a viable means of 
assessing 5-HT1A receptor function in animal models.  Furthermore, 
neuroendocrine challenge tests are clinically relevant because they may be used 
in human patients to assess alterations in receptor function due to 
neuropsychiatric conditions or the effects of psychotropic drugs (Cowen 1998; 
Lee et al., 2003; Almeida et al., 2010).   
The reactivity of the HPA axis is modulated by pubertal development.  Basal 
levels of HPA function remain unchanged, but stress-induced increases in the 
activation of the HPA axis are significantly elevated and prolonged in 
peripubertal rats compared to adults.  With regards to continued exposure to 
stressors, peripubertal animals habituate, or adapt, more rapidly than adult 
animals exposed to the same chronic stressors (Romeo et al., 2006).  Lastly, 
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exposure to stressors during critical periods of maturation can induce long term 
changes in HPA reactivity (Romeo, 2010).  Changes in gonadal hormone levels 
are responsible for some of these differences between peripubertal and adult 
animals.  For example, testosterone attenuates HPA reactivity in response to an 
acute stressor (Goel et al., 2011).  Testosterone also decreases activation of c-fos in 
brain regions with inhibitory feedback on the PVN (Williamson et al., 2010; Goel 
et al., 2011).  Therefore, lower levels of testosterone in a peripubertal animal 
could lead to hyperactivity of the HPA axis. 
Neuropeptides and mental illness 
Oxytocin.  Various studies have indicated that neuropeptides may play a 
major role in the pathology associated with mood disorders and stress responses.  
Neuropeptides may serve as local, autocrine, paracrine, or regulatory agents in 
nearby cells (Sawchenko et al., 1984b).  Oxytocin, a nine-amino acid residue 
neuropeptide, was first isolated in 1953 (Du Vigneaud et al., 1953).  Oxytocin is 
mainly synthesized within the soma of magnocellular neurons located in the 
PVN and supraoptic nucleus in the hypothalamus.  Oxytocin is then transported 
down the axon, packaged in neurosecretory vesicles, and released directly from 
nerve terminals located in the posterior pituitary, arcuate nucleus, lateral 
septum, medial amygdaloid nucleus and median eminence.  Although oxytocin 
is most often associated with the effects it has on maternal behavior, pair 
bonding, and lactation (Marazziti and Catena Dell’Osso 2008), oxytocin is also a 
18 
 
potent neuromodulator and has been found to be anxiolytic in males and females 
(Newman, 2008; Scantamburlo et al., 2009; Slattery and Neumann 2010).  For 
example, intracerebroventricular infusion of oxytocin into the mouse brain 
decreases anxiety behavior (Yoshida et al., 2009), and depressed patients show 
lower plasma oxytocin than controls (Frasch et al., 1995; Ozsoy et al., 2009).  
Intranasal administration of oxytocin has shown to be clinically useful in certain 
depressed individuals (Heinrichs and Gaab 2007).  Although the anxiolytic 
effects of oxytocin may be at least partially mediated through the serotonergic 
system (Yoshida et al., 2009), chronic treatment with SSRIs has no effect on basal 
plasma levels of oxytocin in rats (Uvnas-Moberg et al., 1999) or in depressed 
human patients (Ozsoy et al., 2009).  However, basal plasma levels of oxytocin 
may not reflect changes in central levels of oxytocin (Armstrong et al., 1980) that 
may occur following chronic SSRI treatment. 
CRH.  The interactions of CRH, the HPA axis, and depressive disorders have 
been more extensively investigated than the involvement of oxytocin in 
depressive disorders.  One of the key players in the HPA axis is CRH, a 41 amino 
acid residue neuropeptide that was first characterized in 1981 (Vale et al., 1981).  
Although CRH may access the general circulation (Sawchenko et al., 1984b), the 
classical mechanism of HPA function is triggered by CRH release from the 
hypothalamus into the hypothalamo-hypophyseal portal system, where it 
interacts with one of two types of CRH receptors on corticotrophic cells (CRH-
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R1) in the anterior pituitary (Papadimitriou and Priftis, 2009).  Upon CRH 
receptor stimulation, corticotrophic cells release ACTH into the periphery, where 
it acts on its receptors in the adrenal cortex to synthesize and release 
corticosteroids (namely cortisol in humans and corticosterone in rats).  The 
corticosteroids act throughout the body to affect a variety of mechanisms 
necessary to cope with stressors, including regulating plasma glucose levels, 
metabolism, and CNS effects.  There are corticosteroid receptors at multiple 
levels (e.g., hypothalamus and pituitary) that bind corticosteroids providing a 
negative feedback mechanism in order to attenuate the stress responses (Barrett 
2003).   
Although most CRH immunoreactivity is localized to parvocellular neurons 
in the PVN, CRH is detected in a multitude of other brain regions, which 
strongly suggests that CRH may act as a neuromodulator in extra-hypothalamic 
circuits (Swanson et al., 1983; Liposits et al., 1985; Sakanaka et al., 1987).  Studies 
in both humans and animal models have implicated the CRH system in mood 
disorders and the effects of antidepressants (Nemeroff 1996; Holsboer 1999, 2000; 
Arborelius et al., 1999; Bale and Vale, 2004; Madaan and Wilson, 2009).  Acute 
fluoxetine elevates CRH in hypophyseal portal plasma and subsequently 
increases ACTH in plasma in rats (Gibbs and Vale 1983).  Chronic stress or 
intracerebroventricular injection of CRH induces depressive behaviors in a 
rodent model (Swiergiel et al., 2008).  In the human brain, the ratio of the two 
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subtypes of CRH receptors, CRHR1 to CRHR2, was found to be decreased in the 
brains of suicide victims as compared to controls (Hiroi et al., 2001).  In one 
human study (albeit one with a limited sample size), a certain genetic variant of 
the CRHR1 gene was associated with an increased risk for developing a seasonal 
pattern of depression and an earlier age of onset for the first depressive episode.  
A genetic variant of the CRHR2 gene predicted a poorer outcome when 
individuals expressing this variant were given the SSRI citalopram (Papiol et al., 
2007).  Although these studies represent just a few of the adaptations observed in 
the CRH system associated with stress and mental illness, it is important to note 
that most human studies are performed in adults.  However, studies of HPA 
function in children and adolescents are steadily increasing, and some recent 
studies have also demonstrated HPA alterations in response to stress and mental 
illness in these younger age groups.  For example, children that are bullied 
(Vaillancourt et al., 2007), have been subjected to sexual abuse (Trickett et al., 
2010), have had lost a parent in the September 11, 2001 terrorist attacks (Pfeffer et 
al., 2007), or who have been displaced by Hurricane Katrina (Vigil et al., 2010) 
have decreased cortisol levels and risk for depressive disorders.  Pituitary gland 
volume is increased in adolescents with mood disorders as compared to controls 
(MacMaster et al., 2008). Although these studies provide strong evidence for the 
involvement of the HPA in depressive behavior in children and adolescents, 
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preclinical studies of HPA function and the effects of antidepressants in the 
immature brain are lacking.   
Neuroanatomy of the PVN 
The PVN is localized in the medial hypothalamus and is located rostrally at 
the level of the optic chiasm.  The nucleus is localized laterally to the third 
ventricle near its dorsal surface (Kiss 1988; Paxinos and Watson, 1998).  Each half 
of the PVN receives input from the contralateral side of the PVN (Silverman et 
al., 1981).  The PVN is a center for complex autonomic and neuroendocrine 
control of the periphery and central nervous system (Swanson and Sawchenko 
1980; Sawchenko and Swanson 1983) and consists of several independently 
controlled subdivisions—medial and lateral magnocellular (large cell) groups; 
anterior and medial parvocellular (small cell) cell groups; and ventral, posterior, 
and dorsomedial cap divisions.  The PVN is often subdivided based on the 
cellular content of neuroactive peptides and neurotransmitters; however, 
neurons in the PVN are also organized into subnuclei based on common output, 
size, density, and dendritic morphology (Armstrong 2004).   
Magnocellular neurosecretory cells.  The medial magnocellular region of the 
PVN contains primarily oxytocin-containing and arginine vasopressin (AVP)-
containing cells.  AVP-containing cells are localized in a ball-shaped cluster in 
the lateral magnocellular group located posterior and dorsolateral in the PVN.  
Oxytocin-containing cells are localized in the medial magnocellular portion 
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located anteromedially in the PVN, and also form a ring of cells around the ball-
shaped AVP neuron group.  Magnocellular cells are relatively large (i.e., 20-35 
μm) and send their axons to the neural lobe of the hypophysis, forming the 
hypothalamoneurohypophyseal system.  Oxytocin and AVP are transported 
down these axons for release into the plasma (Armstrong, 2004).  Although most 
CRH-containing cells are localized in the parvocellular cell groups, oxytocin and 
CRH do moderately colocalize in a discrete anterior part of the magnocellular 
division of the nucleus (Sawchenko et al., 1984b).   
Parvocellular neurosecretory cells.  Parvocellular groups are chemically 
diverse (e.g., containing CRH, oxytocin, AVP, and many other neuropeptides) 
and can be divided into anterior and medial cell groups (Armstrong, 2004).  
There is also significant colocalization of CRH with AVP in the PVN (Sawchenko 
et al., 1984a).  Cells from each of the anterior and medial subnuclei project to and 
synapse on the median eminence.  Factors released from parvocellular groups 
are released into the tuberohypophyseal system, where they influence the 
secretion of anterior lobe hormones (e.g. ACTH).   
Although CRH is the classical releasing hormone for ACTH, AVP also plays a 
role in ACTH stimulation (Papadimitriou and Priftis, 2009).  However, although 
5-HT regulates the release of AVP, it is most likely stimulated by 5-HT2C, 5-HT4, 
and 5-HT7 receptors (Jorgensen, 2007) and not 5-HT1A receptors (Bagdy et al., 
1992; Li et al., 1993). 
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Nonendocrine projection cells.  In the PVN, there are also some cell groups 
that send significant descending projections to the brainstem and spinal cord.  
These cells are organized into ventral, posterior, and dorsomedial cap subnuclei 
(Armstrong, 2004).  Projections from these cells also innervate some 
circumventricular organs, pineal gland, and specific nuclei of the thalamus, 
amygdala, and other areas of the hypothalamus (Pittmann et al., 1981). 
Retrograde tracing of neurons reveals that the dorsomedial part of the PVN 
projects to the spinal cord and the dorsolateral cap of the PVN projects to the 
pituitary, indicating that separate cell populations in the PVN project to pituitary 
vs. spinal cord (Swanson and Kuypers 1980).  Oxytocin receptors have been 
found on 5-HT containing cells in the raphe nuclei (Yoshida et al., 2009), 
indicating that oxytocin has the capacity to regulate serotonin release and 
possibly anxiolytic effects via direct activation of oxytocin receptors in the raphe 
nuclei.   
Inputs to PVN.  Neurons in the PVN are highly responsive to both peripheral 
and central stimuli (Saphier and Feldman 1985; Hatton 1990), receiving input 
from the brain stem, most other hypothalamic areas, the amygdala, and other 
forebrain areas (Armstrong 2004).  The PVN receives significant amounts of 
monoamine innervation, primarily by 5-HT (raphe nuclei) and norepinephrine 
(locus coeruleus).  Serotonergic projections arise from the raphe nuclei, and fibers 
from these neurons are found in both oxytocinergic cell groups (Sawchenko et 
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al., 1983) and parvocellular regions.  Considering that 5-HT-containing axons 
overlap with CRH-immunoreactive neurons in the PVN, it is likely that there are 
direct synapses between serotonergic terminals and dendrites and cell bodies of 
CRH cells (Liposits et al., 1987).  Dendrites of both parvocellular and 
magnocellular secretory neurons rarely leave the PVN, but often cross into 
adjacent subnuclei, where they can locally secrete peptide (Armstrong, 2004). 
5-HT1A receptor signaling in the hypothalamic paraventricular nucleus (PVN) 
The serotonin 1A (5-HT1A) receptor was one of the first 5-HT receptor 
subtypes to be identified and investigated with respect to its pharmacology, 
function, and regional distribution in brain.  It was also the first 5-HT receptor to 
be cloned (Albert et al., 1990).  5-HT1A receptors are 7-transmembrane-spanning 
and are part of the G-protein coupled receptor (GPCR) family.  5-HT1A receptors 
on serotonergic neurons are localized to the soma and dendrites where they 
function as inhibitory autoreceptors to regulate cell firing.  This population of 
receptors has generated a great deal of attention since the desensitization of these 
receptors plays a prominent role in the therapeutic efficacy of various drugs used 
to treat mood disorders.  5-HT1A receptors are also associated with anxiolytic 
properties, and knock-out mice lacking this receptor show increased anxiety 
behavior (Celada et al., 2004; Gross et al., 2002).  5-HT1A receptors also are 
expressed on non-serotonergic cells in various brain regions such as the 
hippocampus, frontal cortex, and hypothalamus, where they are postsynaptic 
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receptors that can initiate a variety of signal transduction cascades in response to 
5-HT or an agonist (Kia et al., 1996a; Kia et al., 1996b; Blier and Ward 2003; 
Marvin et al., 2010).  In the paraventricular nucleus, 5-HT1A receptor 
immunoreactivity was localized in the medial parvocellular subnucleus as well 
as in the medial magnocellular subnucleus (Marvin et al., 2010).   
5-HT1A receptors have the capacity to couple to the broadest array of G 
proteins and second messengers.  5-HT1A receptors in hypothalamus can couple 
to Gαi/o and Gαz proteins (Garnovskaya et al., 1996; Raymond et al., 1993; 
Serres et al., 2000a) and localize to at least two populations of cells in the PVN of 
the hypothalamus: oxytocin- and CRH-containing cells (Zhang et al., 2004).  In 
adult rats, post-synaptic 5-HT1A receptors in the PVN mediate separate and 
distinct signal transduction pathways mediated by separate subsets of Gα 
proteins (see Chapter 1, figure 1).  Gαz proteins mediate the 5-HT1A receptor-
induced increase of ACTH and oxytocin into the plasma (Li et al., 1994; Li et al., 
1993; Serres et al., 2000a; Vicentic et al., 1998; Zhang et al., 2004) while pertussis 
toxin-sensitive Gαi/o proteins mediate the activation of the mitogen activated 
protein kinase (MAPK) cascade via the phosphorylation of extracellular signal-
regulated kinase (ERK) (Chen et al., 2002; Crane et al., 2007; Garcia et al., 2006; 
Sullivan et al., 2005).   
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Description of different structural classes of 5-HT1A receptor agonists 
 There are several structural classes of 5-HT1A receptor agonists.  In the current 
studies, representative members of the aminotetralin class ((+)8-OH-DPAT) and 
the azapirone class (tandospirone) are used to determine how these different 
structural classes compare with regards to potency and efficacy with respect to 
the different 5-HT1A receptor responses in the peripubertal PVN.  More details 
regarding the structure, molecular weight, etc. is shown in table 1.     
 (+)8-OH-DPAT has a high affinity and selectivity for 5-HT1A receptors.  
Tandospirone also has a high affinity for 5-HT1A receptors, and has similar 
potency to other members of the azapirone class on the inhibition of neuronal 
cell firing.  Tandospirone is most selective for 5-HT1A than other subtypes of 
receptors (5-HT1A > 5-HT2C > 5-HT1C > α1 and α2 adrenergic > dopamine D1 and 
D2 receptors (Hamik et al., 1990). Tandospirone has lower affinity for dopamine 
D2 receptors than buspirone (Seymour et al., 1990).  
  In rat septal nuclei cultures, 8-OH-DPAT had full agonist activity on neuron 
hyperpolarization while buspirone (an azapirone) only had partial activity (Van 
den Hooff and Gavan, 1992).  8-OH-DPAT is also more potent than azapirones 
on the inhibition of cAMP formation in primary culture of mouse hippocampus 
(Dumuis et al., 1988).  In rat and guinea pig hippocampal membranes, buspirone 
also produced inhibition of forskolin-induced adenylyl cyclase activity, but the 
maximal inhibition was less than that induced by 5-HT, indicating that 
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azapirones display partial agonist activity in this response (DeVivo and Maayani, 
1986).  Tandospirone also displays 60% of the maximal effect of 8-OH-DPAT on 
inhibition of adenylyl cyclase activity (Hamik et al., 1990).  However, 
tandospirone has been shown to act as a full agonist in inducing 5-HT1A receptor-
mediated hypothermia in rats (Millan et al., 1993).  These studies demonstrate 
that the agonist efficacy at 5-HT1A receptors is not dictated exclusively by 
structural class and may vary with respect to signal transduction pathway 
associated with 5-HT1A receptors.   
SSRI-induced desensitization of 5-HT1A receptors in the hypothalamic PVN 
Although several studies have linked the clinical efficacy of antidepressants 
with the time necessary to desensitize 5-HT1A autoreceptors in serotonergic 
neurons of the hindbrain, time-dependent desensitization of post-synaptic 5-
HT1A receptors on non-serotonergic neurons is also observed with long-term 
treatment and may be involved in the therapeutic effects of anxiolytic and 
antidepressant drugs (Borsini 1994).  Desensitization of 5-HT1A receptors can 
occur after prolonged elevations of extracellular 5-HT produced by uptake 
blocking drugs or following prolonged exposure to specific 5-HT1A receptor 
agonists (Albert et al., 1996).  Receptor desensitization may occur after receptor 
phosphorylation by protein kinase C in a complex with calmodulin (Raymond 
1991; Turner et al., 2004).  Receptor desensitization differs from drug tolerance in 
that drug tolerance refers to the attenuation of clinical responsiveness to a drug 
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after repeated administration, while receptor desensitization refers to the 
attenuation in receptor signaling after repeated agonist administration (Bourne 
and von Zastrow, 2004). 
In vivo studies in adult rats have revealed that chronic SSRI treatment has 
specific effects on 5-HT1A receptor signaling pathways in the PVN.  Chronic 
exposure to fluoxetine decreases levels of Gαz proteins in the PVN and 
desensitizes 5-HT1A receptor-mediated hormone responses (Raap et al., 1999).  
However, the Gαi/o-mediated ERK signaling pathway is not desensitized by 
long-term SSRI treatment (Jia et al., 2006).  In fact, maintaining MAPK signaling 
is essential for desensitization of 5-HT1A receptor-mediated neuroendocrine 
responses since blockade of MAPK kinase (MEK), the activating kinase for ERK, 
abolishes SSRI-mediated desensitization of hormone response and associated 
reductions in Gαz proteins (Jia et al., 2007).   
5-HT receptor regulation in the postnatal period 
5-HT receptor expression occurs very early in fetal development; mRNA 
transcripts for the 5-HT1 receptor family can be detected as early as embryonic 
day 14.5 in the mouse brain (Bonnin et al., 2006).  Regional and subtype-specific 
changes in 5-HT receptor mRNA levels continue past the day of birth and persist 
into the early postnatal period (Basura and Walker, 2000; Volgin et al., 2003).  5-
HT1 and 5-HT2 receptor density in the primate brain increases rapidly in the 
postnatal period and reaches its peak around 2-4 months of age.  In general, the 
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density of cortical 5-HT receptors then begins to decline, reaching adult levels 
right around the time of puberty (~3 years of age in the primate) (Lidow and 
Rakic 1992).  However, there have been few studies examining developmental 
changes in 5-HT receptor density in the hypothalamus.  There was no change in 
the density of 5-HT2A receptors in the neonatal rat hypothalamus over the second 
postnatal week of life, but the density of 5-HT1A receptors increased during this 
time in the hypothalamus (Ferrari et al., 1999).  However, the density or 
regulation of 5-HT1A receptors in the hypothalamus around the time of puberty 
has not been determined.  
G proteins 
5-HT1A receptors are part of the G protein coupled receptor family.  G 
proteins are heterotrimeric and mediate signaling from the level of the receptor 
to a variety of intracellular signaling pathways in the cell.  5-HT1A receptors 
specifically couple to members of the Gαi/o protein family: Gαi1, Gαi2, Gαi3, 
Gαo, and Gαz (Mannoury la Cour et al., 2006; Raymond et al., 1992; Serres et al., 
2000a) and mediate 5-HT1A receptor signaling pathways in the hypothalamic 
PVN (i.e., oxytocin and ACTH responses and phosphorylation of ERK).  
Dysfunction of G protein-mediated signaling has been recently linked to 
psychiatric disorders.  The activity and/or protein content of the intermediates of 
G protein-mediated signaling pathways have shown to be disturbed in patients 
with bipolar disorder (Friedman and Wang 1996; Spleiss et al., 1998; Dowlatshahi 
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et al., 1999; Emamghoreishi et al., 2000), schizophrenia (Jope et al., 1998; Yang et 
al., 1998) and alcohol dependence (Jope et al., 1998).  Measuring G protein 
content in mononuclear leukocytes in patients with mood disorders may be a 
viable option to measure the effectiveness of various drug treatments (Avissar et 
al 2001).   
Levels of Gα proteins are known to change throughout several brain regions 
during early postnatal development.  For example, Gαi1, Gαi2, and Gαo proteins 
steadily increase between postnatal days 1 and 25 in the cortex, thalamus, and 
hippocampus of the rat brain, whereas Gαi3 proteins decrease in these regions 
over the same time period (Ihnatovych et al., 2002).  However, no studies have 
determined the developmental regulation of these subtypes of Gα proteins or 
Gαz proteins in the hypothalamus, and no studies have examined the time right 
around puberty, which is an important period for brain growth and maturation.  
Any age-dependent differences in the levels of Gα proteins or mechanisms of 
intracellular signal transduction of these proteins have implications for the 
function of G protein-mediated signaling in both health and disease states in a 
population at different stages in development.  
The MAPK ERK 
Mitogen activated protein kinases (MAPK) make up a family of protein 
kinases that respond to extracellular stimuli (typically by growth factors).  This 
protein family regulates various cellular activities, including gene expression, 
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mitosis, differentiation, cell survival/apoptosis, learning, memory, 
neuroplasticity, and receptor desensitization (Marshall 1995; Pouysségur and 
Lenormand 2003; Trincavelli et al., 2002).  The activation mechanism of 
extracellular signal-regulated kinase (ERK) is classically initiated by receptor 
tyrosine kinases, although it can be activated by GPCRs, including 5-HT1A 
receptors in vitro (Garnovskaya et al., 1996) and in vivo (Chen et al., 2002; Crane 
et al., 2007; Sullivan et al., 2005).  More recently, MAPK function has been 
implicated in stress and the effects of antidepressants.  Acute blockade of MAPK 
signaling produces a depressive-like phenotype and blocks behavioral actions of 
antidepressants in mice (Duman et al., 2007; Qi et al., 2009), while chronic 
corticosterone treatment of mice increases depressive-like behaviors and reduces 
levels of activated ERK in the dentate gyrus (Gourley et al., 2008).  Also, acute 
stress alters levels of activated ERK in several regions of the rat brain (Shen et al., 
2004; Qi et al., 2006), which can be reversed by fluoxetine (Qi et al., 2008).  These 
findings are consistent with findings from our laboratory demonstrating that, in 
adult rat hypothalamus, ERK activation is required for SSRIs to desensitize 5-
HT1A receptor signaling of neuroendocrine responses (Jia et al., 2007).  
Furthermore, a small post-mortem study determined that several intermediate 
proteins of ERK signaling as well as ERK itself, were decreased in content and/or 
activity in the frontal cortex and hippocampus in patients with psychiatric 
disorders, including schizophrenia and major depressive disorder (Yuan et al., 
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2010) and in subjects who had committed suicide (Dwivedi et al., 2001; Dwivedi 
et al., 2006).  Similarly, the activity of MEK (the upstream activating kinase for 
ERK), but not relative protein levels, was decreased in the frontal cortex and 
hippocampus of suicide victims when compared to controls (Dwivedi et al., 
2009).   
The PI3K/Akt/GSK3 signaling pathway 
Multiple lines of evidence indicate that the PI3K/Akt/GSK3 pathway plays a 
role in the pathology of psychological disorders including chronic stress, 
depression, and schizophrenia (Beaulieu et al., 2009).  Akt (protein kinase B, 
previously known as RAC-PK (related to PKA and C protein kinases)) is a 
protein kinase involved with cell survival, apoptosis, protein synthesis, insulin 
signaling, and glucose transport (Franke et al., 2003).  Akt, a 57 kDa 
serine/threonine protein kinases, was first cloned in 1991 (Coffer and Woodgett, 
1991; Jones et al., 1991; Bellacosa et al., 1991).  Akt exists in three isoforms, Akt1 
(PKBα), Akt2 (PKBβ), and Akt3 (PKBγ), with Akt1 having the highest expression 
in brain tissue (Coffer and Woodgett, 1991).  Akt can be activated by receptor 
tyrosine kinases or by G protein-coupled receptors (GPCRs).  In either case, 
receptor activation activates phosphoinositide 3-kinase (PI3K), which catalyzes 
the formation of the phosphatidylinoisitol(3,4,5)P3 (PIP3) molecule.  PIP3 attracts 
phosphoinositide dependent kinase 1 (PDK1) and Akt to the cell membrane, 
where PDK1 phosphorylates Akt at Thr308 (Alessi et al., 1997; Stephens et al., 
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1998).  Akt also must be phosphorylated at Ser473 for full activation of the 
protein (Alessi et al., 1996).  The kinase mammalian target of rapamycin (mTOR) 
is considered to be the candidate responsible for this phosphorylation (Sarbassov 
et al., 2005), although other kinases like integrin-linked kinase may function to 
phosphorylate Akt at Ser473 in transfected cell lines (Delcommenne et al., 1998).  
Although phosphorylation of Akt at Thr308 and Ser473 appear to be 
autonomously regulated (Coffer et al., 1998), phosphorylation at Ser473 may 
assist in the recruitment of Akt to the plasma membrane and to subsequent 
phosphorylation at Thr308 by PDK1 (Andjelkovic et al., 1997; Scheid and 
Woodgett, 2003).  Downstream, activated Akt phosphorylates and inhibits the 
constitutively active glycogen synthase kinase 3 (GSK3), an enzyme that 
regulates the function of a multitude of proteins, including metabolic, signaling, 
and structural proteins (Grimes and Jope 2001).  There are 2 isoforms of GSK3, 
GSK3α and GSK3β, which are both expressed at high levels in the brain 
(Woodgett 1990).     
The Akt signaling pathway been linked to the pathology of mood disorders 
and the effects of antidepressants and other psychotropic drugs in both humans 
and animal models.  For example, the activities of PI3K and Akt were 
significantly decreased in the occipital cortex of suicide victims when compared 
to controls (Hsiung et al., 2003).  Chronic stress increases levels of activated 
(phosphorylated) Akt (pAkt) in the rat hypothalamus, hippocampus, and 
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striatum, with the largest increases observed in the hypothalamus (Lee et al., 
2006).  Alterations were observed in both the activity of Akt and GSK3 in 
schizophrenic patients (Emamian et al., 2004) and in a mouse model of 
schizophrenia (Beaulieu et al., 2004).  Furthermore, acute injection with SSRIs 
increases the levels of phosphorylated GSK3, which serves to inactivate this 
kinase (Li et al., 2004).  Lithium, commonly used in the treatment of bipolar 
disorder, has been shown to activate Akt and/or inhibit the activation of GSK3 in 
vitro and in vivo (Klein and Melton, 1996; Chalecka-Franaszek and Chuang, 1999; 
DeSarno et al., 2002; Zhang et al., 2003; O’Brien et al., 2004; Gould et al., 2004).  
Other psychotropic drugs have also been shown to regulate this pathway, 
including sodium valproate, used in the treatment of bipolar disorder (De Sarno 
et al., 2002; Roh et al., 2005); imipramine, a tricyclic antidepressant (Li et al., 2004; 
Basta-Kaim et al., 2005; Roh et al., 2005); risperidone, an atypical antipsychotic (Li 
et al., 2007); and sertraline, fluoxetine, and fluvoxamine, all SSRIs (Reddy et al., 
2008; Fatemi et al., 2009; Nakano et al., 2010). 
5-HT1A receptor agonists increase the phosphorylation of Akt in both 
neuronal (Adayev et al., 1999; Cowen et al., 2005) and non-neuronal (Hsiung et 
al., 2005) cell cultures as well as in adult rat hippocampus in vivo (Polter et al., 
2010).  5-HT1A receptor activity has also been shown to stimulate mitochondrial 
movement in hippocampal axons in vitro, possibly via activation of Akt and 
blockade of GSK3β (Chen et al., 2007).  Acute injection with the SSRI fluoxetine 
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has also been shown to increase phosphorylated GSK3β in the frontal cortex in 
vivo, possibly via 5-HT1A receptor activation (Li et al., 2004). 
Rationale for developmental time point chosen for these studies 
In this dissertation, a “peripubertal” time period (around postnatal day 42) 
was chosen to further examine the 5-HT1A receptor signaling and drug-induced 
regulation of this receptor in the hypothalamic PVN.  This age roughly 
corresponds to “adolescence” in humans (Spear 2000).  Endocrine studies have 
established that sexual maturation in the male rat begins around postnatal days 
25-30 and is usually complete by postnatal days 50-60 (Pak and Handa, 2007).  
We have also chosen this timeframe due the extensive amount of brain changes, 
neuroplasticity, and behavioral changes occurring during this time.  For 
example, prior to and during puberty, monoamine receptors and synapses (e.g., 
serotonin, dopamine) are being overproduced in the brain, which are later 
pruned to adult levels (Andersen 2003).  Axonal projections from monoamine 
cell bodies also reach adult levels around the time of puberty (Andersen and 
Navalta, 2004).  There are also transformations in the adolescent brain with 
regards to (1) reductions in energy utilization (Spear, 2000), (2) increases in 
cortical white matter (Villablanca et al., 2000; Sowell et al., 2003), and (3) region-
dependent decreases in the relative size of gray matter (Geidd et al., 1999; 
Rapoport et al., 1999).  These changes contribute to the transformation of “the 
more energy utilizing, seemingly less efficient brain of the child into a more 
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rapidly communicative and more energy efficient brain of the adult” (Spear, 
2007).  Considering these global and regional changes, it may be possible that 5-
HT1A receptor signaling may undergo transitional changes during this time 
frame and differ mechanistically from that observed in the adult brain.  
It is important to establish the parameters that constitute “normal” functional 
processes that exist around the time of sexual maturation because both human 
and rodent studies have provided evidence that stress before sexual maturation 
induces permanent changes to the brain and body.  For example, rats exposed to 
early life stress displayed blunted responses of ERK activation along with other 
markers of synaptic signaling in adulthood (Musazzi et al., 2010) and also 
displayed disturbances in other MAPK signaling pathways that were attenuated 
with antidepressant treatment (Budziszewska et al., 2010).  Chronic social stress 
of peripubertal rats alters fat distribution in adulthood, but these changes were 
reversed with SSRI treatment (Schmidt et al., 2009).  In human studies, exposure 
to early life stress before maturity (death of a close relative, parental depression 
or divorce, etc.) can increase sensitivity to depression upon later stressful events 
(Bouma et al., 2008), increase immune activity to psychosocial stress, particularly 
with those suffering from major depressive disorder (Pace et al., 2006), and have 
long-lasting effects on the HPA axis such as decreased cortisol responses as 
adults (Meinlschmidt and Heim 2005).  Individuals exposed to early life stress 
who later developed depressive disorders as adults had increased plasma ACTH 
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responses to challenge with dexamethasone/CRH (a type of neuroendocrine 
challenge test), and the increases were associated with the severity, onset, and 
duration of early abuse (Heim et al., 2008).  The long term implications for 
studying brain changes induced by stress or drug treatment (not to mention the 
functioning of the brain in a basal state) is that clinical interventions or therapies 
could be designed to optimally treat individuals with specific pathologies (Agid 
et al., 2000; Heim et al., 2004).    
Summary and clinical significance 
Depressive disorders can occur in up to 4.6% of children and 8.0% of 
adolescents (Nobile et al., 2003).  SSRIs have been shown to be effective in 
treating childhood and adolescent clinical disorders such as depression, 
obsessive-compulsive disorders, eating disorders, Tourette’s syndrome, autism, 
and panic disorder (Cohen 2007; Rushton and Whitmire, 2001; Wong et al., 2004).  
Although the effectiveness and side effect profile of SSRI use in children and 
adolescent populations is still highly debatable, fluoxetine (Prozac®) is still an 
effective option for treating clinical disorders in younger populations.  Therefore, 
at this point in time, the benefits of these drugs may outweigh the risks, and it is 
highly likely that SSRIs will continue to be prescribed to children and 
adolescents.  Given the involvement of 5-HT, the HPA axis, and protein kinases 
in the pathogenesis of mood disorders and the effects of antidepressants in 
adults, more research is necessary to determine the role these systems may play 
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in the occurrence and treatment of mood disorders in younger individuals.  
Determining the aspects of these systems that differ during development may 
also provide better or more effective targets for the treatment of mood disorders 
in children and adolescents.  Although 5-HT1A receptor signaling and drug-
induced regulation of 5-HT1A receptors have been extensively investigated in 
adult animals, to date no studies have elucidated the specific pathways or 
mechanisms of 5-HT1A receptor signaling and drug-induced desensitization in 
the peripubertal hypothalamic PVN.   
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 Aminotetralin Azapirone 
N
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Drug used in these studies (+)8-OH-DPAT Tandospirone 
Structure  
 
 
Activity at 5-HT1A receptor-
mediated inhibition of 
adenylyl cyclase 
Full Partial 
Molecular weight 247.38 g/mol 383.49 g/mol 
Molecular formula C16H25NO C21H29N5O2 
Usage Prototypical 5-HT1A 
receptor agonist 
(preclinical); not approved 
for clinical use 
One of several preclinically 
used azapirones; anxiolytic, 
antipsychotic augmentation 
(Japan) 
Table 1.  Comparison of the properties of the 5-HT1A receptor agonists used in the current 
studies. 
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CHAPTER 3 
SEROTONIN 1A RECEPTORS ACTIVATE MULTIPLE SIGNALING 
RESPONSES IN THE PERIPUBERTAL RAT HYPOTHALAMIC 
PARAVENTRICULAR NUCLEUS:  EFFECTS OF DIFFERENT STRUCTURAL 
CLASSES OF AGONISTS ON THE TIME- AND DOSE-DEPENDENT 
STIMULATION OF NEUROENDOCRINE REPONSES AND ACTIVATION OF 
EXTRACELLULAR SIGNAL-REGULATED KINASE. 
 
ABSTRACT 
 
In the adult rat hypothalamic paraventricular nucleus (PVN), (+)8-OH-DPAT 
(an aminotetralin full agonist) and tandospirone (an azapirone partial agonist) 
increase plasma levels of oxytocin and ACTH and activate extracellular signal 
regulated kinase (ERK) in the adult PVN (Sullivan et al., 2005; Crane et al., 2007).  
The present studies investigated 5-HT1A receptor signaling in the peripubertal rat 
hypothalamic PVN to determine: (1) if different structural classes of 5-HT1A 
receptor agonists can mediate signaling of both hormone release and kinase 
activation; (2) the onset and longevity of the respective 5-HT1A receptor-mediated 
responses; (3) the efficacy and potency of (+)8-OH-DPAT and tandospirone in 
activating the respective 5-HT1A receptor- mediated responses, (4) potential 
agonist-dependent targeting of any specific response, and (5) an optimal agonist 
dose and post-injection time to investigate the multiple 5-HT1A receptor-
mediated responses in subsequent studies.  With respect to the time-dependent 
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activation of 5-HT1A receptor-mediated responses, (+)8-OH-DPAT (0.20 mg/kg) 
and tandospirone (10 mg/kg) induced rapid (≤ 5 minutes) increases in plasma 
levels of oxytocin that were comparable (~200 pg/ml) and maintained for 15 
minutes before declining to baseline (> 30 minutes).  Both 5-HT1A agonists also 
induced rapid (≤ 5 minutes) increases in plasma levels of ACTH that reached 
comparable maximal levels (~1000 pg/ml) at 10 minutes and remained elevated 
throughout the 30 minute testing period.  (+)8-OH-DPAT and tandospirone also 
produced rapid (≤ 5 minutes) increases in activated (i.e., phosphorylated) ERK 
(pERK) that persisted for at least 30 minutes.  The dose response data indicate 
that both drugs exhibited comparable maximal efficacies in elevating plasma 
oxytocin, but (+)8-OH-DPAT was a more potent agonist than tandospirone.  The 
maximal efficacies of (+)8-OH-DPAT and tandospirone on ACTH responses 
were also comparable.  With respect to ERK activation in the PVN, (+)8-OH-
DPAT was more potent than tandospirone and maximally effective doses of the 
aminotetralin or azapirone agonists produced comparable increases in pERK.  In 
summary, these studies in peripubertal hypothalamic PVN demonstrated 
different structural classes of 5-HT1A receptor agonists activated both 
neuroendocrine responses (i.e., oxytocin and ACTH) from different cell types 
and concomitantly kinase (i.e., pERK) responses, indicating no agonist-
dependent targeting of responses.  While (+)8-OH-DPAT was more potent than 
tandospirone at each of the respective responses, both structural classes of 5-
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HT1A receptor agonists produced rapid and prolonged activation of 
neuroendocrine and kinase responses and similar maximal efficacies.   
INTRODUCTION 
 
In adult rats, 5-HT1A receptors are localized on oxytocin-containing and 
corticotrophin releasing hormone (CRH)-containing cells (Zhang et al., 2004), 
and activation of these receptors produces respective increases in plasma levels 
of oxytocin and ACTH hormones (Bagdy and Kalogeras, 1993; Gilbert et al., 1988; 
Vicentic et al., 1998).  5-HT1A receptor stimulation concomitantly activates the 
mitogen-activated protein kinase (MAPK) cascade in the adult PVN (Crane et al., 
2007; Sullivan et al., 2005).  The 5-HT1A receptor-mediated activation of ERK by 
the aminotetralin full agonist (+)8-OH-DPAT is rapid but transient, since levels 
of activated ERK are increased at 5 minutes but return to basal levels by 15 
minutes post-injection (Crane et al., 2007).  In contrast, 8-OH-DPAT-induced 
elevations in plasma hormone levels of oxytocin and ACTH are more prolonged, 
since hormone levels reach a peak at 15 minutes and remain significantly 
elevated 30 minutes after agonist injection (Di Sciullo et al., 1990; D’Souza et al., 
2004).  In addition to differences in onset and longevity, the respective 5-HT1A 
receptor-mediated responses also differ in terms of the dose-dependence of 
activation.  In the adult, 5-HT1A receptor-mediated oxytocin and ACTH 
neuroendocrine responses occur at doses of (+)8-OH-DPAT lower than doses 
required to significantly increase the levels of pERK in the PVN.  Tandospirone, 
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an azapirone “partial” agonist at postsynaptic 5-HT1A receptors, also increases 
plasma levels of oxytocin and ACTH and increases pERK in the adult rat PVN 
(Sullivan et al., 2005).  However, it remains to be determined if this class of 5-
HT1A receptor agonist exhibits potency, efficacy, and a time-course of activation 
comparable to (+)8-OH-DPAT at each of the respective 5-HT1A receptor-
mediated responses.  We have previously reported (Garcia et al., 2006) that 
hypothalamic 5-HT1A receptors in the adult PVN mediate neuroendocrine versus 
kinase responses via different subsets of Gα proteins and that these responses 
can be activated independent of each other.  Consequently, different classes of 
receptor agonists may preferentially or exclusively activate one of these multiple 
5-HT1A receptor-mediated responses.  This is referred to as “biased agonism,” a 
phenomenon observed in receptor systems where different classes of receptor 
agonists may induce a variety of conformational changes in a receptor that 
facilitates signaling via one or more distinct pathways (Kenakin 1995; Berg et al., 
1998; Galandrin and Bouvier, 2006; Rajagopal et al., 2010; Whalen et al., 2011).  
For example, in a cell line expressing 5-HT2C receptors, the piperazine derivative 
3-trifluoromethylphenyl-piperazine preferentially activates the phospholipase C 
pathway, whereas lysergic acid diethylamide (LSD), a member of the ergoline 
family, preferentially activates the phospholipase A2 pathway (Berg et al., 1998).  
To date, no in vivo studies have investigated the phenomenon of “biased 
agonism” for 5-HT1A receptor-mediated signaling pathways in hypothalamic 
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PVN at any age.  Furthermore, no studies have examined, in vivo, the multiplicity 
of responses mediated by 5-HT1A receptors nor the time-course, efficacy, and 
potency of different classes of agonists in simulating respective neuroendocrine 
and kinase responses in the peripubertal hypothalamic PVN.   
The first experiment described in this chapter will determine the time-course 
of classes of 5-HT1A receptor agonists that differ in chemical structure ((+)8-OH-
DPAT, an aminotetralin, and tandospirone, an azapirone) to stimulate: (A) 
increases in plasma oxytocin, (B) increases in plasma ACTH, and (C) increases in 
pERK in the peripubertal rat hypothalamic PVN.  The second experiment will 
test the dose-dependent effects of the two different agonists on signaling of 5-
HT1A receptor-mediated: (A) oxytocin hormone responses, (B) ACTH hormone 
responses, and (C) increases in pERK in the peripubertal rat hypothalamic PVN.   
These studies will provide information regarding: (1) the onset and longevity 
of the respective 5-HT1A receptor-mediated responses, (2) differences in agonist 
potency and efficacy for the respective 5-HT1A receptor-mediated responses, (3) 
potential agonist-dependent preference or exclusive activation of any of the 
respective 5-HT1A receptor-mediated pathways in the hypothalamic PVN of 
peripubertal rats, and (4) an optimal agonist dose and post-injection time to 
obtain multiple 5-HT1A receptor-mediated responses for subsequent studies. 
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MATERIALS AND EXPERIMENTAL PROCEDURES (for detailed methods, 
see Chapter 7) 
Animals. Peripubertal male Sprague-Dawley rats (postnatal day 35; 100-125 g) 
were purchased from Harlan (Indianapolis, IN).  The determination of post-natal 
day zero (day of birth) was carried out by the supplier.   
Drugs.  (+)-8-Hydroxy-2-(di-n-propylamino)tetralin hydrobromide [(+)8-OH-
DPAT] was purchased from Tocris Cookson Inc. (Ellisville, MO). Tandospirone 
citrate was a generous gift of Dr. K. Matusubara, Asahikawa Medical College, 
Japan.  All drugs were dissolved in saline (0.9% NaCl).  For the dose-response 
experiment, the highest dose of drug was dissolved in saline and lower 
concentrations were made by serial dilution.  The drugs were injected at a 
volume of 1 ml/kg and were freshly prepared immediately prior to the injections.  
 Experiment 1:  Time-dependent activation of 5-HT1A receptor-mediated 
responses.  At least 3 days of handling preceded any injections.  Peripubertal 
male Sprague-Dawley rats (post-natal day 42) were injected with either saline (1 
ml/kg, s.c.), the aminotetralin full agonist (+)8-OH-DPAT (0.20 mg/kg, s.c.), or 
the azapirone partial agonist tandospirone (10 mg/kg, s.c.).  These agonist doses 
have been shown to significantly elevate plasma oxytocin and ACTH 
concentrations in peripubertal rats (Battaglia et al., 2002; Petrunich et al., 2008) 
and significantly increase plasma levels of oxytocin and ACTH and increase 
pERK in the PVN of adult rats (Crane et al., 2007; Sullivan et al., 2005).  The 
46 
 
animals were sacrificed by decapitation at 5, 10, 15, 20, or 30 minutes post-
injection.  The brains were carefully removed from the skull within one minute of 
the decapitation and were quickly frozen by submersion in chilled 2-
methylbutane (-35°C) for 1 minute and then subsequently kept in dry ice for an 
additional 10 minutes.  Each brain was then securely wrapped and stored at         
-80°C prior to dissection for Western blot studies for the determination of 
pERK/ERK levels in the PVN.  The trunk blood was collected and prepared for 
subsequent determination of plasma levels of oxytocin, ACTH, and testosterone.   
 Experiment 2:  Dose-dependent activation of 5-HT1A receptor-mediated 
responses.  At least 3 days of handling preceded any injections.  Peripubertal 
male Sprague-Dawley rats (post-natal day 42) were injected with either saline (1 
ml/kg, s.c.), (+)8-OH-DPAT (0.04, 0.10, 0.20, or 0.50 mg/kg, s.c.), or tandospirone 
(1, 3, 10, or 20 mg/kg, s.c.) and were sacrificed by decapitation at 10 minutes 
post-injection.  These agonist doses have been shown to produce dose-dependent 
responses in plasma levels of oxytocin and ACTH and pERK in the PVN of adult 
rats (Battaglia et al., 2009; Sullivan et al., 2005).  The brains were carefully 
removed from the skull within one minute of the decapitation and were quickly 
frozen by submersion in chilled 2-methylbutane (-35°C) for 1 minute and then 
subsequently kept in dry ice for an additional 10 minutes.  Each brain was then 
securely wrapped and stored at -80°C prior to dissection for Western blot studies 
for the determination of pERK/ERK levels in the PVN.  The trunk blood was 
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collected and prepared for subsequent determination of plasma levels of 
oxytocin, ACTH, and testosterone.   
RESULTS 
1.  Experiment 1:  Time-dependent activation of 5-HT1A receptor-mediated 
responses. The specific objectives of this experiment were: (1) to determine the 
onset and longevity of the 5-HT1A receptor-mediated increases in (A) plasma 
levels of oxytocin, (B) plasma levels of ACTH, and (C) phosphorylation of ERK in 
PVN; (2) to identify potential agonist-dependent differences in onset and 
longevity of the respective 5-HT1A receptor-mediated signaling pathways; and (3) 
establish one optimal post-injection time (for use in subsequent studies) to 
measure agonist-induced increases in these functional markers.   
A.  Time-course of (+)8-OH-DPAT and tandospirone-induced increases in 
plasma oxytocin in the peripubertal rat.  As shown in figure 3, (+)8-OH-DPAT 
(0.20 mg/kg) and tandospirone (10 mg/kg) induced rapid (≤ 5 minutes) and 
comparable increases in plasma levels of oxytocin that were maintained for 15 
minutes before gradually approaching baseline.  Although (+)8-OH-DPAT-
induced increases in plasma oxytocin attenuate more rapidly than tandospirone, 
plasma oxytocin responses induced by either agonist did not return to baseline 
within the time period tested.   
The two-way ANOVA for oxytocin indicated a significant main effect of acute 
challenge injection (saline, (+)8-OH-DPAT, or tandospirone) [F2,115 = 269.13, p < 
48 
 
0.0001] and a significant main effect of post-injection time [F4,115 = 24.46, p < 
0.0001].  There was also a significant interaction between acute challenge 
injection and post-injection time [F8,115 = 8.51 p < 0.0001].  A Newman-Keuls’ test 
indicated that (+)8-OH-DPAT increased plasma oxytocin levels above saline at 5, 
10, 15, 20 minutes (p < 0.01) and 30 minutes (p < 0.05).  Tandospirone increased 
plasma oxytocin levels above saline at 5, 10, 15, 20, and 30 minutes (p < 0.01).  
These data indicate that (+)8-OH-DPAT (0.20 mg/kg) and tandospirone (10 
mg/kg) elicit comparable changes in plasma oxytocin with respect to the 
magnitude and general overall time-course of the response (although (+)8-OH-
DPAT approached baseline more rapidly than tandospirone).   
B.  Time-course of (+)8-OH-DPAT and tandospirone-induced increases in plasma 
ACTH in the peripubertal rat.  As shown in figure 4, (+)8-OH-DPAT (0.20 mg/kg) 
and tandospirone (10 mg/kg) induced rapid (≤ 5 minutes) increases in plasma 
levels of ACTH that reached comparable maximal levels at 10 minutes and 
remained elevated throughout the testing period.   
The two-way ANOVA for ACTH indicated a significant main effect of acute 
challenge injection (saline, (+)8-OH-DPAT, or tandospirone) [F2,120 = 412.46, p < 
0.0001] and a significant main effect of post-injection time [F4,120 = 10.18, p < 
0.0001].  There was also a significant interaction between acute challenge 
injection and post-injection time [F8,120 = 3.04 p = 0.004].  A Newman-Keuls’ test 
indicated that (+)8-OH-DPAT significantly increased (p < 0.01) plasma ACTH 
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levels above saline at 5, 10, 15, 20, and 30 minutes.  Tandospirone also 
significantly increased (p < 0.01) plasma ACTH levels above saline at 5, 10, 15, 20, 
and 30 minutes.  These data indicate that (+)8-OH-DPAT (0.20 mg/kg) and 
tandospirone (10 mg/kg) elicit comparable changes in plasma levels of ACTH 
with respect to the magnitude and overall time-course of the response (e.g., peak 
levels around 10 minutes with a slight attenuation and plateau for subsequent 
time points for both drugs). 
C.  Time-course of (+)8-OH-DPAT-induced increases in phosphorylated ERK in 
the peripubertal PVN.  As shown in figure 5, (+)8-OH-DPAT (0.20 mg/kg) 
induced a rapid (≤ 5 minutes) increase in pERK levels in the PVN that was 
maintained for 20 minutes before declining to baseline (> 30 minutes).   
The two-way ANOVA for (+)8-OH-DPAT-induced increases of pERK in the 
PVN indicated a significant main effect of acute challenge injection (saline or 
(+)8-OH-DPAT) [F1,78 = 43.92, p < 0.0001] but no significant main effect of post-
injection time [F4,78 = 1.02, p = 0.4022].  There was also no significant interaction 
between acute challenge injection and post-injection time [F4,78 = 1.02, p = 0.4022].  
A Newman-Keuls’ test indicated that (+)8-OH-DPAT significantly increased (p < 
0.01) pERK in the PVN over saline at 5, 10, 15, and 20 minutes.  These data 
indicate that (+)8-OH-DPAT rapidly increases activated ERK in the peripubertal 
PVN, and that this response is sustained for a longer response time than 
previously published for the adult PVN (Crane et al., 2007).   
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D.  Time-course of tandospirone-induced increases in phosphorylated ERK in the 
peripubertal PVN.  As shown in figure 6, tandospirone (10 mg/kg) induced a 
rapid (≤ 5 minutes) increase in pERK in the PVN that was maintained 
throughout the testing period, although the magnitude of the response induced 
by tandospirone (↑ ~50% above basal) was much less than that induced by (+)8-
OH-DPAT (↑ ~200% above basal, see figure 5).   
The two-way ANOVA for tandospirone-induced increases of pERK in the 
PVN indicated a significant main effect of acute challenge injection (saline or 
tandospirone) [F1,75 = 25.87, p < 0.0001] but no significant main effect of post-
injection time [F4,75 = 0.05, p = 0.944].  There was also no significant interaction 
between acute challenge injection and post-injection time [F4,75 = 0.05, p = 0.944].  
A Newman-Keuls’ test indicated that tandospirone significantly increased (p < 
0.05) pERK over saline at 5, 10, and 20 minutes.   
E.  Optimal sacrifice time for future experiments.  These results indicate that a 
sacrifice time of 10 minutes post-injection can be used in subsequent studies to 
measure robust increases in 5-HT1A receptor-mediated increases in plasma 
oxytocin and ACTH and increases in pERK in the PVN of peripubertal rats 
produced by injection with (+)8-OH-DPAT.   
F.  Single injection of (+)8-OH-DPAT or tandospirone does not alter testosterone 
levels in the peripubertal rat.  As shown in figure 7, neither (+)8-OH-DPAT (0.20 
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mg/kg) nor tandospirone (10 mg/kg) had any effect on plasma levels of 
testosterone at any time point tested.   
The two-way ANOVA for plasma testosterone levels indicated no significant 
main effect of acute challenge injection (saline, (+)8-OH-DPAT, or tandospirone) 
[F2,97 = 0.42, p = 0.66] and no significant main effect of post-injection time [F4,97 = 
1.94, p = 0.11].  There was also no significant interaction between acute challenge 
injection and post-injection time [F8,97 = 0.68, p = 0.71].  These data indicate that 
the stage of sexual maturation was comparable between treatment groups and 
that the in vivo challenge injections and sacrifice times did not alter the 
testosterone levels in these animals.   
2.  Experiment 2:  Dose-dependent activation of 5-HT1A receptor-mediated 
responses.  The objectives of this experiment were: (1) to determine potency and 
efficacy of agonists from two different structural drug classes ((+)8-OH-DPAT, 
an aminotetralin and tandospirone, an azapirone) on (A) oxytocin hormone 
responses, (B) ACTH hormone responses, and (C) phosphorylation of ERK in 
PVN; (2) to determine if either agonist preferentially activates any one of the 
multiple 5-HT1A receptor-mediated responses; and (3) to establish one optimal 
dose of (+)8-OH-DPAT that evokes 5-HT1A receptor-mediated increases in 
plasma levels of oxytocin and ACTH and increases pERK in the PVN (to be used 
in subsequent studies).   
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A.  Dose-response of (+)8-OH-DPAT and tandospirone on plasma levels of 
oxytocin in the peripubertal rat.  As shown in figure 8, (+)8-OH-DPAT and 
tandospirone dose-dependently increase plasma oxytocin levels above those in 
saline-challenged peripubertal rats.  The maximal responses induced by both 
agonists were similar; however, (+)8-OH-DPAT is more potent agonist than 
tandospirone, since lower doses of (+)8-OH-DPAT were sufficient to induce 
oxytocin responses.  In addition, the dosing range (less than 1 log unit) required 
by (+)8-OH-DPAT to achieve a maximal effect on oxytocin responses was much 
narrower than the dosing range (over 1 log unit) required by tandospirone for 
maximal effects on plasma levels of oxytocin. 
The two-way ANOVA for oxytocin indicated a significant main effect of acute 
challenge injection (saline, (+)8-OH-DPAT, or tandospirone) [F2,103 = 182.82, p < 
0.0001] and a significant main effect of agonist dose [F3,103 = 44.24, p < 0.0001].  
There was also a significant interaction between acute challenge injection and 
agonist dose [F6,103 = 13.73 p < 0.0001].  A Newman-Keuls’ test indicated that 
(+)8-OH-DPAT significantly increased (p < 0.01) plasma oxytocin levels above 
saline-injected controls at 0.10, 0.20, and 0.50 mg/kg, but not 0.04 mg/kg.  
Tandospirone significantly increased (p < 0.01) plasma oxytocin levels above 
saline-injected controls at all doses tested (1, 3, 10, and 20 mg/kg).  These data 
suggest that the highest doses of each agonist elicit similar maximal responses 
with regard to 5-HT1A receptor-mediated increases of plasma oxytocin levels, 
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although the potency and dosing range necessary to induce maximal responses 
differ between these two drugs.   
B.  Dose-response of (+)8-OH-DPAT and tandospirone on plasma levels of 
ACTH the peripubertal rat.  As shown in figure 9, all tested doses of (+)8-OH-
DPAT and tandospirone increased plasma ACTH levels over saline-challenged 
peripubertal rats.  The maximal responses induced by both agonists were similar, 
with (+)8-OH-DPAT inducing a dose-dependent increase in plasma ACTH over 
a narrow dosing range (less than 1 log unit).  As all tested doses of tandospirone 
elicited a maximal response, neither the potency nor the dosing range could be 
determined for tandospirone. 
The two-way ANOVA for ACTH indicated a significant main effect of acute 
challenge injection (saline, (+)8-OH-DPAT, or tandospirone) [F2,102 = 526.44, p < 
0.0001] and a significant main effect of agonist dose [F3,102 = 43.20, p < 0.0001].  
There was also a significant interaction between acute challenge injection and 
agonist dose [F6,102 = 23.09, p < 0.0001].  A Newman-Keuls’ test indicated that 
(+)8-OH-DPAT significantly increased plasma ACTH levels over saline at 0.04 
mg/kg (p < 0.05), 0.10, 0.20, and 0.50 mg/kg (p < 0.01).  Tandospirone 
significantly increased (p < 0.01) plasma ACTH levels above saline-injected 
controls at all doses tested (1, 3, 10, and 20 mg/kg).  These data suggest that the 
highest doses of each agonist elicit similar maximal responses (Emax) with regards 
to 5-HT1A receptor-mediated increases of plasma ACTH levels, although the 
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potency and dosing ranges was not obvious for tandospirone and cannot be 
easily compared to the values obtained for (+)8-OH-DPAT.   
C.  Dose-response of (+)8-OH-DPAT on levels of pERK in peripubertal rat 
hypothalamic PVN.  As shown in figure 10, the highest doses of (+)8-OH-DPAT 
tested increased pERK levels in the peripubertal PVN over saline-challenge.  
Within the dosing range tested, these responses approximate the maximal 
response, although the additional data points at higher doses would better 
substantiate the respective Emax values.  (+)8-OH-DPAT is a potent agonist on 5-
HT1A receptor-mediated pERK responses in the PVN, with a more narrow dosing 
range (≤ 1 log unit). 
The two-way ANOVA for (+)8-OH-DPAT-induced increases of pERK in the 
PVN indicated a significant main effect of acute challenge injection (saline or 
(+)8-OH-DPAT) [F1,71 = 11.55, p = 0.0012] and a significant main effect of agonist 
dose [F3,71 = 4.90, p = 0.0039].  There was also a significant interaction between 
acute challenge injection and agonist dose [F3,71 = 4.90, p = 0.0039].  A Newman-
Keuls’ test indicated that (+)8-OH-DPAT increased levels of pERK in the PVN 
over saline at 0.20 mg/kg (p < 0.05) and at 0.50 mg/kg (p < 0.01).   
D.  Dose-response of (+)8-OH-DPAT and tandospirone on levels of pERK in 
peripubertal rat hypothalamic PVN.  As shown in figure 11, the highest doses of 
tandospirone tested increased pERK levels in the peripubertal PVN over saline-
challenge.   Again, within the dosing range tested, these responses approximate 
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the maximal response, although the additional data points at higher doses would 
better substantiate the respective Emax values.  These dose-response data indicate 
that (+)8-OH-DPAT (figure 10) is a more potent agonist than tandospirone on 5-
HT1A receptor-mediated pERK responses in the PVN, with a more narrow dosing 
range (≤ 1 log unit) compared to tandospirone (≥ 1 log unit).    
The two-way ANOVA for tandospirone-induced increases of pERK in the 
PVN indicated a significant main effect of acute challenge injection (saline or 
tandospirone) [F1,69 = 19.66, p < 0.0001] but no significant main effect of agonist 
dose [F3,69 = 1.22, p = 0.3085].  There was also no significant interaction between 
acute challenge injection and agonist dose [F3,69 = 1.22, p = 0.3085].  A Newman-
Keuls’ test indicated that tandospirone increased levels of pERK in the PVN over 
saline-injected controls at 10 and 20 mg/kg (p < 0.05).   
E.  Optimal challenge dose of (+)8-OH-DPAT for future experiments.  These 
results indicate that 0.20 mg/kg of (+)8-OH-DPAT can be used in subsequent 
studies to produce robust increases in 5-HT1A receptor-mediated plasma 
oxytocin and ACTH and levels of pERK in the peripubertal rat hypothalamic 
PVN.   
F.  Single injection of (+)8-OH-DPAT or tandospirone at any dose does not 
change testosterone levels in the peripubertal rat.  As shown in figure 12, neither 
(+)8-OH-DPAT nor tandospirone had any effect on plasma levels of testosterone 
at any dose tested.   
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The two-way ANOVA for plasma testosterone levels indicated no significant 
main effect of acute challenge injection (saline, (+)8-OH-DPAT, or tandospirone) 
[F2,91 = 0.07, p = 0.94] and no significant main effect of agonist dose [F3,91 = 0.34, p 
= 0.79].  There was also no significant interaction between acute challenge 
injection and agonist dose [F6,91 = 0.19, p = 0.98].  These data indicate that stage of 
sexual maturation was comparable between treatment groups and that the in vivo 
challenge injections and doses did not alter the testosterone levels in these 
animals.   
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Figure 3. Time-course of (+)8-OH-DPAT and tandospirone-induced increases in plasma levels of 
oxytocin in the peripubertal rat.  *, ** indicates significant difference (p < 0.05 and p < 0.01, 
respectively) from the respective saline-challenged group; #, ## indicates significant difference (p 
< 0.05 and p < 0.01, respectively) from the respective (+)8-OH-DPAT-challenged group; +, ++ 
indicates significant difference (p < 0.05 and p < 0.01, respectively) from corresponding response 
at 5 minute post-injection (two-way ANOVA and Newman-Keuls multiple-range test). N = 7-10 
per group. 
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Figure 4. Time-course of (+)8-OH-DPAT and tandospirone-induced increases in plasma levels of 
ACTH in the peripubertal rat.  ** indicates significant difference (p < 0.01) from the respective 
saline-challenged group; # indicates significant difference (p < 0.05) from the respective (+)8-OH-
DPAT-challenged group; ++ indicates significant difference (p < 0.01) from corresponding 
response at 5 minute post-injection (two-way ANOVA and Newman-Keuls multiple-range test). 
N = 7-10 per group.  
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Figure 5. (A) Time-course of (+)8-OH-DPAT-induced elevations of pERK in peripubertal PVN.  ** 
indicates significant difference (p < 0.01) from the saline-challenged group (two-way ANOVA 
and Newman-Keuls multiple-range test). (B) Representative western blot of pERK (above) and 
ERK (below) from the PVN of rats treated with either saline or (+)8-OH-DPAT. N = 7-8 per group. 
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Figure 6. (A) Time-course of tandospirone-induced elevations of pERK in peripubertal PVN.         
* indicates significant difference (p < 0.05) from the saline-challenged group (two-way ANOVA 
and Newman-Keuls multiple-range test). (B) Representative western blot of pERK (above) and 
ERK (below) from the PVN of rats treated with either saline or tandospirone. N = 6-8 per group. 
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Figure 7. Injection with either (+)8-OH-DPAT (0.20 mg/kg) or tandospirone (10 mg/kg) had no 
effect on plasma levels of testosterone in the peripubertal rat at any post-injection time point 
(two-way ANOVA). N = 3-9 per group. 
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Figure 8. Effects of different doses of (+)8-OH-DPAT and tandospirone on plasma levels of 
oxytocin in the peripubertal rat.  ** indicates significant difference (p < 0.01) from the saline-
challenged group; ++ indicates significant difference (p < 0.01) from corresponding lowest-dose 
challenge injection; ## indicates significant difference (p < 0.01) from the 0.01 mg/kg (+)8-OH-
DPAT-challenged group; @ indicates significant difference (p < 0.05) from the 3 mg/kg 
tandospirone-challenged group (two-way ANOVA and Newman-Keuls multiple-range test). N = 
7-11 per group. 
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Figure 9. Effects of different doses of (+)8-OH-DPAT and tandospirone on plasma levels of 
ACTH in the peripubertal rat.  *,** indicates significant difference (p < 0.05 and p < 0.01, 
respectively) from the saline-challenged group; ++ indicates significant difference (p < 0.01) from 
corresponding lowest-dose challenge injection; ## indicates significant difference (p < 0.01) from 
the 0.01 mg/kg (+)8-OH-DPAT-challenged group; ^^ indicates significant difference (p < 0.01) 
from the 0.02 mg/kg (+)8-OH-DPAT-challenged group; @ indicates significant difference (p < 0.05) 
from the 3 mg/kg tandospirone-challenged group (two-way ANOVA and Newman-Keuls 
multiple-range test). N = 7-10 per group. 
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Figure 10. (A) Effects of different doses of (+)8-OH-DPAT on levels of pERK in peripubertal PVN.  
*, ** indicates significant difference (p < 0.05 and p < 0.01, respectively) from the saline-
challenged group; +, ++ indicates significant difference (p < 0.05 and p < 0.01 respectively) from 
the 0.04 mg/kg (+)8-OH-DPAT-challenged group; #, ## indicates significant difference (p < 0.05 
and p < 0.01 respectively) from the 0.01 mg/kg (+)8-OH-DPAT-challenged group (two-way 
ANOVA and Newman-Keuls multiple-range test). (B) Representative western blot of pERK 
(above) and ERK (below) from the PVN of rats treated with either saline or (+)8-OH-DPAT. N = 
6-12 per group.  
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Figure 11. (A) Effects of different doses of tandospirone on levels of pERK in peripubertal PVN.     
* indicates significant difference (p < 0.05) from the saline-challenged group (two-way ANOVA 
and Newman-Keuls multiple-range test). (B) Representative western blot of pERK (above) and 
ERK (below) from the PVN of rats treated with either saline or tandospirone. N = 4-12 per group.  
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Figure 12. Injection with different doses of either (+)8-OH-DPAT or tandospirone had no effect 
on plasma levels of testosterone in the peripubertal rat (two-way ANOVA). N = 4-10 per group. 
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DISCUSSION 
Several immunohistochemical studies have determined that 5-HT1A receptors 
are expressed on many types of neuroendocrine-containing cells (e.g., 
neuropeptide Y-, proopiomelanocortin-, orexin-containing, etc.) throughout the 
hypothalamus (Collin et al., 2002; Aznar et al., 2003; Muraki et al., 2004; Marvin 
et al., 2010).  5-HT1A receptors have also been localized to glial cells in other brain 
regions (Whitaker-Azmitia et al., 1993; Azmitia et al., 1996; Paterson et al., 2004).  
In the adult PVN, oxytocin-containing and CRH-containing cells express 5-HT1A 
receptors (Zhang et al., 2004).  Stimulation of these receptors with different 
classes of 5-HT1A receptor agonists such as (+)8-OH-DPAT (an aminotetralin) or 
tandospirone (an azapirone) can increase plasma levels of oxytocin and ACTH 
hormones (Bagdy and Kalogeras, 1993; Gilbert et al., 1988; Vicentic et al., 1998).  
In the adult PVN, these agonists also concomitantly activate ERK (Chen et al., 
2002; Crane et al., 2007; Sullivan et al., 2005).  The data from the present studies 
are the first to demonstrate in the peripubertal PVN: (1) that both (+)8-OH-DPAT 
and tandospirone increased plasma levels of oxytocin and ACTH and increased 
levels of pERK (indicating that 5-HT1A receptors also can concomitantly activate 
multiple responses prior to sexual maturation) and (2) the pharmacodynamic 
properties of these different classes of 5-HT1A receptor agonists at each of the 
respective signaling responses.  These studies indicate that, although 5-HT1A 
receptors activate neuroendocrine responses and ERK in both the adult and 
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peripubertal PVN, there are some aspects of 5-HT1A receptor-mediated activation 
of ERK that differ between these age groups that may play a role in acute drug 
responsivity or to long term drug-induced neuroadaptations. 
One notable difference observed between adult and peripubertal 5-HT1A 
receptor signaling is in the duration of MAPK responses.  In the adult PVN, 5-
HT1A receptors activate ERK in a rapid and transient manner, as the 
aminotetralin agonist (+)8-OH-DPAT significantly elevates levels of activated 
ERK at 5 minutes but returns to basal levels by 15 minutes post-injection (Crane 
et al., 2007).  The current studies have demonstrated that 5-HT1A receptor-
stimulated pERK in the peripubertal PVN is also rapid, but the response is more 
prolonged than in adults.  This prolonged activation of ERK occurs following 5-
HT1A receptor activation by either class of agonist, since both (+)8-OH-DPAT and 
tandospirone injections resulted in elevations in pERK lasting up to at least 30 
minutes post-injection.  In a variety of mammalian cell lines, the duration of ERK 
signaling is associated with distinct cell behavior (Traverse et al., 1992; Nguyen 
et al., 1993; Mansour et al., 1994; Sharp et al., 1997; Whalen et al., 1997; Murphy et 
al., 2002; Murphy et al., 2004; Sinnett-Smith et al., 2004).  For example, prolonged 
but not transient ERK activation was associated with (1) neuronal differentiation 
in PC-12 cells (Traverse et al., 1992), (2) nuclear translocation of ERK in PC12 
cells (Nguyen et al., 1993), and (3) c-fos accumulation and DNA synthesis in 
Swiss 3T3 cells (Sinnett-Smith et al., 2004).  Therefore, developmental differences 
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in the longevity of ERK activation may impact a variety of functions under the 
control of ERK (e.g., cell survival, gene expression, learning, memory, and 
receptor desensitization) (Marshall 1995; Pouysségur and Lenormand 2003; 
Trincavelli et al., 2002).  Considering that ERK signaling has also recently been 
implicated in stress behaviors and the effects of antidepressants in animal 
models (Duman et al., 2007; Duric et al., 2010; Gourley et al., 2008; Qi et al., 2006; 
Qi et al., 2008; Qi et al., 2009; Shen et al., 2004), a prolonged ERK response in 
response to 5-HT1A receptor activation in the peripubertal brain could possibly 
influence the mechanism of action of antidepressants in this age group.  For 
example, Duric et al., (2010) determined that overexpression (by viral vectors or 
induction via chronic stress) of MAP kinase phosphatase (MKP-1) in the 
hippocampus results in depressive behavior in a rodent model, presumably due 
to the more rapid dephosphorylation of ERK and termination of its signal.  
Further studies are required to determine if the temporal differences between 
peripubertal and adult are due to mechanisms involving ERK activation or 
phosphatase activity. 
With respect to comparative studies using an aminotetralin versus azapirone 
5-HT1A receptor agonists, (+)8-OH-DPAT is classified a “full” agonist and 
tandospirone is considered a “partial” agonist at post-synaptic 5-HT1A receptors.  
In rat hippocampal homogenates, tandospirone partially inhibits forskolin-
induced adenylyl cyclase activity (Hamik et al., 1990; Rabin and Winter, 1993).  
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Buspirone, another azapirone, also acts as a partial agonist on neuronal 
hyperpolarization in vitro (Van den Hooff and Galvan, 1992).    However, in the 
peripubertal rat, maximally effective doses of the aminotetralin ((+)8-OH-DPAT) 
or azapirone (tandospirone) agonists produce comparable increases in each of 
the respective 5-HT1A receptor-mediated responses.  The current studies suggest 
that tandospirone can act as a full agonist on 5-HT1A receptor-mediated oxytocin 
and ACTH plasma hormone responses and activation of ERK in the PVN.  This 
finding is not unprecedented, given that tandospirone has been shown to act as a 
full agonist in inducing 5-HT1A receptor-mediated hypothermia in rats (Millan et 
al., 1993). 
Given the multiplicity of 5-HT1A receptor signaling responses in peripubertal 
PVN, these studies also sought to determine the existence of “biased agonism” of 
5-HT1A receptor-mediated responses in the peripubertal PVN.  This phenomenon 
(which expands upon the two-state model of receptor activation) states that, 
whereas one class of receptor agonists stabilize the active conformation (R → R*1) 
that favors the activation of pathway 1, another class of receptor agonists 
stabilize an alternate active receptor conformation (R → R*2) that favors 
activation of pathway 2 (Rozengurt 2007).  This phenomenon is observed in other 
receptor systems in vitro (Berg et al., 1998; Galandrin and Bouvier, 2006; Kenakin 
1995).  Berg et al. demonstrated that a piperazine derivative preferentially 
activates the 5-HT2C receptor-mediated phospholipase C pathway, whereas a 
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member of the ergoline family preferentially activates the 5-HT2C receptor-
mediated phospholipase A2 pathway (Berg et al., 1998).  A literature search 
revealed that no in vivo studies have investigated this phenomenon of “biased 
agonism” for 5-HT1A receptor-mediated signaling pathways.  Our results suggest 
that 5-HT1A receptor responses in the peripubertal PVN are not subject to “biased 
agonism” with respect to azapirone versus aminotetralin agonists since each 
agonist elicited similar maximal responses in 5-HT1A receptor-mediated oxytocin, 
ACTH, and pERK responses.  However, this finding must be considered 
preliminary, considering that it has not been determined whether these receptor 
responses in the peripubertal PVN are activated as a result of dependent vs. 
multiple independent pathways mediated by separate subsets of second 
messenger proteins (e.g., G proteins).  The role of pertussis toxin-sensitive G 
proteins will be investigated in Chapter 4.     
Although both agonists tested in the current experiments had similar 
maximal efficacies for 5-HT1A receptor-mediated neuroendocrine responses, (+)8-
OH-DPAT is generally more potent than tandospirone for 5-HT1A receptor-
mediated oxytocin and pERK responses.  The current data also indicate that (+)8-
OH-DPAT generally has a narrower dosing range for 5-HT1A receptor-mediated 
increases in plasma levels of oxytocin than tandospirone.  Consequently, (+)8-
OH-DPAT may be able to occupy a fewer number of receptors to induce 5-HT1A 
receptor-mediated responses than tandospirone, suggesting that it more 
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efficiently couples receptor occupation to response.  A more likely explanation is 
that (+)8-OH-DPAT may become more readily bioavailable compared to 
tandospirone.  Bioavailablity is a pharmacokinetic property that refers to the 
percentage of unchanged drug that reaches systemic circulation following any 
route of administration (Holford 2004).  Therefore, depending on drug class, a 
greater percentage of active drug my reach the brain.  Although it was been 
determined that within 15 minutes of subcutaneous administration of (+)8-OH-
DPAT, approximately 0.1% of the active drug dose was detected in rat 
hypothalamus (Yu and Lewander 1997), comparable studies have not examined 
hypothalamic concentrations after acute subcutaneous tandospirone injection in 
rats.  However, about 0.04% of tandospirone was detected in cortex within 30 
minutes of intraperitoneal injection (1-20 mg/kg) in mice (Miller et al., 1992).  
Similarly, the clinically prescribed azapirone drug buspirone has been reported 
to have a very low bioavailability (Mahmood and Sahajwalla, 1999).  Also of note, 
lower doses of tandospirone increased maximal plasma levels of ACTH, but not 
oxytocin or increased pERK in PVN.  This is likely due to the 5-HT1A receptor-
mediated activation of the sequential pathway (e.g. CRH → ACTH) mediated 
oxytocin plasma hormone responses.  Although not as obvious, lower doses of 
(+)8-OH-DPAT also significantly elevated plasma ACTH responses over saline, 
but had no significant effect on plasma levels of oxytocin and pERK responses in 
PVN. 
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 Lastly, although 5-HT1A receptors have been localized to both oxytocin-
containing and CRH-containing cells in the rat PVN (Zhang et al., 2004), it is 
unknown whether each of these respective receptor populations are responsible 
for mediating both plasma hormone responses and increases in pERK measured 
at the level of the whole PVN.  Studies in other receptor systems (α1 adrenergic) 
have shown that receptor-stimulated pERK in the PVN can be observed in CRH-
containing cells (Khan et al., 2007).  However, although stimulation with 
prolactin or IL-1β  increases levels of pERK in the hypothalamus, there is little 
localization of pERK to oxytocin-containing cells (Blume et al., 2009; Wang et al., 
2006).  Cellular localization of 5-HT1A receptor-mediated pERK will be further 
examined in Chapter 5 of this dissertation. 
From the current experiments, we have determined that a dose of 0.20 mg/kg 
(+)8-OH-DPAT and a sacrifice time of 10 minutes post-injection will be used in 
future experiments examining 5-HT1A receptor signaling pathways following 
acute receptor stimulation since it produces robust increases in each of the 
respective endpoints and is devoid of altering testosterone levels which could 
complicate any interpretation of the data.  Since 0.20 mg/kg of (+)8-OH-DPAT 
elicits the maximal 5-HT1A receptor-mediated oxytocin and ACTH responses, the 
dose of (+)8-OH-DPAT may not be sensitive to detect desensitization of 5-HT1A 
receptor-mediated hormone responses due to chronic treatment with 
antidepressants or other drugs. 
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CHAPTER 4 
 
SEROTONIN 1A RECEPTOR-ASSOCIATED Gα PROTEIN SUBTYPES IN THE 
PERIPUBERTAL RAT HYPOTAHLAMIC PARAVENTRICULAR NUCLEUS: 
UNIQUE ASPECTS OF MODIFICATION AND REGULATION. 
 
ABSTRACT 
 
In adult rats, injection with Bordetella pertussis toxin (PTX) into the 
paraventricular nucleus (PVN) reduces levels of Gαi1, Gαi2, Gαi3, and Gαo 
proteins and blocks serotonin 1A (5-HT1A) receptor-mediated extracellular 
signal-regulated kinase (ERK) activation but has no effect on Gαz proteins or 5-
HT1A receptor-mediated plasma oxytocin or ACTH responses (Garcia et al., 2006).  
These data indicate that 5-HT1A receptors in the adult PVN activate separate and 
distinct signal transduction pathways.  Consistent with these data, chronic 
treatment of adult rats with fluoxetine, a selective serotonin reuptake inhibitor 
(SSRI), selectively reduces hypothalamic levels of Gαz and desensitizes 5-HT1A 
receptor-mediated neuroendocrine responses but does not reduce any of the 
other Gα proteins or affect 5-HT1A receptor-mediated increases in pERK.  In 
contrast, chronic fluoxetine treatment of peripubertal rats desensitizes 5-HT1A 
receptor-mediated in the absence in reductions of Gαz proteins (Chen et al., 2006), 
suggesting that, prior to maturation, Gαz is not the exclusive Gα subtype 
mediating hormone responses as it is in adults.  Given that 5-HT1A receptor- 
75 
mediated activation of ERK was not determined in that previous study, the Gα 
protein subtype(s) specificity for the respective 5-HT1A receptor-mediated 
responses prior to sexual maturation has not been identified.  The present studies 
examined 5-HT1A receptor-associated Gα proteins in the peripubertal rat 
hypothalamic PVN with respect to: (1) levels of the respective membrane-
associated Gα proteins at peripubertal versus younger (prepubertal) and adult 
ages, (2) the role of PTX-sensitive and PTX-insensitive Gα proteins on 5-HT1A 
receptor-mediated increases in oxytocin and ACTH and increases of pERK in the 
PVN, and (3) the effects of chronic fluoxetine treatment (7 or 14 days) in 
regulating Gα protein subtypes and 5-HT1A receptor-mediated activation of ERK 
in PVN.  The present studies indicate that, in peripubertal rats: (1) Gαo is the 
only Gα protein subject to developmental regulation (i.e., Gαo levels increased 
with age) whereas Gαi1, Gαi2, Gαi3, and Gαz were present at comparable levels 
in PVN, hippocampus, and frontal cortex of the prepubertal, peripubertal, and 
adult brain, (2) PTX treatment reduced levels of membrane-associated Gαi1 and 
Gαi2, markedly increased levels of Gαo, but did not alter Gαi3 or Gαz in the 
peripubertal hypothalamus, (3) PTX-induced reductions in Gαi1 and Gαi2 
proteins did not affect 5-HT1A receptor-mediated oxytocin or ACTH responses, 
suggesting a role for Gαi3, Gαo, and/or Gαz proteins in 5-HT1A receptor-
mediated signaling, (4) PTX increased basal pERK levels, suggesting an increased 
constitutive activity of pERK consistent with increases in Gαo, (5) chronic 
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fluoxetine did not reduce levels either cytosol- or membrane-associated Gαz or 
any other Gα protein subtype, suggesting a novel mechanism responsible for 
fluoxetine-induced desensitization of 5-HT1A receptor-mediated neuroendocrine 
responses, and (6) chronic fluoxetine did alter basal levels of pERK but did not 
desensitize 5-HT1A receptor-mediated increases in pERK in the PVN.  In 
summary, the data from the current studies identify a different profile of Gα 
protein sensitivity to PTX and chronic fluoxetine in the peripubertal rat than 
previously established in the adult rat.  These aspects of Gα protein subtypes not 
observed in adults but unique to the peripubertal brain, precluded any effective 
use of PTX or fluoxetine to differentiate the role of Gαi/o versus Gαz proteins in 
the respective roles of these subtypes in 5-HT1A receptor-mediated 
neuroendocrine versus kinase responses.   
INTRODUCTION 
 5-HT1A receptors can couple to multiple signal transduction pathways 
(Raymond et al., 2001) via different subsets of PTX-sensitive Gα proteins (Gαi1, 
Gαi2, Gαi3, and Gαo) or PTX-insensitive Gαz proteins (Mannoury la Cour et al., 
2006; Raymond et al., 1992; Serres et al., 2000a).  The in vivo signal transduction 
pathways mediated by these two subsets of proteins in hypothalamic PVN and 
their regulation by different drug treatments have thus far only been 
investigated in adult rats.  In the adult PVN, Gαz proteins (insensitive to 
pertussis toxin) mediate the 5-HT1A receptor-induced increases in plasma ACTH 
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and oxytocin (Serres et al., 2000a).  In contrast, one or more subtypes of Gαi/o 
proteins mediate the 5-HT1A receptor-induced increase in activated ERK in 
hypothalamus, since intra-PVN injection with PTX completely inhibits 5-HT1A 
receptor activation of ERK and reduces Gαi1, Gαi2, Gαi3, and Gαo proteins.  In 
contrast, intra-PVN injection with PTX does not alter 5-HT1A receptor-mediated 
stimulation of neuroendocrine responses or reduce levels of Gαz proteins (Garcia 
et al., 2006).  Thus, in the adult rat, PTX provides a useful tool to differentiate 
signaling by these respective subsets of G proteins (i.e., PTX-sensitive or PTX-
insensitive).  These 5-HT1A receptor-mediated pathways in the adult PVN were 
also differentially regulated by chronic drug treatment: fluoxetine consistently 
produced reductions in Gαz and desensitized 5-HT1A receptor-mediated 
neuroendocrine responses but did not alter 5-HT1A receptor-mediated activation 
of ERK or levels of Gi/o proteins in adult rats (Jia et al., 2006).  Therefore, it is 
likely that Gαi/o and Gαz proteins mediate signaling of separate and distinct 
pathways following acute activation of 5-HT1A receptors in the adult rat PVN.   
 A preliminary study from our laboratory suggested that the signaling of 5-
HT1A receptor-mediated responses in peripubertal animals occurred via 
mechanism(s) that differ from adult animals.  In peripubertal rats, chronic 
fluoxetine treatment produced desensitization of 5-HT1A receptor-mediated 
hormone responses and also decreased levels of hypothalamic Gαi3 and Gαo 
proteins but had no effect on hypothalamic levels of Gαz proteins (Chen et al., 
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2006).  This differential profile of reductions in Gα protein subtypes and the lack 
of reduction in Gαz despite a desensitization of 5-HT1A receptor-mediated 
hormone responses suggest that, prior to sexual maturation, other G proteins or 
mediators are responsible for the desensitization of hormone responses.  
Consequently, reductions in Gαz are not responsible for desensitization of 
hormone responses.   
 Differences observed in fluoxetine-induced reductions in G proteins in 
peripubertal vs. adult hypothalamus may be simply due to developmental 
differences in the levels of Gα proteins, which could affect the subtype associated 
with hormone stimulation.  Gα protein levels vary in early postnatal 
development in several brain regions.  For example, Gαi1, Gαi2, and Gαo 
proteins increase between postnatal day 1 and 25 in the cortex, thalamus, and 
hippocampus, where Gαi3 proteins decrease in these regions over the same time 
period (Ihnatovych et al., 2002).  However, no studies have determined the 
developmental regulation of Gαz in any brain region, or any Gα protein subset 
in the hypothalamus.  In addition, no studies have examined the regional 
distribution of Gα proteins in brain during peripubertal development, an 
important period for brain growth and remodeling.  Any developmental change 
in the availability of 5-HT1A receptor-coupled Gα proteins may impact the role 
that these Gα proteins play in 5-HT1A receptor-mediated signaling of 
neuroendocrine vs. kinase responses.   
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 Fluoxetine is one of two SSRIs currently approved for clinical use for the 
treatment of depressive disorders in children and adolescents (National 
Institutes of Health, 2010).  Fluoxetine is one of the most commonly used SSRI in 
preclinical studies, particularly those involving peripubertal animal models (Oh 
et al., 2009; Iniguez et al., 2010). 
 The objectives of the experiments described in this chapter were to determine:  
(1) if the relative levels of Gα protein subtypes in different regions in the 
peripubertal brain vs. younger (prepubertal) and adult brains, (2) the role of 
PTX-sensitive Gα proteins in 5-HT1A receptor-mediated neuroendocrine 
responses and phosphorylation of ERK in the peripubertal PVN using an intra-
PVN injection of PTX, and (3) the regulation Gα proteins and 5-HT1A receptor-
mediated activation of ERK in the peripubertal PVN upon chronic (7 and 14 day) 
fluoxetine treatment.   
MATERIALS AND EXPERIMENTAL PROCEDURES (for detailed methods, 
see Chapter 7) 
 Animals.  Prepubertal, peripubertal and adult male Sprague-Dawley rats 
were purchased from Harlan (Indianapolis, IN).  The determination of post-natal 
day zero (day of birth) was carried out by the supplier.   
 Drugs. Pertussis toxin (PTX; Bordetella pertussis) was purchased from EMD 
Chemicals, Gibbstown, NJ (catalog number 516560), and was diluted to a 
concentration of 1 μg/μl with ddH2O.  Fluoxetine hydrochloride (FLX) was 
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purchased from LKT Laboratories, Inc., St. Paul, MN (catalog number F4780), 
and was dissolved in saline (0.9% NaCl) to 10 mg/kg and was injected at a 
volume of 2 ml/kg.  (R)-(+)-8-Hydroxy-2-(di-n-propylamino)tetralin 
hydrobromide [(+)8-OH-DPAT] was purchased from Tocris Cookson Inc., 
Ellisville, MO (catalog number 1080) and was dissolved in saline (0.9% NaCl) to 
0.20 mg/ml and was injected at a volume of 1 ml/kg.  All drugs were freshly 
prepared immediately prior to the injections.  
 Experiment 1:  Age-dependent brain levels of Gα protein subtypes that 
mediate signaling of 5-HT1A receptors.  Male Sprague-Dawley rats at three 
different ages (prepubertal, peripubertal, and adult) were handled for several 
days to reduce the stress of handling upon sacrifice.  Each rat was sacrificed by 
decapitation on postnatal day (PD) 28 (prepubertal), PD 42 (peripubertal), or PD 
70 (adult), and the brains were quickly removed and frozen on dry ice for 
western blot determination of Gα protein levels in different brain regions.  The 
trunk blood was collected in tubes and prepared for subsequent determination of 
plasma levels of testosterone. 
 Experiment 2:  Pertussis toxin inactivation of Gα proteins in the peripubertal 
rat hypothalamic PVN.  Cannula implantation and administration of PTX was 
performed according to procedures previously established in adult rats (Garcia 
et al., 2006), and detailed in Chapter 7.  Seventy-two hours after intracerebral 
injection of vehicle (100 mM sodium phosphate + 500 mM NaCl, 0.5 μl/side) or 
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PTX (1 μg/μl, 0.5 μl/side), the rats were given a systemic challenge injection of 
saline (1 ml/kg) or (+)8-OH-DPAT (0.20 mg/kg) and were sacrificed by 
decapitation 15 minutes later (postnatal day 42).  The brains were carefully 
removed from the skull within one minute of the decapitation and were quickly 
frozen by submersion in chilled 2-methylbutane (-35°C) for 1 minute and then 
subsequently kept in dry ice for an additional 10 minutes.  Each brain was then 
securely wrapped and stored at -80°C prior to dissection for Western blot studies 
for the determination of Gα protein levels and pERK/ERK levels in the PVN.  
The trunk blood was collected in tubes and prepared for subsequent 
determination of plasma levels of oxytocin, ACTH, and testosterone.   
 Experiment 3:  Determination of fluoxetine-induced effects on 5-HT1A 
receptor-associated G proteins and 5-HT1A receptor-mediated increases of 
pERK in the peripubertal PVN.  Rats were weighed on a digital scale daily and 
were subsequently given an i.p. injection of saline (2 ml/kg) or fluoxetine (10 
mg/kg), once per day for either 7 (PD 35-41) or 14 days (PD 28-41).  This 
fluoxetine dosing regimen has been previously shown to desensitize 5-HT1A 
receptor-mediated oxytocin and ACTH responses and to inhibit weight gain in 
peripubertal rats (Chen et al., 2006).  Eighteen hours after the last injection, the 
rats (postnatal day 42) were given a systemic challenge injection of saline (1 
ml/kg) or (+)8-OH-DPAT (0.20 mg/kg) and were sacrificed by decapitation 10 
minutes later.  The brains were carefully removed from the skull within one 
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minute of the decapitation and were quickly frozen by submersion in chilled 2-
methylbutane (-35°C) for 1 minute and then subsequently kept in dry ice for an 
additional 10 minutes.  Each brain was then securely wrapped and stored at         
-80°C prior to dissection for Western blot studies for the determination of Gα 
protein levels and pERK/ERK levels in the PVN.  The trunk blood was collected 
in tubes and prepared for subsequent determination of plasma levels of oxytocin, 
ACTH, and testosterone.   
RESULTS 
 
1. Experiment 1:  Determination of relative levels of Gα proteins in the PVN and 
other brain regions at different developmental stages.  The objective of this 
experiment was to determine the levels of the respective Gα proteins at 
peripubertal versus younger (prepubertal) and adult ages in various brain 
regions.  The body weights and plasma testosterone levels were also measured 
for each rat. 
A.  Average body weight of prepubertal, peripubertal, and adult rats.  Rats 
gained weight with age.  Prepubertal rats weighed, on average, 76.96 ± 0.76 g, 
peripubertal rats weighed about twice as much as prepubertal rats (164.76 ± 0.91 
g), and adult rats weighed about four times as much as prepubertal rats (325.79 ± 
1.36 g) (figure 13).   
 The one-way ANOVA for body weight indicated a significant main effect of 
age [F2,29 = 14608.16, p < 0.0001].  A Newman-Keuls’ test indicated that 
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peripubertal rats weighed significantly more than prepubertal rats (p < 0.01) and 
that adults weighed significantly more than both prepubertal and peripubertal 
rats (p < 0.01).   
B.  Plasma testosterone levels of prepubertal, peripubertal, and adult rats.  
Plasma levels of testosterone increased with age.  Prepubertal rats  had an 
average plasma testosterone level of 13.56 ± 2.04 ng/dl, peripubertal rats had 
about 4.5 times higher levels than prepubertal rats (61.30 ± 9.73 ng/dl), and adult 
rats had about 17.5 times higher levels than prepubertal rats (236.97 ± 25.80 
ng/dl) (figure 14).   
 The one-way ANOVA for plasma testosterone levels indicated a significant 
main effect of age [F2,29 = 54.31, p < 0.0001].  A Newman-Keuls’ test indicated that 
peripubertal rats had greater levels of plasma testosterone than prepubertal rats 
(p < 0.05) and that adults had greater levels of plasma testosterone than both 
prepubertal and peripubertal rats (p < 0.01).   
C.   Gα protein levels in the PVN of prepubertal, peripubertal, and adult rats.  In 
the PVN, Gαo proteins, but not Gαi1, Gαi2, Gαi3, or Gαz proteins, increased with 
age.  Gαo proteins were present in the prepubertal PVN at about 40% adult 
levels and in the prepubertal PVN at about 68% adult levels (figure 15, table 2).   
 The one-way ANOVA for Gαi1 (figure 15A) indicated no significant main 
effect of age [F2,23 = 0.12, p = 0.8856].  The one-way ANOVA for Gαi2 (figure 15B) 
indicated no significant main effect of age [F2,22 = 0.94, p = 0.4082].  The one-way 
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ANOVA for Gαi3 (figure 15C) indicated no significant main effect of age [F2,19 = 
0.06, p = 0.9407].  The one-way ANOVA for Gαz (figure 15D) indicated no 
significant main effect of age [F2,19 = 0.73, p = 0.4969]. The one-way ANOVA for 
Gαo (figure 15E) indicated a significant main effect of age [F2,20 = 5.53, p = 
0.0123].  A Newman-Keuls’ test indicated that the adults had significantly higher 
levels of Gαo proteins than prepubertal rats (p < 0.01).   
D.  Gα protein levels in the hippocampus of prepubertal, peripubertal, and 
adults rats.  In the hippocampus, Gαo proteins, but not Gαi1, Gαi2, Gαi3, or Gαz 
proteins, increased with age.  Gαo proteins were present in the prepubertal 
hippocampus at about 26% adult levels and in the prepubertal PVN at about 58% 
adult levels (table 3).   
 The one-way ANOVA for Gαi1 indicated no significant main effect of age 
[F2,21 = 1.55, p = 0.237].  The one-way ANOVA for Gαi2 indicated no significant 
main effect of age [F2,19 = 0.25, p = 0.7805].  The one-way ANOVA for Gαi3 
indicated no significant main effect of age [F2,21 = 0.06, p = 0.9463].  The one-way 
ANOVA for Gαo indicated a significant main effect of age [F2,22 = 14.52, p = 
0.0001].  A Newman-Keuls’ test indicated that peripubertal rats had significantly 
more Gαo protein levels in the hippocampus than prepubertal rats (p < 0.05) and 
that adults had significantly higher levels of Gαo proteins than prepubertal rats 
and peripubertal rats (p < 0.01).  The one-way ANOVA for Gαz indicated no 
significant main effect of age [F2,22 = 0.16, p = 0.8506].   
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E. Gα protein levels in the frontal cortex of prepubertal, peripubertal, and adult 
rats.  In the frontal cortex, Gαo proteins, but not Gαi1, Gαi2, Gαi3, or Gαz 
proteins, increased with age.  Gαo proteins were present in the prepubertal 
frontal cortex at about 45% adult levels and in the prepubertal PVN at about 62% 
adult levels (table 4).   
 The one-way ANOVA for Gαi1 indicated no significant main effect of age 
[F2,20 = 0.15, p = 0.8652].  The one-way ANOVA for Gαi2 indicated no significant 
main effect of age [F2,21 = 0.47, p = 0.6326].  The one-way ANOVA for Gαi3 
indicated no significant main effect of age [F2,22 = 0.26, p = 0.7728].  The one-way 
ANOVA for Gαo indicated a significant main effect of age [F2,22 = 43.66, p < 
0.0001].  A Newman-Keuls’ test indicated that peripubertal rats had significantly 
more Gαo protein levels in the frontal cortex than prepubertal rats (p < 0.01) and 
that adults had significantly higher levels of Gαo proteins than prepubertal rats 
and peripubertal rats (p < 0.01).  The one-way ANOVA for Gαz indicated no 
significant main effect of age [F2,20 = 0.44, p = 0.6522]. 
2. Experiment 2:  Determination of the role of PTX-sensitive Gi/o proteins in 
5-HT1A receptor-mediated signaling in peripubertal hypothalamic PVN.  The 
objective of this experiment was to use pertussis toxin (PTX) as previously 
demonstrated in adult rats (Garcia et al., 2006) to ADP ribosylate and 
functionally inactivate Gαi/o proteins to determine if this subset of proteins 
plays a role in 5-HT1A receptor-induced increases of plasma levels of oxytocin 
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and ACTH and increases in pERK in the peripubertal PVN.    
A. Effects of PTX treatment on hypothalamic levels of Gα proteins.  Intra-PVN 
injection of PTX in peripubertal rats reduced hypothalamic levels of Gαi1 and 
Gαi2 (by 36% and 47%, respectively), increased levels of Gαo (by 96%), and had 
no effect on the levels of Gαi3 and Gαz (figure 16).   
 The Student’s t-test indicated that PTX treatment significantly decreased Gαi1 
proteins [t value = 4.03, p = 0.0007].  The Student’s t-test indicated that PTX 
treatment significantly decreased Gαi2 proteins [t value = 3.49, p = 0.0026].  The 
Student’s t-test for Gαi3 indicated no effect of PTX treatment [t value = 0.98, p = 
3411].  The Student’s t-test indicated that PTX treatment significantly increased 
Gαo proteins [t value = -3.86, p = 0.0012].  The Student’s t-test for Gαz indicated 
no effect of PTX treatment [t value = -1.06, p = 0.3030].   
B. Effects of PTX treatment on 5-HT1A receptor-mediated increases in plasma 
levels of oxytocin in the peripubertal rat.  (+)8-OH-DPAT increased plasma levels 
of oxytocin over 20 times that over saline injection.   Intra-PVN injection with 
PTX in peripubertal rats did not significantly reduce (+)8-OH-DPAT-induced 
increases in plasma oxytocin levels over saline injection (figure 17).   
The two-way ANOVA for oxytocin indicated no main effect of PTX treatment 
[F1,64 = 1.38, p = 0.2448] but a significant main effect of challenge injection [F1,64 = 
452.23, p < 0.0001].  There was no significant interaction between treatment and 
challenge injection [F1,64 = 2.47, p = 0.121].  A Newman-Keuls’ test indicated that 
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(+)8-OH-DPAT challenge significantly elevated plasma oxytocin levels over 
saline-challenged in both vehicle-treated and PTX-treated groups (p < 0.01).   
C. Effects of PTX treatment on 5-HT1A receptor-mediated increases in plasma 
levels of ACTH in the peripubertal rat.  (+)8-OH-DPAT increased plasma levels 
of ACTH roughly 10 times that over saline injection.   Intra-PVN injection with 
PTX in peripubertal rats slightly increased basal levels of ACTH but did not 
significantly reduce the (+)8-OH-DPAT-induced increase in ACTH over saline 
injection (figure 18).   
The two-way ANOVA for ACTH indicated no main effect of PTX treatment 
[F1,65 = 1.00, p = 0.3207] but a significant main effect of challenge injection [F1,65 = 
672.81, p < 0.0001].  There was no significant interaction between treatment and 
challenge injection [F1,65 = 3.76, p = 0.0571].  A Newman-Keuls’ test indicated that 
(+)8-OH-DPAT challenge significantly elevated plasma ACTH levels over saline-
challenged in both vehicle-treated and PTX-treated groups (p < 0.01).   
D. Effects of PTX treatment on basal and 5-HT1A receptor-mediated increases in 
levels of pERK in PVN.  Challenge with (+)8-OH-DPAT increased pERK in the 
PVN in the vehicle-treated group about 97% over saline challenge.  Intra-PVN 
injection with PTX in peripubertal rats increased basal (saline) levels of 
phosphorylated ERK in the PVN increased about 95%.  (+)8-OH-DPAT mediated 
a further increase of only 40% over its respective basal (figure 19).  Therefore, 
injection with PTX either attenuated 5-HT1A receptor-mediated phosphorylation 
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of ERK in the PVN or increased basal levels of pERK to a degree that further 
receptor stimulation did not induce a statistically significant change over basal. 
The two-way ANOVA for levels of phosphorylated ERK in the PVN 
indicated a main effect of PTX treatment [F1,28 = 4.36, p = 0.0471] and a significant 
main effect of challenge injection [F1,28 = 4.51, p = 0.0438].  There was no 
significant interaction between treatment and challenge injection [F1,28 = 0.06, p = 
0.8148].  Although the basal levels of phosphorylated ERK in the PVN increased 
by about 95% with PTX treatment, this did not reach statistical significance, nor 
did 5-HT1A receptor-stimulated elevations of pERK in vehicle-treated (↑97% over 
respective basal) and PTX-treated (↑40% over respective basal) groups.   
E. Effects of PTX on plasma levels of testosterone in the peripubertal rat.  Intra-
PVN injection with PTX or challenge injection with (+)8-OH-DPAT in 
peripubertal rats had no effect on the plasma levels of testosterone.  The average 
plasma testosterone levels of all treatment groups ranged between 15-28 ng/dl 
(figure 20).   
The two-way ANOVA for plasma testosterone levels indicated no significant 
main effect of PTX treatment [F1,37 = 1.11, p = 0.3005] and no significant main 
effect of challenge injection [F1,37 = 1.65, p = 0.2073].  There was also no 
significant interaction between PTX treatment and challenge injection [F1,37 = 0.13, 
p = 0.7165].   
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3. Experiment 3:  Determination of SSRI-induced regulation of 5-HT1A receptor-
coupled Gα proteins and 5-HT1A receptor-mediated ERK signaling in 
peripubertal hypothalamic PVN.  The objective of this experiment was to use 
chronic fluoxetine (FLX) injections (once per day for 7 or 14 days) to selectively 
reduce Gαi3 and Gαo proteins (as previously observed in Chen et al., 2006) to 
determine if these Gα proteins play a role in 5-HT1A receptor-mediated pERK 
responses in the peripubertal PVN.  In the peripubertal rat, 14 days of chronic 
FLX induced desensitization of 5-HT1A receptor-mediated increases of plasma 
levels of both oxytocin and ACTH in response to challenge with a dose of (+)8-
OH-DPAT (0.04 mg/kg) that is submaximal for 5-HT1A receptor-mediated 
neuroendocrine responses (Chen et al., 2006).  In the current experiment, we used 
a higher challenge dose of (+)8-OH-DPAT (0.20 mg/kg) in order to measure 
pERK responses in the PVN.  However, this dose is near the maximal dose 
necessary to elicit neuroendocrine responses (see chapter 3).  Therefore, we did 
not expect to observe a blunted neuroendocrine response in response to 
fluoxetine treatment at this dose of (+)8-OH-DPAT.   
A. Effect of chronic fluoxetine treatment of peripubertal rats on body weight 
gain.   Rats from all chronic treatment groups gained weight with age.  Chronic 
fluoxetine (7 and 14 days) treatment attenuated body weight gain in peripubertal 
rats, with significant effects emerging around treatment day 4 (figure 21).   
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For 7 days of treatment, a repeated measures ANOVA indicated that there 
was no significant main effect of treatment [F1,407 = 0.42, p = 0.5188] but a 
significant main effect of 7 days treatment time [F7,407 = 3433.34, p < 0.0001].  
There was also a significant interaction between treatment group and treatment 
time [F7,407 = 12.71, p < 0.0001].  A Newman-Keuls’ test indicated that fluoxetine 
significantly attenuated weight gain as compared to saline-treated rats on 
injection days 4 (p < 0.05) and 5-7 (p < 0.01).   
For 14 days of treatment, a repeated measures ANOVA indicated that there 
was no significant main effect of treatment [F1,719 = 2.02, p = 0.1624] but there was 
a significant main effect of 14 days treatment time [F14,719 = 4642.33, p < 0.0001].  
There was also a significant interaction between treatment group and treatment 
time [F14,719 = 4.06, p < 0.0001].  A Newman-Keuls’ test indicated that fluoxetine 
significantly attenuated weight gain as compared to saline-treated rats on 
injection days 5 (p < 0.05) and 7-14 (p < 0.01).   
B. Effect of chronic fluoxetine treatment of peripubertal rats on membrane-
associated and cytosol-associated Gα proteins in PVN.  In peripubertal rats, 
chronic fluoxetine treatment for either 7 days (figure 22) or 14 days (figure 23) 
did not reduce membrane-or cytosol-associated Gαi1, Gαi2, Gαi3, Gαo, or Gαz 
protein levels in the PVN.   
 The Student’s t-test for membrane-bound Gα proteins in the PVN after 7 days 
of saline or FLX injections indicated as follows:  no effect on Gαi1 proteins [t 
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value = -1.70, p = 0.1109], no effect on Gαi2 proteins [t value = -0.49, p = 0.6318], 
no effect on Gαi3 proteins [t value = 0.25, p = 0.8105], no effect on Gαo proteins [t 
value = -0.39, p = 0.7001], and no effect on Gαz proteins [t value = -0.34, p = 
0.7354].   
 The Student’s t-test for cytosol-associated Gα proteins in the PVN after 7 days 
of saline or FLX injections indicated as follows:  no effect on Gαi1 proteins [t 
value = -0.29, p = 0.7796], no effect on Gαi2 proteins [t value = -1.04, p = 0.598], 
no effect on Gαi3 proteins [t value = -0.53, p = 0.6069], no effect on Gαo proteins 
[t value = 0.36, p = 0.7215], and no effect on Gαz proteins [t value = 0.47, p = 
0.6472].   
 The Student’s t-test for membrane-bound Gα proteins in the PVN after 14 
days of saline or FLX injections indicated as follows:  no effect on Gαi1 proteins [t 
value = -1.46, p = 0.1669], no effect on Gαi2 proteins [t value = 1.11, p = 0.8952], 
no effect on Gαi3 proteins [t value = -0.11, p = 0.9157], no effect on Gαo proteins 
[t value = -1.00, p = 0.3337], and no effect on Gαz proteins [t value = 0.08, p = 
0.939].   
 The Student’s t-test for cytosol-associated Gα proteins in the PVN after 14 
days of saline or FLX injections indicated as follows:  no effect on Gαi1 proteins [t 
value = 3.11, p = 0.1576], no effect on Gαi2 proteins [t value = 1.22, p = 0.8015], no 
effect on Gαi3 proteins [t value = -0.94, p = 0.3642], no effect on Gαo proteins [t 
value = -0.01, p = 0.994], and no effect on Gαz proteins [t value = -0.79, p = 
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0.4403].  
C. Effects of chronic fluoxetine treatment of peripubertal rats on 5-HT1A 
receptor-mediated oxytocin responses.  (+)8-OH-DPAT increased plasma levels 
of oxytocin around 18 times compared with saline.  Chronic fluoxetine treatment 
for either 7 or 14 days did not alter (+)8-OH-DPAT (0.20 mg/kg) induced 
increases in plasma levels of oxytocin in the peripubertal rat (figure 24).   
The two-way ANOVA for oxytocin for 7 days of treatment indicated no main 
effect of FLX [F1,49 = 0.16, p = 0.6889] but a significant main effect of challenge 
injection [F1,49 = 475.22, p < 0.0001].  There was no significant interaction between 
treatment and challenge injection [F1,49 = 0.14, p = 0.7122].  A Newman-Keuls’ test 
indicated that (+)8-OH-DPAT challenge significantly elevated plasma oxytocin 
levels over saline-challenged in both chronic saline-treated and FLX-treated 
groups (p < 0.01).   
The two-way ANOVA for oxytocin for 14 days of treatment indicated no 
main effect of FLX [F1,46 = 1.57, p = 0.2167] but a significant main effect of 
challenge injection [F1,46 = 839.85, p < 0.0001].  There was no significant 
interaction between treatment and challenge injection [F1,46 = 0.92, p = 0.344].  A 
Newman-Keuls’ test indicated that (+)8-OH-DPAT challenge significantly 
elevated plasma oxytocin levels over saline-challenged in both chronic saline-
treated and FLX-treated groups (p < 0.01).   
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D. Effects of chronic fluoxetine treatment of peripubertal rats on 5-HT1A 
receptor-mediated ACTH responses.  (+)8-OH-DPAT increased plasma levels of 
ACTH around 8 times compared with saline.  Chronic fluoxetine treatment 
increased (+)8-OH-DPAT (0.20 mg/kg)-induced increases in plasma levels of 
ACTH in the peripubertal rat over its respective saline-treated/(+)8-OH-DPAT-
challenged group (15% over 7 day and 23% over 14 day) (figure 25).   
The two-way ANOVA for ACTH for 7 days of treatment indicated no main 
effect of FLX [F1,48 = 3.43, p = 0.0707] but a significant main effect of challenge 
injection [F1,48 = 385.02, p < 0.0001].  There was a significant interaction between 
treatment and challenge injection [F1,48 = 6.29, p = 0.0158].  A Newman-Keuls’ test 
indicated that (+)8-OH-DPAT challenge significantly elevated plasma ACTH 
levels over saline-challenged in both chronic saline-treated and FLX-treated 
groups (p < 0.01).  Additionally, (+)8-OH-DPAT challenge elicited a significantly 
higher ACTH response in those rats treated with 7 days of FLX over those 
treated chronically with saline (p < 0.05).   
The two-way ANOVA for ACTH for 14 days of treatment indicated a main 
effect of FLX [F1,44 = 20.40, p < 0.0001] and a significant main effect of challenge 
injection [F1,44 = 1084.84, p < 0.0001].  There was also a significant interaction 
between treatment and challenge injection [F1,44 = 25.61, p < 0.0001].  A Newman-
Keuls’ test indicated that (+)8-OH-DPAT challenge significantly elevated plasma 
ACTH levels over saline-challenged in both chronic saline-treated and FLX-
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treated groups (p < 0.01).  Again, (+)8-OH-DPAT challenge elicited a 
significantly higher ACTH response in those rats treated with 14 days of FLX 
over those treated chronically with saline (p < 0.01).   
E. Effects of chronic fluoxetine treatment of peripubertal rats on 5-HT1A 
receptor-mediated and basal levels of pERK in the PVN.  In the rats treated for 7 
days with fluoxetine, (+)8-OH-DPAT injection increased levels of pERK in the 
PVN (↑ 200% above basal).  (+)8-OH-DPAT challenge after treatment for 14 days 
with saline (PD 28-41) increased pERK in the PVN, although this response was 
not as robust (↑ ~50%).  For both 7 day and 14 day chronic treatments, FLX had 
no significant effect on (+)8-OH-DPAT-induced increases in pERK, although 
basal levels were increased (↑ ~80%) with 7 day treatment (figure 26).   
The two-way ANOVA for levels of phosphorylated ERK in the PVN 
indicated no significant main effect of 7 days of FLX treatment [F1,23 = 1.75, p = 
0.2011] but a significant main effect of challenge injection [F1,23 = 31.30, p < 
0.0001].  There was no significant interaction between treatment and challenge 
injection [F1,23 = 1.48, p = 0.2373].  The Newman-Keuls’ test indicated that the 
(+)8-OH-DPAT challenge significantly elevated pERK in the PVN over the 
saline-challenged group in both chronic saline-treated (p < 0.01) and chronic 
FLX-treated (p < 0.05).  Although the basal levels of phosphorylated ERK in the 
PVN increased by about 79% with FLX treatment, this did not reach statistical 
significance.    
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The two-way ANOVA for levels of phosphorylated ERK in the PVN 
indicated no significant main effect of 14 days of FLX treatment [F1,23 = 0.76, p = 
0.3934] but a significant main effect of challenge injection [F1,23 = 5.19, p = 0.0338].  
There was no significant interaction between treatment and challenge injection 
[F1,23 = 0.28, p = 0.6047].  Although the basal levels of phosphorylated ERK in the 
PVN decreased by about 31% with chronic fluoxetine treatment, this did not 
reach statistical significance, nor did 5-HT1A receptor-stimulated elevations of 
pERK in chronic saline-treated (↑39%) and chronic FLX-treated (↑91%) groups.   
F. Effect of chronic fluoxetine of peripubertal rats on plasma levels of 
testosterone.  Neither 7 nor 14 days of chronic FLX treatment of peripubertal rats 
had any effect on the plasma levels of testosterone.  All treatment groups had 
average plasma testosterone levels between 50-75 ng/dl (figure 27).   
The two-way ANOVA for plasma testosterone levels indicated no significant 
main effect of treatment time [F1,90 = 1.12, p = 0.2918] and no significant main 
effect of treatment [F1,90 = 0.04, p = 0.8415].  There was also no significant 
interaction between treatment time and treatment [F1,90 = 1.24, p = 0.2679].   
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Figure 13. Rat body weights in prepubertal (PD 28), peripubertal (PD 42), and adult (PD > 70) 
rats.  ** indicates significant difference (p < 0.01) from the prepubertal age group; ## indicates 
significant difference (p < 0.01) from the peripubertal age group (one-way ANOVA and 
Newman-Keuls multiple-range test). N = 10 per group. 
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Figure 14. Plasma testosterone levels in prepubertal (PD 28), peripubertal (PD 42), and adult (PD 
> 70) rats.  *, ** indicates significant difference (p < 0.05 and p < 0.01, respectively) from the 
prepubertal age group; ## indicates significant difference (p < 0.01) from the peripubertal age 
group (one-way ANOVA and Newman-Keuls multiple-range test). N = 10 per group. 
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Figure 15. PVN levels of membrane-associated (A) Gαi1, (B) Gαi2, (C) Gαi3, (D) Gαz, and (E) 
Gαo proteins in prepubertal (PD 28), peripubertal (PD 42), and adult (PD > 70) rats.  ** indicates 
significant difference (p < 0.01) from the prepubertal age group (one-way ANOVA and Newman-
Keuls multiple-range test). N = 5-8 per group. (F) Representative western blots of Gi1, Gi2, 
Gi3/Go, and Gz from the PVN of prepubertal, peripubertal, and adult rats. 
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Gα proteins in PVN 
 Prepubertal Peripubertal Adult 
 Average ± SEM N Average ± SEM N Average ± SEM N 
Gαi1 97.2 ± 12.1 8 105.5 ± 14.8 8 102.9 ± 9.2 8 
Gαi2 79.9 ± 9.1 8 78.1 ± 9.2 8 96.2 ± 12.2 7 
Gαi3 117.5 ± 16.5 7 123.7 ± 25.0 5 113.9 ± 17.4 8 
Gαo 43.7 ±  11.6 8 76.2 ± 14.4 7 111.4 ± 17.4** 8 
Gαz 96.4 ± 17.2 6 97.9 ± 22.0 8 126.3 ± 13.5 6 
 
Table 2.  PVN levels of membrane-associated Gαi1, Gαi2, Gαi3, Gαo, and Gαz proteins in 
prepubertal (PD 28), peripubertal (PD 42), and adult (PD > 70) rats.  ** indicates significant 
difference (p < 0.01) from the prepubertal (PD 28) age group (one-way ANOVA and Newman-
Keuls multiple-range test). 
 
Gα proteins in Hippocampus 
 Prepubertal Peripubertal Adult 
 Average ± SEM N Average ± SEM N Average ± SEM N 
Gαi1 77.6 ± 11.4 7 102.7 ± 12.1 7 107.7 ± 14.2 8 
Gαi2 80.5 ± 14.6 8 91.3 ± 16.8 6 93.6 ± 10.3 6 
Gαi3 95.1 ± 11.0 7 95.7 ± 17.9 7 100.4 ± 7.7 8 
Gαo 25.7 ±  3.3 7 56.7 ± 11.6* 8 97.3 ± 9.8**,## 8 
Gαz 94.1 ± 15.9 8 89.3 ± 20.9 8 101.9 ± 9.3 8 
 
Table 3.  Hippocampal levels of membrane-associated Gαi1, Gαi2, Gαi3, Gαo, and Gαz proteins 
in prepubertal (PD 28), peripubertal (PD 42), and adult (PD > 70) rats.  *, ** indicates significant 
difference (p< 0.05 and p < 0.01, respectively) from the prepubertal (PD 28) age group; ## 
indicates significant difference (p < 0.01) from the peripubertal age group (PD 42) (one-way 
ANOVA and Newman-Keuls multiple-range test). 
Gα proteins in Frontal Cortex 
 Prepubertal Peripubertal Adult 
 Average ± SEM N Average ± SEM N Average ± SEM N 
Gαi1 106.3 ± 18.6 6 96.0 ± 13.4 7 101.1 ± 7.8 8 
Gαi2 88.4 ± 19.9 7 83.8 ± 9.6 7 102.1 ± 11.7 8 
Gαi3 104.8 ± 7.3 7 97.8 ± 6.9 8 102.5 ± 6.9 8 
Gαo 44.9 ± 2.9 7 62.3 ± 4.4** 8 100.3 ± 4.9 **,## 8 
Gαz 102.0 ± 11.5 6 114.2 ± 17.6 7 97.1 ± 6.5 8 
  
Table 4.  Frontal cortex levels of membrane-associated Gαi1, Gαi2, Gαi3, Gαo, and Gαz proteins 
in prepubertal (PD 28), peripubertal (PD 42), and adult (PD > 70) rats.  ** indicates significant 
difference (p < 0.01) from the prepubertal (PD 28) age group; ## indicates significant difference (p 
< 0.01) from the peripubertal age group (PD 42) (one-way ANOVA and Newman-Keuls multiple-
range test). 
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Figure 16.  (A) The effects of intra-PVN injection with either vehicle or pertussis toxin (PTX) on 
hypothalamic levels of Gαi1, Gαi2, Giα3, Gαo, and Gαz proteins. ** indicates significant 
difference (p < 0.01) from the respective vehicle-treated group (Student’s t-test). N = 9-12 per 
group. (B) Representative western blots of Gi1, Gi2, Gi3/Go, and Gz from the 
hypothalamus of peripubertal rats 72 hours after intra-PVN injection of vehicle or PTX. 
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Figure 17. The effects of intra-PVN injection with either vehicle or pertussis toxin (PTX) on basal 
and 5-HT1A receptor-mediated increases in plasma oxytocin. ** indicates significant difference (p 
< 0.01) from the respective saline-challenged group (two-way ANOVA and Newman-Keuls 
multiple-range test). N = 10-23 per group. 
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Figure 18.  The effects of intra-PVN injection with either vehicle or pertussis toxin (PTX) on basal 
and 5-HT1A receptor-mediated increases in plasma ACTH.  ** indicates significant difference (p < 
0.01) from the respective saline-challenged group (two-way ANOVA and Newman-Keuls 
multiple-range test). N = 11-23 per group. 
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Figure 19. (A) The effects of intra-PVN injection with either vehicle or pertussis toxin (PTX) on 
basal and 5-HT1A receptor-mediated increases in pERK in the PVN (two-way ANOVA and 
Newman-Keuls multiple-range test). N = 5-9 per group. (B) Representative western blot of pERK 
(above) and ERK (below) from the PVN of peripubertal rats given an intra-PVN injection of 
either vehicle or PTX and, 72 hours later, given a challenge injection of either saline or (+)8-OH-
DPAT.   
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Figure 20. Plasma testosterone levels were not significantly altered by pertussis toxin (PTX) 
treatment or acute injection of (+)8-OH-DPAT (two-way ANOVA). N = 8-10 per group. 
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Figure 21. The effects of (A) 7 day and (B) 14 day treatment with either saline or fluoxetine on rat 
body weight.  *, ** indicates significant difference (p < 0.05 and p < 0.01, respectively) from the 
saline-treated group (repeated measures ANOVA and Newman-Keuls multiple-range test). N = 
24-27 per group. 
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Figure 22.  The effects of 7 day treatment with either saline or fluoxetine on (A) membrane-
associated and (B) cytosol-associated levels of Gαi1, Gαi2, Gαi3, Gαo, and Gαz proteins 
(Student’s t-test). N = 6-8 per group. (C) Representative western blots of membrane-associated 
(left) and cytosol-associated (right) Gi1, Gi2, Gi3/Go, and Gz from the PVN of peripubertal 
rats treated with either saline or FLX for 7 days. 
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Figure 23. The effects of 14 day treatment with either saline or fluoxetine on (A) membrane-
associated and (B) cytosol-associated levels of Gαi1, Gαi2, Gαi3, Gαo, and Gαz proteins 
(Student’s t-test). N = 7-8 per group. (C) Representative western blots of membrane-associated 
(left) and cytosol-associated (right) Gi1, Gi2, Gi3/Go, and Gz from the PVN of peripubertal 
rats treated with either saline or FLX for 14 days. 
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Figure 24. The effects of (A) 7 day and (B) 14 day treatment with saline or fluoxetine on basal and 
5-HT1A receptor-mediated increases in plasma oxytocin.  ** indicates significant difference (p < 
0.01) from the respective saline-challenged group (two-way ANOVA and Newman-Keuls 
multiple-range test). N = 8-18 per group. 
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Figure 25. The effects of (A) 7 day and (B) 14 day treatment with saline or fluoxetine on basal and 
5-HT1A receptor-mediated increases in plasma ACTH.  ** indicates significant difference (p < 0.01) 
from the respective saline-challenged group, ## indicates significant difference (p < 0.01) from the 
saline-treated/(+)8-OH-DPAT-challenged group (two-way ANOVA and Newman-Keuls 
multiple-range test). N = 8-18 per group. 
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Figure 26. The effects of (A) 7 day and (B) 14 day treatment with saline or fluoxetine on basal and 
5-HT1A receptor-mediated increases in levels of pERK in the PVN.  *, ** indicates significant 
difference (p < 0.05 and p < 0.01, respectively) from the respective saline-challenged group). N = 
6 per group. (C) Representative western blot of pERK (above) and ERK (below) from the PVN of 
rats treated with Sal or FLX and subsequently challenged with either saline or (+)8-OH-DPAT.  
7D treatment is on the left and 14D treatment is on the right. 
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Figure 27. Plasma testosterone levels were not significantly altered by treatment with fluoxetine 
for either 7 or 14 days (two-way ANOVA). N = 22-24 per group. 
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DISCUSSION 
 5-HT1A receptors on hypothalamic neurons stimulate the release of various 
hormones and contribute to the serotonergic activation of the hypothalamic-
pituitary-adrenal (HPA) axis (Sullivan-Hanley and Van de Kar 2003).  5-HT1A 
receptors in the hypothalamus also activate the mitogen-activated protein kinase 
(MAPK) ERK pathway (Sullivan et al., 2005; Crane et al., 2007).  However, most 
in vivo studies on 5-HT1A receptor signaling in the hypothalamic PVN have 
focused on adult animal models.  In the adult rat PVN, 5-HT1A receptors mediate 
increases in plasma levels of oxytocin and ACTH via pertussis toxin (PTX)-
insensitive Gαz proteins, whereas 5-HT1A receptor-mediated increases in 
activated ERK (pERK) in the PVN occurs via one or more subtypes of PTX-
sensitive Gα proteins (i.e., Gαi1,2,3 and Gαo proteins).  However, prior to sexual 
maturation, it is not known if these respective signaling pathways are mediated 
by the dichotomy of G protein subunits that can be identified as PTX-sensitive 
vs. PTX-insensitive.  Differences in the density or in the regulation of Gα protein 
subtypes may underlie any observed developmental differences between 
peripubertal and adult 5-HT1A receptor signaling and receptor desensitization in 
the PVN.  Therefore, in the present studies, we investigated the density, 
signaling, and regulation of Gα proteins that have the capacity to couple 5-HT1A 
receptors in the peripubertal rat PVN.   
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 With regards to density, Gα protein levels vary in early postnatal 
development in several brain regions.  Gαi1, Gαi2, and Gα3 proteins reach adult 
levels around postnatal day 18 in the cortex, thalamus, and hippocampus, 
whereas Gαo proteins continue to increase past early postnatal development in 
these regions (Ihnatovych et al., 2002).  However, until the present dissertation 
studies, no studies had examined developmental regulation of Gαz in any brain 
region, or Gα protein levels in the immature hypothalamus.  The current data 
revealed that, consistent with the findings in other brain regions (Ihnatovych et 
al., 2002), Gαo proteins increased with age.  Gαo was present at lower levels in 
prepubertal (PD 28) and peripubertal (PD 42) PVN, hippocampus, and frontal 
cortex compared to adult.  Also consistent with the literature, levels of Gi1, Gi2, 
and Gi3 in both prepubertal and peripubertal brain were similar to levels 
observed in adult brain.  We also determined that Gαz levels in the prepubertal 
and peripubertal PVN, hippocampus, and frontal cortex were comparable to 
adult.  Global changes in Gαo, but no other Gα protein, may be important with 
regards to signaling because a relatively lower density of Gαo proteins may lead 
to a decrease in Gαo coupling to the 5-HT1A receptor in the hypothalamus and 
other brain regions of younger aged rats as compared to that previously 
established in the adult rat brain (Mannoury la Cour et al., 2006).  Therefore, Gαo 
proteins may be prevented from performing its specific signaling function.  
However, multiple Gα proteins may subserve the same function in 5-HT1A 
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receptor-mediated signaling pathways in the peripubertal brain (i.e., redundancy 
in Gα mediated pathways); therefore, a lower level of Gαo proteins in younger 
developmental groups may not necessarily alter 5-HT1A receptor signaling if 
other Gα protein subtypes compensate for the lack of Gαo proteins.  The 
limitation of the western blotting technique used in this experiment is that 
relative levels of Gα proteins cannot be compared to one another.  Comparisons 
can only be made of the levels of a single Gα protein at different ages.  Another 
possibility for developmental increases in Gαo is that the other Gα proteins 
(Gαi1, Gαi2, Gαi3, and Gαz) may be able to perform a wider array of functions in 
the pre-adult brain, and the “pruning” of functions as the animal ages only then 
necessitates an increase in Gαo.  It also should be noted that the cytosol-
associated proteins were not examined in this study.  The increase in membrane-
associated Gαo protein levels may be due to a redistribution of Gαo proteins 
from cytosol to membrane as the animal ages rather than a total increase in Gαo.  
However, if Gαo proteins are redistributed from cytosol to membrane in the 
respective brain regions after sexual maturation, then it would corroborate the 
evidence indicating the unique regulation of Gαo proteins in the developing 
brain.   
 In addition to developmental regulation of Gα protein levels, the present 
studies also indicated that Gα proteins exhibit unique responses to drug 
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treatments.  Using a PTX treatment paradigm that had previously been shown to 
be effective in adult rats, we investigated, in the peripubertal PVN, the role of 
PTX-sensitive Gαi/o proteins in 5-HT1A receptor signaling of neuroendocrine 
responses and phosphorylation of ERK.  In adult rats, intra-PVN injection of PTX 
reduced Gαi1, Gαi2, Gαi3, and Gαo, but not Gαz in the hypothalamus and 
inhibited 5-HT1A receptor-mediated phosphorylation of ERK in the PVN (Garcia 
et al., 2006).  Therefore, PTX had been shown to be a useful tool to differentiate 
signaling by these respective subsets of G proteins (i.e., PTX-sensitive or 
insensitive).  The current data indicate that, in peripubertal rats, an intra-PVN 
injection of PTX did not reduce all subsets of Gαi/o proteins in the 
hypothalamus (as in the adult) but only reduced Gαi1 and Gαi2, increased Gαo 
protein levels, and did not change Gαi3 and Gαz protein levels in the 
hypothalamus.  Therefore, this study revealed that G proteins in the 
peripubertal hypothalamus may be subject to unique regulation by PTX that 
prevents reductions in Gi3 and increases Go.  However, although Gα protein 
levels were measured at the level of the hypothalamus and not the PVN, there 
may have been changes in specific Gα proteins at the level at the PVN that were 
masked by changes in the whole hypothalamus.  However, considering that 
there were no significant reductions in 5-HT1A receptor-mediated 
neuroendocrine responses, these data suggest that Gαi3, Gαo, and/or Gαz could 
potentially mediate 5-HT1A receptor stimulation of hormone responses in the 
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PVN of peripubertal rats.  We cannot rule out Gαi3 and Gαo proteins in 
mediating the 5-HT1A receptor activation of ERK considering that there was no 
clear effect of PTX on (+)8-OH-DPAT-induced increases in pERK in the PVN, 
due to the elevation in basal levels of pERK.  However, PTX-induced increases in 
Gαo may be responsible for the elevations observed in basal levels of activated 
ERK in the PVN.  A difference in the Gαi3/Gαo protein structure or binding 
ability could be preventing ADP-ribosylation in the peripubertal rat brain.  In 
peripubertal prostate tissue, the ability of PTX to ADP-ribosylate Gi/o proteins 
was reduced compared to adults, which may be attributed to reduced binding 
ability of the G proteins to guanosine triphosphate (GTP) in the peripubertal rats 
(Chen et al., 1995).  Another possibility is that there is a difference in post-
translational modifications of the proteins.  Fatty acylation of Gαo has been 
observed in the cortex of postnatal rats (Li et al., 1995); however, a search of the 
literature suggests there has not been much other research on Gα protein post-
translational modifications in the developing brain.  Another possibility for the 
differences observed in the peripubertal hypothalamus with PTX treatment is 
that a 72-hour incubation time is not sufficient (or is perhaps too short) to 
functionally inactivate Gαi3 and Gαo proteins.  It could be that these proteins are 
more resilient to ADP-ribosylation and begin to reverse the effect of the toxin or 
are replenished by transcription and translation of their respective genes before 
the end of the 3-day time period.  Similarly, Gαi3 and Gαo may be compensating 
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for the loss of Gαi1 and Gαi2 proteins.  Compensatory increases in levels of Gαo 
have been observed with knockdown of Gα1-3 proteins in vitro (Krumins and 
Gilman, 2006).  There may also be developmental differences in the effects of PTX.  
In the literature, there has been only one other study comparing the effects of 
PTX in peripubertal vs. adult brain:  using adult rat brain membranes in vitro, 
GABAB receptor/G protein binding was reduced upon incubation with PTX in 
cortex, hippocampus, and cerebellum but not the striatum.  However, when PTX 
was incubated with peripubertal rat brain membranes, GABAB receptor/G 
protein binding was reduced in striatum and hippocampus but not cortex or 
cerebellum (Knott et al., 1993).  In sum, Gα proteins (namely Gαi3 and Gαo) may 
not have functionally matured in the peripubertal brain and may possibly impact 
the signaling of the 5-HT1A receptor in the PVN and other regions in the brain.  
To determine the specific Gα protein contribution to 5-HT1A receptor-mediated 
signaling pathways in the peripubertal PVN, a more selective method is 
necessary, such as adenoviral-delivered siRNA for Gαi3 and Gαo proteins.   
 In the pertussis toxin experiment, we also observed a trend towards lower 
plasma levels of testosterone in all treatment groups, which approximated 
prepubertal levels as determined in experiment 1.  This may be due to additional 
stress effects of surgery and recovery that all rats from the experiment 
experienced.  Increased activity of the HPA axis via intracerebroventricular 
injections of CRH or a CRH receptor agonist was shown to delay the onset of 
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puberty in female rats (Kinsey-Jones et al., 2010).  If CRH signaling also plays a 
role in pubertal timing in male rats, then additional stress may account for this 
slight reduction in testosterone levels in the cannulated rats.  
  In a previous study conducted in peripubertal rats, chronic fluoxetine (FLX) 
injections (once per day for 14 days) reduced 5-HT1A receptor-mediated 
neuroendocrine responses and selectively reduced Gαi3 and Gαo proteins (Chen 
et al., 2006); however, any effects of FLX-induced reductions of Gαi3 and Gαo on 
5-HT1A receptor-mediated ERK activation were not examined.  Therefore, 
peripubertal rats were given chronic fluoxetine (7 and 14 days) to determine the 
role of these proteins in 5-HT1A receptor-mediated phosphorylation of ERK in the 
PVN.  Since FLX-induced desensitization of 5-HT1A receptor-mediated 
neuroendocrine responses had already been established in peripubertal rats, the 
dose of the challenge drug, (+)8-OH-DPAT, was set at 0.20 mg/kg.  This dose is 
submaximal for the 5-HT1A receptor-mediated phosphorylation of ERK but near 
the maximum dose necessary for 5-HT1A receptor-mediated neuroendocrine 
responses (Chapter 3).  Therefore, we did not expect to observe a desensitization 
of either oxytocin or ACTH hormone responses. Although neither 7 nor 14 days 
of FLX had any effect on (+)8-OH-DPAT (0.20 mg/kg)-induced increases in 
plasma levels of oxytocin, this combination of either 7 or 14 days FLX treatment 
with 0.20 mg/kg (+)8-OH-DPAT challenge may have elicited a supersensitive 
plasma ACTH response.  Since this supersensitivity was not observed in the 
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plasma oxytocin responses, FLX may be inducing changes specific to the CRH 
receptor system, downstream of 5-HT1A receptor activation on CRH-containing 
cells in the PVN.  FLX treatment has shown to increase CRH mRNA in the PVN 
(Jorgensen et al., 2002), which could potentially lead to increased release of CRH 
from the PVN with a maximal dose of the 5-HT1A receptor agonist (+)8-OH-
DPAT.  With regards to the effects of chronic FLX on ERK activation, neither 7 
nor 14 days of FLX had any significant effect on either basal or 5-HT1A receptor-
mediated phosphorylation of ERK in the PVN.  However, in contrast to the 
preliminary study that indicated that chronic fluoxetine reduces Gαi3 and Gαo in 
peripubertal hypothalamus (Chen et al., 2006), the current study revealed that 
there were no significant changes in any Gα protein subtype (cytosol-associated 
or membrane-associated) in the PVN with chronic FLX treatment.  However, we 
did replicate the finding that Gαz proteins were not reduced with chronic 
fluoxetine in the peripubertal hypothalamus.  Considering that, in adults, Gαz is 
the exclusive Gα protein mediator of 5-HT1A receptor-mediated neuroendocrine 
responses and the only Gα protein that is decreased in the PVN upon chronic 
FLX treatment, the results from this study indicate very strongly that, in the 
peripubertal hypothalamus, either Gαz is not the exclusive mediator of 5-HT1A 
receptor-mediated neuroendocrine responses or FLX-induced desensitization of 
neuroendocrine responses occur via a different mechanism than that operative in 
the adult PVN.  However, there is also the possibility that the activity, but not 
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protein level, of Gz proteins are being reduced with chronic FLX treatment.  
Phosphorylation of Gz, which has been observed in other systems (Carlson et 
al., 1989; Lounsbury et al., 1991), could potentially block its association with Gβγ 
proteins (Fields and Casey 1995) and subsequent activation by 5-HT1A proteins.  
If chronic FLX did induce a phosphorylation of Gz rather than a reduction in 
protein levels (as observed in the adult hypothalamus), then Gz proteins could 
still play a role in 5-HT1A receptor-mediated responses in the peripubertal PVN. 
 Chronic FLX attenuates weight gain in both adult and peripubertal rats.  The 
findings from the current study are in agreement with the current literature that 
suggests that peripubertal rats are more resilient to the attenuation in weight 
gain that is prominent in adult rats treated with chronic fluoxetine (Iniguez et al., 
2010; Homberg et al., 2011), since the average body weight of peripubertal rats 
treated for 14 days saline vs. FLX differed by only about 2%.  Published studies 
in adult rats indicate that the average body weight of rats treated for 14 days of 
saline vs. FLX differ between 5-10% (Raap et al., 1999; Homberg et al., 2010). 
 Not only do 5-HT1A receptors signal to phosphorylate the protein kinase ERK 
in the PVN via a different time-course than that previously established in adults 
(see Chapter 3 and Crane et al., 2007), but we also have established that the Gα 
proteins associated with this receptor are subject to both developmental and 
drug-induced regulation that differ from mechanisms previously established in 
the adult PVN.  These findings have far-reaching implications for the global 
121 
 
signaling of the 5-HT1A receptor in the peripubertal PVN and also for the 
receptor desensitization and regulation induced by antidepressants and other 
serotonergic modulators.  
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CHAPTER 5 
 
IMMUNOHISTOCHEMICAL DETECTION OF OXYTOCIN AND SEROTONIN 
1A RECEPTOR-MEDIATED INCREASES IN PHOSPHORYLATED 
EXTRACELLULAR SIGNAL-REGULATED KINASE ARE LOCALIZED TO 
DIFFERENT REGIONS OF THE PERIPUBERTAL HYPOTHALAMIC 
PARAVENTRICULAR NUCLEUS. 
 
ABSTRACT 
 
 Serotonin 1A (5-HT1A) receptor activation in the hypothalamic 
paraventricular nucleus (PVN) stimulates increases in plasma levels of oxytocin 
and adrenocorticotropic hormone (ACTH) and also increases levels of activated 
extracellular signal-regulated kinase (ERK).  In adult rat PVN, 5-HT1A receptors 
are localized on oxytocin-containing and CRH-containing cells (Zhang et al., 
2004); however, the specific cellular localization of 5-HT1A receptor-mediated 
activation of ERK in these neuroendocrine cells has not been determined.   
 Blockade of mitogen activated protein kinase (MAPK) kinase (the upstream 
activating kinase for ERK) abolishes SSRI-induced desensitization of 5-HT1A 
receptor-mediated increases of plasma oxytocin responses (Jia et al., 2007).  
Therefore, it is possible that 5-HT1A receptors can activate ERK in oxytocin-
containing cells in the PVN.  However, other studies indicating low levels of ERK 
phosphorylation in oxytocin-containing cells in adult brain (Blume et al., 2009; 
Wang et al., 2006) suggest otherwise.  Previous studies in this dissertation project 
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demonstrated that 5-HT1A receptor activation can also stimulate increases in 
plasma hormone responses (oxytocin and ACTH) and phosphorylation of ERK in 
the peripubertal PVN.  However, these studies did not determine the cellular 
localization of receptor activated ERK in the hypothalamus of peripubertal rats.  
Therefore, the objective of the current study was to determine, at the cellular 
level, if 5-HT1A receptor-mediated pERK responses can be detected in oxytocin-
containing cells in the peripubertal hypothalamic PVN.  In the present study, 
peripubertal (PD 42) rats received an injection of saline or the 5-HT1A receptor 
agonist (+)8-OH-DPAT (0.20 mg/kg) 10 minutes prior to sacrifice.  Injection with 
(+)8-OH-DPAT produced marked increases in pERK immunoreactivity in the 
PVN in peripubertal PVN; however, we did not find any evidence that pERK-
positive cells were also immunoreactive for oxytocin.  Preliminary data 
presented here suggest that, in the adult brain, oxytocin and 5-HT1A receptor-
mediated pERK were also localized to distinct regions of the PVN.  These 
findings are consistent with previously published data that suggest that pERK 
stimulation is minimal in oxytocin-containing cells.   
 In the adult rat hypothalamic PVN, an intact ERK signaling pathway is 
necessary for SSRI-induced desensitization of 5-HT1A receptor-mediated oxytocin 
responses.  The data from the present studies suggest that SSRI-induced 
desensitization of 5-HT1A receptor-mediated oxytocin responses occur via ERK 
activation on non-oxytocin-containing cells and involve transynaptic vs. 
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intracellular mechanisms.  This indicates that 5-HT1A receptor-mediated ERK 
signaling may play a more widespread role in PVN control, since it could 
potentially affect the function of cells outside of the small population of cells 
where ERK is directly activated.         
INTRODUCTION 
 The paraventricular nucleus (PVN) is one of several cell groups of the medial 
hypothalamus and is a center for complex neuroendocrine and autonomic 
control of the CNS and periphery (Swanson and Sawchenko 1980; Sawchenko 
and Swanson 1983).  The PVN consists of both magnocellular and parvicellular 
divisions (Swanson and Kuypers 1980).  The magnocellular region contains 
many oxytocin cells, whereas the parvicellular region (medial portion) includes 
CRH-containing cells as well as some oxytocin-containing cells.  Although there 
are distinct populations of oxytocin-containing and CRH-containing cells within 
the PVN, oxytocin and CRH do moderately colocalize in a discrete anterior part 
of the magnocellular division of the nucleus (Sawchenko et al., 1984).   
 In adult rat PVN, 5-HT1A receptors localize to both oxytocin-containing and 
CRH-containing cell types (Zhang et al., 2004).  5-HT1A receptor activation 
increases levels of phosphorylated ERK at the level of the whole PVN in the 
adult rat (Crane et al., 2007; Sullivan et al., 2005) and peripubertal rat (Chapter 3); 
however, the cellular localization of 5-HT1A receptor-mediated ERK activation in 
the hypothalamic PVN has not been determined in any age group.  In CRH-
125 
 
containing cells in the adult rat PVN, increases in pERK have been observed 
upon stimulation with (1) norepinephrine (via activation of α1 receptors; Khan et 
al., 2007) and (2) prolactin (Blume et al., 2009).  Since blockade of MAPK kinase 
(the activating kinase for ERK) abolishes SSRI-induced desensitization of 5-HT1A 
receptor-mediated increases in ACTH responses (Jia et al., 2007), increases in 
pERK mediated by 5-HT1A receptor activation are most likely contained in CRH-
containing cells.  MAPK kinase inhibition also abolishes SSRI-induced 
desensitization of 5-HT1A receptor-mediated oxytocin responses; therefore, it is 
also likely that 5-HT1A receptors can activate ERK in oxytocin-containing cells in 
the PVN.  However, a study from the literature reveals that, while around 70% of 
CRH-containing cells also contained phosphorylated ERK, only about 15% of 
oxytocin-containing cells contained prolactin-stimulated pERK (Blume et al., 
2009).  A low level of pERK stimulation in oxytocin-containing cells (around 10%) 
was also demonstrated upon injection with the cytokine interleukin 1β (IL-1β; 
Wang et al., 2006).  Together, these data suggest that oxytocin-containing cells 
contain low levels of MAPK activity. 
 5-HT1A receptor activation results in a rapid and prolonged elevation of 
phosphorylated ERK at the level of the whole PVN in the peripubertal brain 
(Chapter 3); however, no studies have investigated if 5-HT1A receptor-activated 
ERK is localized to specific neuroendocrine cells in the PVN of peripubertal rats.  
Therefore, the purpose of the current study was to determine, at the cellular level, 
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if 5-HT1A receptor-mediated increases in pERK can be detected in oxytocin-
containing cells in the peripubertal hypothalamic PVN.  Specifically, the 
objective was to determine (1) if (+)8-OH-DPAT induces a measurable or 
significant increase in phosphorylated ERK in peripubertal PVN using 
immunohistochemistry and, if so, (2) if 5-HT1A receptor-mediated 
phosphorylation of ERK is localized to oxytocin-containing cells in the PVN.  We 
also performed preliminary studies to determine the localization of 5-HT1A 
receptor-stimulated pERK immunoreactivity in oxytocin-containing cells in the 
adult PVN.  In addition, plasma oxytocin and ACTH concentrations were 
determined to confirm activation of 5-HT1A receptor-mediated responses.  
Plasma levels of testosterone were also determined to ensure that the stage of 
sexual maturation were not different between different challenge injection 
groups. 
MATERIALS AND EXPERIMENTAL PROCEDURES (for detailed methods, 
see Chapter 7) 
Animals.  Peripubertal (100-125 g; postnatal day 35) and adult (275-300 g; 
postnatal day 63) male Sprague-Dawley rats were purchased from Harlan 
(Indianapolis, IN).  The determination of post-natal day zero (day of birth) was 
carried out by the supplier.   
Drugs.  (+)-8-Hydroxy-2-(di-n-propylamino)tetralin hydrobromide [(+)8-OH-
DPAT] was purchased from Tocris Cookson Inc. (Ellisville, MO) and was 
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dissolved in saline (0.9% NaCl).  (+)8-OH-DPAT was injected at a volume of 1 
ml/kg and was freshly prepared immediately prior to the injections.  
 Experiment 1:  Localization of 5-HT1A receptor-mediated activation of ERK 
in the peripubertal and adult PVN.  Peripubertal and adult animals were 
assigned randomly to treatment groups and were handled for at least 3 days 
before injections to minimize stress.  On postnatal day (PD) 42 for peripubertal 
animals and PD 70 for adult animals, the rats were given an injection of saline (1 
ml/kg, s.c.) or (+)8-OH-DPAT (0.20 mg/kg, s.c.) with sacrifice occurring 10 
minutes after injection for peripubertal rats (the optimal sacrifice time for 
observing elevations in pERK in peripubertal PVN with western blotting, see 
Chapter 3) or 5 minutes after injection for adult animals (Crane et al., 2007).  As 
an additional control, two peripubertal animals were also handled for 3 days but 
were not injected.  The trunk blood was collected in tubes and prepared for 
subsequent determination of plasma levels of oxytocin, ACTH, and testosterone.  
Brains were harvested within one minute of the decapitation and were preserved 
using the immersion fixation procedure (adapted from Khan and Watts, 2004). 
RESULTS 
1.  Experiment 1:  Localization of 5-HT1A receptor-mediated activation of ERK in 
the PVN.  The objectives of this experiment were to determine (1) if (+)8-OH-
DPAT induces phosphorylation of ERK in the PVN of peripubertal rats using 
immunofluorescence and, if so, (2) if 5-HT1A receptor-mediated phosphorylation 
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of ERK is localized to oxytocin-containing cells in the PVN.  We also performed 
preliminary studies to determine the localization of 5-HT1A receptor-stimulated 
pERK immunoreactivity in oxytocin-containing cells in the adult PVN.   
A.  Immunoreactivity for 5-HT1A receptor-mediated phosphorylation of ERK did 
not localize to oxytocin-immunoreactive cells in the peripubertal hypothalamic 
PVN.  As shown in figure 28, injection with (+)8-OH-DPAT increased pERK 
immunoreactivity in the peripubertal PVN; however, none of these cells were 
also immunoreactive for oxytocin.  This finding was also confirmed with higher 
powered-magnification using confocal imaging (figure 29).  The oxytocin-
containing cells concentrate more laterally in magnocellular divisions of the PVN, 
while the pERK-containing cells were concentrated medially (closer to the third 
ventricle) in parvocellular cell groups.   
B.  The effect of (+)8-OH-DPAT on the measure of integrated density for pERK 
and oxytocin labeling in the peripubertal PVN.  As shown in table 5, (+)8-OH-
DPAT had no effect on the integrated density (defined as the product of the pixel 
area and the optical density) in the peripubertal PVN.  However, due to the 
intense baseline signal of fibers and vessels with the pERK antibody in the PVN 
(Khan et al., 2007), evaluating the integrated density alone for the whole  PVN in 
peripubertal rats may not be as sensitive as counting labeled cells (as shown in 
section C below).    
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 The Student’s t-test for oxytocin indicated no significant effect of (+)8-OH-
DPAT challenge compared to saline challenge [t value = 0.84, p = 0.4204].  The 
Student’s t-test for pERK also indicated no significant effect of (+)8-OH-DPAT 
challenge compared to saline challenge [t value = -0.07, p = 0.9474].   
C.  The effect of (+)8-OH-DPAT on number of cells labeled for pERK and 
oxytocin in the PVN of peripubertal rats.  As shown in table 6, particle analysis 
using ImageJ software (identifying round cells and eliminating narrow fiber or 
vessel labeling) indicated that (+)8-OH-DPAT had no effect on the number of 
oxytocin-immunoreactive cells, but increased the number of pERK-
immunoreactive cells ~2.9 fold above saline-injected controls in the peripubertal 
PVN.   
 The Student’s t-test for oxytocin indicated no significant effect of (+)8-OH-
DPAT injection compared to saline injection [t value = 1.10, p = 0.2975].  The 
Student’s t-test for pERK, however, indicated a significant effect of (+)8-OH-
DPAT challenge compared to saline challenge [t value = -3.19, p = 0.0129].  
Therefore, these data suggest that stimulation of 5-HT1A receptors in vivo induces 
a measurable increase in the number of pERK immunoreactive cells but has no 
effect on the number of cells that were immunoreactive for oxytocin in the 
peripubertal PVN.      
D.   Immunoreactivity for 5-HT1A receptor-mediated phosphorylation of ERK 
was not found in oxytocin-containing cells in the adult hypothalamic PVN.  
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Preliminary data suggest that, in the adult PVN, injection with 0.20 mg/kg (+)8-
OH-DPAT markedly increased pERK-immunoreactivity.  However, none of 
these cells were also immunoreactive for oxytocin (figure 30).   
E.  (+)8-OH-DPAT increased plasma levels of oxytocin in peripubertal and adult 
rats.  Plasma hormone levels were measured in order to confirm that the in vivo 
injection with 0.20 mg/kg (+)8-OH-DPAT stimulated 5-HT1A receptors in the 
PVN.  As shown in figure 31, challenge with (+)8-OH-DPAT increased plasma 
levels of oxytocin in both peripubertal (~36 fold over saline) and adult (~13 fold 
over saline) rats.  
F.  (+)8-OH-DPAT increased plasma levels of ACTH in peripubertal and adult 
rats.  As shown in figure 32, injection of 0.20 mg/kg (+)8-OH-DPAT increased 
plasma levels of ACTH in both peripubertal (~8 fold over saline) and adult (~4 
fold over saline) rat groups.  These data indicate that the in vivo injection of 0.20 
mg/kg (+)8-OH-DPAT stimulated neuroendocrine responses in both 
peripubertal and adult rats, presumably via 5-HT1A receptor-mediated activation 
in the PVN. 
G.  (+)8-OH-DPAT had no effect on plasma levels of testosterone in peripubertal 
and adult rats.  Plasma levels of testosterone were measured in order to ensure 
that the state of sexual maturation was consistent within treatment groups and 
age groups.  (+)8-OH-DPAT had no effect on the plasma levels of testosterone in 
peripubertal or adult animals compared to saline-challenged rats or untreated 
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rats.  As expected, adult rats had higher plasma levels of testosterone than did 
peripubertal rats (figure 33).  
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Figure 28.  Representative images of oxytocin, pERK, and overlays in peripubertal PVN of rats 
injected with either (A) saline or (B) 0.20 mg/kg (+)8-OH-DPAT (untreated not shown).   
Magnification = 10x; yellow scale bar = 100 μm. 
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Figure 29.  Representative confocal images of oxytocin-immunoreactive cells, pERK 
immunoreactive cells, and overlays of immunoreactive cells taken from three different randomly 
chosen areas of the PVN from one (+)8-OH-DPAT-injected (0.20 mg/kg) peripubertal rat.  Red = 
oxytocin-immunoreactive cells; green = pERK-immunoreactive cells. 
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Effects of 5-HT1A Receptor Stimulation on Integrated Density 
of Immunoreactivity in Peripubertal PVN 
Treatment Oxytocin pERK N 
Untreated 4.5 1.1 2 
Saline 3.8 ± 0.3 3.4 ± 1.2 6 
(+)8-OH-DPAT 3.3 ± 0.6 3.5 ± 0.9 6 
 
Table 5.  Average integrated density (x100) of oxytocin immunoreactivity and 5-HT1A receptor-
stimulated pERK immunoreactivity in the peripubertal PVN.  Numbers are displayed as the 
average integrated density (optical density multiplied by the area of a 850x950 pixel section) of 
each group ± SEM for groups with more than 2 rats.  Student t-test indicated no effect of (+)8-
OH-DPAT challenge injection for either oxytocin or pERK integrated density of 
immunoreactivity compared to rats injected with saline.   
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Effects of 5-HT1A Receptor Stimulation on 
Immunoreactive Cell Density in Peripubertal PVN 
Treatment Oxytocin pERK N 
Untreated 124.7 9.3 2 
Saline 115.7 ± 8.9 15.1 ± 5.9 5 
(+)8-OH-DPAT 96.2 ± 17.5 44.0 ± 6.9 * 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6.  Average cell density of 850x950 pixel area for oxytocin-immunoreactive cells and cells 
immunoreactive for 5-HT1A receptor-stimulated pERK in the PVN of peripubertal rats.  Numbers 
are displayed as the average cell number of each group ± SEM for groups with more than 2 rats.  
* p < 0.05 with respect to saline (Student’s t-test).   
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Figure 30.  Representative images of oxytocin, pERK, and overlays in adult PVN from animals 
that have been injected with (A) saline or (B) (+)8-OH-DPAT (0.20 mg/kg). Magnification = 10x; 
white scale bar = 100 μm. 
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Figure 31. Plasma oxytocin responses in (A) peripubertal and (B) adult rats used in 
immunohistochemistry experiments.   
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Figure 32. Plasma ACTH responses in (A) peripubertal and (B) adult rats used in 
immunohistochemistry experiments.   
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Figure 33. Plasma levels of testosterone in peripubertal and adult rats used in 
immunohistochemistry experiments.   
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DISCUSSION 
 
 Activation of 5-HT1A receptors via in vivo injection with (+)8-OH-DPAT 
increases plasma levels of oxytocin and ACTH and increases levels of pERK in 
the PVN (as measured by western blotting) in both peripubertal and adult brains 
(Chapter 3 and Crane et al., 2007).  Although increases in pERK mediated by 
neuroactive ligands such as norepinephrine or prolactin have been identified in 
specific neuroendocrine-containing cell types in the PVN, 5-HT1A receptor-
mediated activation of ERK has not been demonstrated in the specific cell types 
in the PVN of rats at any age.  The study described in this chapter is the first to 
demonstrate 5-HT1A receptor-mediated increases in pERK immunoreactivity in 
the peripubertal PVN using immunohistochemistry.  The present study 
determined that 5-HT1A receptor-mediated increases in pERK immunoreactivity 
did not localize to cells that were immunoreactive for oxytocin.  Preliminary data 
obtained in this study also suggest that 5-HT1A receptor-induced increases in 
pERK immunoreactivity and oxytocin immunoreactivity were contained in 
distinct cell groups in the adult PVN, indicating this finding is not unique to the 
immature brain.   
 The current preliminary data are consistent with the literature in that 
receptor-activated ERK localizes to very few oxytocin-containing cells (Wang et 
al., 2006; Blume et al., 2009).  Since 5-HT1A receptor-mediated increases in pERK 
immunoreactivity and oxytocin immunoreactivity were localized to distinct cell 
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groups in the peripubertal PVN, 5-HT1A receptor-mediated pERK and 5-HT1A 
receptor-mediated increases in plasma oxytocin responses are likely mediated by 
separate pathways in different cell populations.  Similarly, little to no localization 
of 5-HT1A receptor-activated ERK on oxytocin-containing cells in the adult PVN 
support previous findings indicating that 5-HT1A receptors mediate increases in 
plasma levels of oxytocin and increases in ERK activation via independent 
pathways in the adult PVN (Garcia et al., 2006).   
 In the adult PVN, ERK signaling is necessary for SSRI-induced 
desensitization of 5-HT1A receptor-mediated oxytocin (and ACTH) 
neuroendocrine responses, since blockade of MAPK kinase (MEK), the activating 
kinase for ERK, abolishes SSRI-induced desensitization of 5-HT1A receptor-
mediated hormone responses and associated reductions in Gαz proteins (Jia et al., 
2007).  The current results imply that activated ERK in the adult PVN may 
function via an indirect, cell-to-cell mechanism rather than a direct, intracellular 
mechanism to mediate SSRI-induced desensitization of 5-HT1A receptor-
mediated oxytocin responses.  In the peripubertal PVN, it is unknown if ERK is 
required for SSRI-induced desensitization of 5-HT1A receptor mediated oxytocin 
responses.  If ERK is necessary, then a similar cell-to-cell mechanism for SSRI-
induced desensitization of 5-HT1A receptor-mediated oxytocin responses may be 
operant in the immature brain as suggested in the adult brain.   
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 The labeling of CRH in the PVN has proved to be challenging, and many labs 
have found it necessary to treat rats in vivo with colchicine in order to prevent 
axonal transport of CRH, thereby concentrating the CRH in the cells.  It is also 
standard procedure in most labs to perfuse animals rather than post-fix the brain 
tissue.  These techniques may be necessary to determine the extent of 5-HT1A 
receptor-mediated pERK on CRH-containing cells in both peripubertal and adult 
PVN.  Despite these issues, we have gathered some preliminary data (not shown) 
that indicates that 5-HT1A receptor-mediated activation of ERK can occur on 
CRH-containing cells in the peripubertal PVN.  5-HT1A receptor-mediated 
increases in pERK immunoreactivity may extensively colocalize with CRH 
immunoreactivity, since 70% of cells immunopositive for CRH have been shown 
to express prolactin-induced ERK activation (Blume et al., 2009).  If 5-HT1A 
receptor-mediated pERK extensively localizes to cells that are immunoreactive 
for CRH, then it could be possible that ERK activation could potentially lead to 5-
HT1A receptor-mediated plasma levels of ACTH in the peripubertal age group 
(i.e., 5-HT1A receptor-mediated pathways are dependent on one another in CRH-
containing cells in the peripubertal PVN).  Furthermore, if we were to find that 
ERK is necessary for SSRI-induced desensitization of 5-HT1A receptor-mediated 
increases in plasma oxytocin and ACTH responses in the peripubertal PVN, 
CRH cells could have the capacity to send out projections or a local agent to 
regulate nearby oxytocin-containing cells and their outputs to the pituitary gland 
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while using an intracellular mechanism to desensitize CRH-containing cell 
outputs.  Potentially, the small population of cells in the PVN that contain 5-HT1A 
receptor-mediated pERK could exert a wide range of control over multiple cell 
subtypes within the PVN and in other areas of the hypothalamus.   
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CHAPTER 6 
 
INITIAL IDENTIFICATION OF IN VIVO SEROTONIN 1A RECEPTOR 
ACTIVATION OF PROTEIN KINASE B (AKT) IN THE HYPOTHALAMIC 
PARAVENTRICULAR NUCLEUS OF PERIPUBERTAL RATS. 
 
ABSTRACT 
 
Protein kinase B (Akt) and its downstream signaling effector glycogen 
synthase kinase 3β (GSK3β) have been associated with cell survival and may 
represent a common target for antidepressants and other drugs used to treat 
mood disorders (Beaulieu et al., 2009).  Serotonin 1A (5-HT1A) receptor agonists 
increase levels of phosphorylated Akt (pAkt) in several cell lines (Adayev et al., 
1999; Cowen et al., 2005; Hsiung et al., 2005) and in adult hippocampus in vivo 
(Polter et al., 2010).  To date, no preclinical studies have determined 5-HT1A 
receptor-mediated activation of the Akt signal transduction pathway in the 
hypothalamus in any age group.  Since hypothalamic dysfunction has been 
observed in studies of childhood and adolescent stress and depression 
(Vaillancourt et al., 2007; Lopez-Duran et al., 2009; Vigil et al., 2010; Hankin et al., 
2010), the present studies investigated 5-HT1A receptor signaling of the Akt 
signaling pathway in the peripubertal hypothalamic paraventricular nucleus 
(PVN) with respect to: (1) the onset and longevity of increases in pAkt at two 
activating residues (Thr308 and Ser473) by two different classes of 5-HT1A 
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receptor agonists, (2) potential agonist-dependent differences in the potency and 
efficacy of different 5-HT1A receptor agonists to phosphorylate Akt at each of the 
respective phosphorylation sites, (3) the 5- HT1A receptor selectivity of (+)8-OH-
DPAT-mediated increases of pAkt, (4) the potential role of pertussis toxin-
sensitive Gα protein subtypes in 5-HT1A receptor-mediated increases of pAkt, (5) 
the effects of chronic (7 and 14 days) fluoxetine (FLX) on 5-HT1A receptor-
mediated increases in phosphorylated Akt, and (6) the effects of chronic (7 and 
14 days) FLX on 5-HT1A receptor-mediated increases in GSK3β.   
Together, these data provide the first in vivo demonstration in the 
peripubertal PVN that 5-HT1A receptors can activate Akt via phosphorylation at 
both Thr308 and Ser473.  Given the previous studies demonstrating that 5-HT1A 
receptors can stimulate hormone responses and also activate ERK in the 
peripubertal PVN (Chapter 3), these findings are the first to show that 5-HT1A 
receptors can mediate the concomitant activation of three signaling pathways in 
peripubertal hypothalamic PVN.  (+)8-OH-DPAT had full agonist activity and 
tandospirone only partial agonist activity on the phosphorylation of Akt at both 
Thr308 and Ser473, despite these both drugs displaying full agonist activity at 5-
HT1A receptor-mediated neuroendocrine responses and ERK activation in the 
peripubertal PVN (Chapter 3).  With regards to receptor selectivity, pretreatment 
with the 5-HT1A receptor antagonist WAY100635 completely blocked (+)8-OH-
DPAT-induced elevations of pAkt at Ser473 in the PVN.  Intra-PVN injection of 
146 
 
pertussis toxin (which only reduced Gαi1 and Gα2 proteins in the peripubertal 
hypothalamus, see Chapter 4) precluded any significant increase in (+)8-OH-
DPAT-induced phosphorylation of Akt (at Ser473) compared to its respective 
basal level.  Therefore, Gαi1 and Gαi2 may play a role in Akt phosphorylation; 
however, since pertussis toxin also produced a non-significant 23% increase in 
basal levels of phosphorylated Akt at Ser473, this could have precluded 
obtaining a significant (+)8-OH-DPAT-induced increase above basal levels.  
Lastly, chronic FLX does not alter basal levels of Akt, basal levels of GSK3β, or 5-
HT1A receptor-mediated activation of Akt.  However, chronic FLX can selectively 
regulate 5-HT1A receptor-mediated phosphorylation of GSK3β, implicating 
phosphatases or a unique mechanism in FLX-induced GSK3β desensitization in 
the peripubertal PVN.   
INTRODUCTION 
Akt (protein kinase B) is a protein kinase involved in cell survival, apoptosis, 
protein synthesis, insulin signaling, and glucose transport (Franke et al., 2003).  
Receptor tyrosine kinases (RTKs) typically initiate the activation of Akt, although 
stimulation of G protein coupled receptors such as dopamine D2 receptors 
(Beaulieu et al., 2005) and 5-HT1A receptors (Adayev et al., 1999; Cowen et al., 
2005; Hsiung et al., 2005) has recently been shown to activate this pathway in 
vitro.  Receptor activation stimulates phosphoinositide 3-kinase (PI3K) to catalyze 
the formation of phosphatidylinoisitol(3,4,5)P3 (PIP3).  PIP3 binds to and brings 
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phosphoinositide-dependent kinase 1 (PDK1) and Akt into close proximity at the 
cell membrane, where PDK1 then phosphorylates Akt at Thr308 (Alessi et al., 
1997; Anderson et al., 1998; Stephens et al., 1998).  Akt is also phosphorylated in 
the hydrophobic motif at Ser473 by a complex containing rictor and mTOR 
proteins (Sarbossov et al., 2005).  Although the exact sequence of Akt 
phosphorylation at Thr308 and Ser473 is still under investigation and is likely to 
differ with respect to brain region and cell type, both sites must be 
phosphorylated in order for Akt to be fully activated (Alessi et al., 1996; 
Andjelkovic et al., 1996).  Downstream, activated Akt phosphorylates and 
inhibits glycogen synthase kinase 3 (GSK3) (Cross et al., 1995), an enzyme that 
regulates the function of a multitude of proteins, including metabolic, signaling, 
and structural proteins (Grimes and Jope 2001).  GSK3 exists in 2 isoforms, 
GSK3α and GSK3β, and are both constitutively active until phosphorylation by 
Akt (Woodgett 1990; Sutherland et al., 1993).  Although both isoforms are highly 
expressed in brain (Woodgett 1990), GSK3β has received particular attention due 
to the ability of lithium and other drugs used to treat bipolar and other mood 
disorders to phosphorylate and inactivate GSK3β (Klein and Melton 1996; 
DeSarno et al 2002; Zhang et al., 2003; Gould et al., 2004; O’Brien et al., 2004; Li et 
al., 2007; Fatemi et al., 2009). 
Dysfunction of the PI3K/Akt/GSK3 pathway has been implicated in the 
pathology of psychological disorders including chronic stress, depression, and 
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schizophrenia (Beaulieu et al., 2009).  For example, the activity of PI3K and Akt 
were significantly decreased in the occipital cortex of suicide victims (with no 
recent psychotropic drug consumption) compared to controls (Hsiung et al., 
2003).  In addition, decreases were observed in the activity of Akt (with 
subsequent increased activation of GSK3) in schizophrenic patients (Emamian et 
al., 2004) and in a mouse model of schizophrenia (Beaulieu et al., 2004).  In a rat 
model of chronic stress, levels of pAkt were increased in the hypothalamus, 
hippocampus, and striatum, with the largest increases observed in the 
hypothalamus (Lee et al., 2006), a region containing 5-HT1A receptors that 
stimulate hormone responses and activate ERK, but have yet to be studied with 
respect to Akt activation. 
5-HT1A receptors can activate the PI3K/Akt/GSK3 pathway in vitro and in 
vivo.  5-HT1A receptors increase the phosphorylation of Akt in both neuronal 
(Adayev et al., 1999; Cowen et al., 2005) and non-neuronal (Hsiung et al., 2005) 
cell cultures.  The 5-HT1A receptor agonist 8-OH-DPAT has recently been shown 
to increase the levels of phosphorylated Akt and GSK3β in vivo in the adult 
hippocampus, although the specificity of 5-HT1A receptors for this response has 
yet to be determined (Polter et al., 2010 and personal communications).  Acute 
SSRI treatment increases levels of phosphorylated GSK3β in mouse frontal 
cortex, hippocampus, and striatum, which is thought to be due to increased 
levels of 5-HT stimulating post-synaptic 5-HT1A receptors to mediate subsequent 
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activation of Akt (Li et al., 2004).  These data indicate that 5-HT1A receptors in 
vivo likely activate the Akt signaling pathway in the brain and that this signaling 
cascade may be involved with the effects of antidepressants. 
5-HT1A receptor-mediated phosphorylation of Akt and its downstream target 
GSK3β has not been demonstrated in the hypothalamus in an in vivo model. 
Given the potential role of Akt in stress responses and effects of antidepressants, 
the present studies investigated 5-HT1A receptor signaling of the Akt signaling 
pathway in the peripubertal PVN with respect to: (1) the onset and longevity of 
5-HT1A receptor-induced phosphorylation of Akt at Thr308 and Ser473 by two 
classes of 5-HT1A receptor agonists, (2) potential agonist-dependent differences in 
the potency and efficacy of different 5-HT1A receptor agonists to phosphorylated 
Akt at each of its respective phosphorylation sites, (3) the 5-HT1A receptor 
selectivity of (+)8-OH-DPAT-mediated increases in pAkt, (4) the potential role of 
pertussis toxin-sensitive Gα protein subtypes in 5-HT1A receptor-mediated 
increases in pAkt, (5) the effects of chronic (7 and 14 days) FLX on 5-HT1A 
receptor-mediated phosphorylation of Akt, and (6) the effects of chronic (7 and 
14 days) FLX on 5-HT1A receptor-mediated phosphorylation of GSK3β.  
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MATERIALS AND EXPERIMENTAL PROCEDURES (for detailed methods, 
see Chapter 7) 
 Animals. Peripubertal male Sprague-Dawley rats (100-125 g) were purchased 
from Harlan (Indianapolis, IN).  The determination of post-natal day zero (day of 
birth) was carried out by the supplier.   
 Drugs.  (+)-8-Hydroxy-2-(di-n-propylamino)tetralin hydrobromide [(+)8-OH-
DPAT] was purchased from Tocris Cookson Inc. (Ellisville, MO). Tandospirone 
citrate was a generous gift of Dr. K. Matusubara, Asahikawa Medical College, 
Japan.  (+)8-OH-DPAT and tandospirone were dissolved in saline (0.9% NaCl) 
and were injected at a volume of 1 ml/kg.  For the dose-response experiment, the 
highest dose of drug was dissolved in saline and lower concentrations were 
made by serial dilution.  N-[2-[4-(2-Methoxyphenyl)-1-piperazinyl]ethyl]-N-2-
pyridinylcyclohexanecarboxamide maleate salt (WAY100635) was purchased 
from Sigma (catalog number W108), and was dissolved in saline (0.9% NaCl) and 
injected at a volume of 1 ml/kg.  Pertussis toxin (PTX; Bordetella pertussis) was 
purchased from EMD Chemicals, Gibbstown, NJ (catalog number 516560), and 
was diluted to a concentration of 1 μg/μl with ddH2O.  Fluoxetine hydrochloride 
was purchased from LKT Laboratories, Inc., St. Paul, MN (catalog number 
F4780), and was dissolved in saline (0.9% NaCl) to 10 mg/kg and was injected at 
a volume of 2 ml/kg.  All drugs were freshly prepared immediately prior to the 
injections.  
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Experiment 1:  Time-dependent 5-HT1A receptor-mediated phosphorylation of 
Akt at Thr308 and Ser473.  At least 3 days of handling preceded any injections.  
Peripubertal male Sprague-Dawley rats (post-natal day 42) were injected with 
either saline (1 ml/kg, s.c.), the aminotetralin agonist (+)8-OH-DPAT (0.20 
mg/kg, s.c.), or the azapirone agonist tandospirone (10 mg/kg, s.c.).  The 
animals were sacrificed by decapitation at 5, 10, 15, 20, or 30 minutes post-
injection.  The brains were carefully removed from the skull within one minute of 
the decapitation and were quickly frozen by submersion in chilled 2-
methylbutane (-35°C) for 1 minute and then subsequently kept in dry ice for an 
additional 10 minutes.  Each brain was then securely wrapped and stored at         
-80°C prior to dissection for Western blot studies for the determination of 
pAkt/Akt levels in the PVN.   
Experiment 2:  Dose-dependent 5-HT1A receptor-mediated phosphorylation of 
Akt at Thr308 and Ser473.  At least 3 days of handling preceded any injections.  
Peripubertal male Sprague-Dawley rats (post-natal day 42) were injected with 
either saline (1 ml/kg, s.c.), (+)8-OH-DPAT (0.04, 0.10, 0.20, or 0.50 mg/kg, s.c.), 
or tandospirone (1, 3, 10, or 20 mg/kg, s.c.) and were sacrificed by decapitation at 
10 minutes post-injection.  The brains were carefully removed from the skull 
within one minute of the decapitation and were quickly frozen by submersion in 
chilled 2-methylbutane (-35°C) for 1 minute and then subsequently kept in dry 
ice for an additional 10 minutes.  Each brain was then securely wrapped and 
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stored at -80°C prior to dissection for Western blot studies for the determination 
of pAkt/Akt levels in the PVN.   
Experiment 3:  Determination of 5-HT1A receptor specificity of (+)8-OH-
DPAT-mediated phosphorylation of Akt at Ser473.  At least 3 days of handling 
preceded any injections.  Peripubertal male Sprague-Dawley rats (post-natal day 
47) were injected with either saline (1 ml/kg, s.c.) or the 5-HT1A receptor 
antagonist WAY100635 (0.10 mg/kg, s.c.) 30 minutes prior to a challenge 
injection with either saline (1 ml/kg, s.c.) or (+)8-OH-DPAT (0.20 mg/kg, s.c.).  
The animals were sacrificed by decapitation at 15 minutes post-injection.  The 
brains were carefully removed from the skull within one minute of the 
decapitation and were quickly frozen by submersion in chilled 2-methylbutane (-
35°C) for 1 minute and then subsequently kept in dry ice for an additional 10 
minutes.  Each brain was then securely wrapped and stored at -80°C prior to 
dissection for Western blot studies for the determination of pAkt/Akt levels in 
the PVN.   
 Experiment 4:  Determination of the role of PTX-sensitive Gα proteins in 5-
HT1A receptor-mediated phosphorylation of Akt at Ser473 in the peripubertal 
PVN.  Cannula implantation and administration of PTX was performed 
according to procedures previously established in adult rats (Garcia et al., 2006), 
and detailed in Chapter 7.  Seventy-two hours after intracerebral injection of 
vehicle (100 mM sodium phosphate + 500 mM NaCl, 0.5 μl/side) or PTX (1 
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μg/μl, 0.5 μl/side), the rats were given a systemic challenge injection of saline (1 
ml/kg) or (+)8-OH-DPAT (0.20 mg/kg) and were sacrificed by decapitation 15 
minutes later (postnatal day 42).  The brains were carefully removed from the 
skull within one minute of the decapitation and were quickly frozen by 
submersion in chilled 2-methylbutane (-35°C) for 1 minute and then 
subsequently kept in dry ice for an additional 10 minutes.  Each brain was then 
securely wrapped and stored at -80°C prior to dissection for Western blot studies 
for the determination of pAkt/Akt levels in the PVN.   
 Experiment 5:  Determination of chronic FLX-induced effects on (A) basal and 
5-HT1A receptor-mediated increases of pAkt (Thr308) and (B) basal and 5-HT1A 
receptor-mediated increases pGSK3β in the peripubertal PVN.  Rats were given 
an i.p. injection of saline (2 ml/kg) or FLX (10 mg/kg), once per day for either 7 
(PD 35-41) or 14 days (PD 28-41).  Eighteen hours after the last injection, the rats 
(postnatal day 42) were given a systemic challenge injection of saline (1 ml/kg) 
or (+)8-OH-DPAT (0.2 mg/kg) and were sacrificed by decapitation 10 minutes 
later.  The brains were carefully removed from the skull within one minute of the 
decapitation.  The brains were quickly frozen by submersion in chilled 
isopentane for 1 minute and then subsequently kept in dry ice for an additional 
10 minutes.  Each brain was then securely wrapped and stored at -80°C prior to 
dissection for Western blot studies for the determination of pAkt (Thr308)/Akt 
and pGSK3β/GSK3β levels in the PVN.   
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RESULTS 
1.  Experiment 1:  5-HT1A receptor-mediated time-dependent phosphorylation of 
Akt at Thr 308 and Ser473. The specific objectives of this experiment were to: (1) 
determine the onset and longevity of the 5-HT1A receptor-mediated increases in 
(A) pAkt at Thr308 and (B) pAkt at Ser473 in PVN; and (2) identify potential 
differences in onset and longevity of the different 5-HT1A receptor agonists to 
increase (A) pAkt at Thr308 and (B) pAkt at Ser473 in PVN. 
A.  Time-course of (+)8-OH-DPAT-induced increases in pAkt (Thr308) in the 
peripubertal rat.  As shown in figure 34, a single injection of (+)8-OH-DPAT (0.20 
mg/kg) produced rapid (≤ 5 minutes) and prolonged increases in pAkt at Thr308.  
The magnitude of elevation of (+)8-OH-DPAT-induced pAkt at Thr308 was 
about 300% over saline baseline.   
The two-way ANOVA for (+)8-OH-DPAT-induced increases in pAkt (Thr308) 
in the PVN indicated a significant main effect of challenge drug (saline or (+)8-
OH-DPAT) [F1,78 = 53.74, p < 0.0001] but no significant main effect of post-
injection time [F4,78 = 1.19, p = 0.3219].  There was also no significant interaction 
between challenge drug and post-injection time [F4,78 = 1.19, p = 0.3219].  A 
Newman-Keuls’ test indicated that (+)8-OH-DPAT increased pAkt at Thr308 in 
the PVN over saline at 5, 10, and 15 minutes (p < 0.01), and 20 minutes (p < 0.05).   
B.  Time-course of tandospirone-induced increases in pAkt (Thr308) in the 
peripubertal rat.  As shown in figure 35, a single injection of tandospirone (10 
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mg/kg) produced rapid (≤ 5 minutes) and prolonged increases in pAkt at Thr308.  
However, the magnitude of elevation of pAkt at Thr308 over saline induced by 
(+)8-OH-DPAT was much greater (↑300%, figure 34) than that induced by 
tandospirone (↑85%).   
The two-way ANOVA for tandospirone-induced increases in pAkt (Thr308) 
in the PVN indicated a significant main effect of challenge drug (saline or 
tandospirone) [F1,78 = 16.551, p = 0.0001] but no significant main effect of post-
injection time [F4,78 = 0.38, p = 0.8200].  There was also no significant interaction 
between challenge drug and post-injection time [F4,78 = 0.38, p = 0.8200].  A 
Newman-Keuls’ test indicated that tandospirone increased pAkt at Thr308 in the 
PVN over saline at 10 minutes (p < 0.05).   
C.  Time-course of (+)8-OH-DPAT-induced increases in pAkt (Ser473) in the 
peripubertal rat.  As shown in figure 36, a single injection of (+)8-OH-DPAT (0.20 
mg/kg) produced a rapid (≤ 5 minutes) increase (~↑60% over saline) in pAkt at 
Ser473 that returned to baseline by 30 minutes post-injection.   
The two-way ANOVA for (+)8-OH-DPAT-induced increases in pAkt (Ser473) 
in the PVN indicated a significant main effect of challenge drug (saline or (+)8-
OH-DPAT) [F1,79 = 27.33, p < 0.0001] but no significant main effect of post-
injection time [F4,79 = 1.63, p = 0.1771].  There was also no significant interaction 
between challenge drug and post-injection time [F4,79 = 1.63, p = 0.1771].  A 
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Newman-Keuls’ test indicated that (+)8-OH-DPAT increased pAkt at Ser473 in 
the PVN over saline at 5 and 10 minutes (p < 0.01), and 15 minutes (p < 0.05).   
D.  Time-course of tandospirone-induced increases in pAkt (Ser473) in the 
peripubertal rat.  As shown in figure 37, a single injection of tandospirone (10 
mg/kg) produced a rapid (≤ 5 minutes) increase (~↑60% over saline) in pAkt at 
Ser473 that was comparable in magnitude than that induced by (+)8-OH-DPAT 
(figure 36).   
The two-way ANOVA for tandospirone-induced increases in pAkt (Ser473) in 
the PVN indicated a significant main effect of challenge drug (saline or 
tandospirone) [F1,78 = 17.97, p < 0.0001] but no significant main effect of post-
injection time [F4,78 = 0.77, p = 0.5480].  There was also no significant interaction 
between challenge drug and post-injection time [F4,78 = 0.77, p = 0.5480].  A 
Newman-Keuls’ test indicated that tandospirone increased pAkt at Ser473 in the 
PVN over saline at 10 minutes (p < 0.05) post-injection.   
2.  Experiment 2:  Dose-dependent 5-HT1A receptor-mediated phosphorylation of 
Akt at Thr308 and Ser473 in the peripubertal hypothalamic PVN.  The objectives 
of this experiment were: to determine potency and efficacy of agonists from 
different structural drug classes ((+)8-OH-DPAT, an aminotetralin and 
tandospirone, an azapirone) on (A) phosphorylation of Akt at Thr308 and (B) 
phosphorylation of Akt at Ser473 in the PVN.  
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A.  Effects of different doses of (+)8-OH-DPAT on levels of phosphorylated Akt 
at Thr308 in peripubertal rat hypothalamic PVN.  As shown in figure 38, (+)8-
OH-DPAT dose-dependently increased levels of pAkt (Thr308) over saline-
challenged peripubertal rats.  The phosphorylation of Akt at Thr308 induced by 
(+)8-OH-DPAT reached levels around 3.5 fold over basal.   
The two-way ANOVA for (+)8-OH-DPAT-induced increases in pAkt (Thr308) 
in the PVN indicated a significant main effect of challenge drug (saline or (+)8-
OH-DPAT) [F1,71 = 69.44, p < 0.0001] and a significant main effect of agonist dose 
[F3,71 = 12.24, p < 0.0001].  There was also a significant interaction between 
challenge drug and agonist dose [F3,71 = 12.24, p < 0.0001].  A Newman-Keuls’ 
test indicated that (+)8-OH-DPAT increased levels of pAkt (Thr308) in the PVN 
over saline at 0.10, 0.20, and 0.50 mg/kg (p < 0.01).   
B.  Effects of different doses of tandospirone on levels of phosphorylated Akt at 
Thr308 in peripubertal rat hypothalamic PVN.  As shown in figure 39, most 
tested doses of tandospirone maximally increased levels of pAkt (Thr308) over 
saline-challenged peripubertal rats (to about 2.5 fold over basal).  The maximal 
phosphorylation of Akt at Thr308 induced by (+)8-OH-DPAT was higher (~3.5 
fold over basal) than tandospirone (~2.5 fold over basal).  (+)8-OH-DPAT was 
also more potent in phosphorylating Akt at Thr308 (figure 38).   
The two-way ANOVA for tandospirone-induced increases in pAkt (Thr308) 
in the PVN indicated a significant main effect of challenge drug (saline or 
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tandospirone) [F1,71 = 104.89, p < 0.0001] but no significant main effect of agonist 
dose (although there was a trend towards significance) [F3,71 = 2.46, p = 0.703].  
There was also no significant interaction (although a trend towards significance) 
between challenge drug and agonist dose [F3,71 = 2.46, p = 0.703].  A Newman-
Keuls’ test indicated that tandospirone increased levels of pAkt (Thr308) in the 
PVN over saline at 1 mg/kg (p < 0.05) and at 3, 10, and 20 mg/kg (p < 0.01).   
C.  Effects of different doses of (+)8-OH-DPAT on levels of phosphorylated Akt 
at Ser473 in peripubertal rat hypothalamic PVN.  As shown in figure 40, (+)8-
OH-DPAT dose-dependently increased levels of pAkt (Ser473) over saline-
challenged peripubertal rats.  (+)8-OH-DPAT increased the phosphorylation of 
Akt at Ser473 ~1.75 fold over basal.   
The two-way ANOVA for (+)8-OH-DPAT-induced pAkt (Ser473) in the PVN 
indicated a significant main effect of challenge drug (saline or (+)8-OH-DPAT) 
[F1,71 = 20.55, p < 0.0001] and a significant main effect of agonist dose [F3,71 = 6.37, 
p = 0.0008].  There was also a significant interaction between challenge drug and 
agonist dose [F3,71 = 6.37, p = 0.0008].  A Newman-Keuls’ test indicated that (+)8-
OH-DPAT at 0.50 mg/kg increased levels of pAkt (Ser473) in the PVN over 
saline (p < 0.01).   
D.  Effects of different doses of tandospirone on levels of phosphorylated Akt at 
Ser473 in peripubertal rat hypothalamic PVN.  As shown in figure 41, most 
tested doses of tandospirone maximally increased levels of pAkt (Ser473) over 
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saline-challenged peripubertal rats (~1.4 fold over basal).  (+)8-OH-DPAT was 
more potent than tandospirone for this response and had a higher maximal level 
of pAkt (Ser473) (~1.75 fold vs. ~1.4 fold over basal) (figure 40).   
The two-way ANOVA for tandospirone-induced increases in pAkt (Ser473) in 
the PVN indicated a significant main effect of challenge drug (saline or 
tandospirone) [F1,71 = 21.97, p < 0.0001] but no significant main effect of agonist 
dose [F3,71 = 1.16, p = 0.3307].  There was also no significant interaction between 
challenge drug and agonist dose [F3,71 = 1.16, p = 0.3307].  A Newman-Keuls’ test 
indicated that tandospirone at 3, 10, and 20 mg/kg increased levels of pAkt 
(Ser473) in the PVN over saline (p < 0.05).   
3.  Experiment 3:  Determination of 5-HT1A receptor specificity for (+)8-OH-
DPAT-mediated phosphorylation of Akt at Ser473.  The objective of this 
experiment was to administer a specific 5-HT1A receptor antagonist 
(WAY100635) to block receptor activation to determine if (+)8-OH-DPAT is 
acting specifically through 5-HT1A receptors (and not any other subtype of 5-HT 
receptors, e.g., 5-HT7) to induce increases of pAkt at Ser473 in the peripubertal 
PVN.  5-HT1A receptor-mediated phosphorylation at Ser473 was the focus of this 
experiment, since there is some evidence that the phosphorylation of Akt at 
Ser473 by the mTOR complex occurs prior to the recruitment of Akt to the 
plasma membrane and subsequent phosphorylation at Thr308 by its upstream 
kinase PDK1 (Sarbossov et al., 2005). 
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A.  Effects of WAY100635 treatment on basal and 5-HT1A receptor-mediated 
increases in levels of pAkt (Ser473) in PVN.  As shown in figure 42, (+)8-OH-
DPAT significantly increased pAkt (Ser473) in the PVN by about 50% over saline.  
Treatment with the 5-HT1A receptor antagonist WAY100635 prior to challenge 
injection completely blocks (+)8-OH-DPAT-mediated increases in pAkt (Ser473) 
in the PVN.  WAY100635 had no affect on basal levels of pAkt (Ser473) in the 
PVN.   
The two-way ANOVA for levels of pAkt (Ser473) in the PVN indicated no 
main effect of WAY100635 treatment [F1,25 = 2.73, p = 0.1129] and no significant 
main effect of challenge injection [F1,25 = 3.39, p = 0.0791].  However, there was a 
significant interaction between treatment and challenge injection [F1,25 = 7.02, p = 
0.0147].  The Newman-Keuls’ test indicated that saline treatment/(+)8-OH-DPAT 
challenge significantly elevated pAkt (Ser473) in the PVN over the saline-
treated/saline-challenged group (p < 0.05) and also that WAY100635 treatment 
completely blocked 5-HT1A receptor-induced increases in pAkt (Ser473) in the 
peripubertal PVN (p < 0.05).   
4.  Experiment 4:  Determination of the role of PTX-sensitive Gα proteins in 5-
HT1A receptor-mediated phosphorylation of Akt at Ser473 in the peripubertal 
PVN. 5-HT1A receptor-mediated activation of Akt has been shown to be blocked 
with pertussis toxin (PTX) in hippocampal cell cultures (Cowen et al, 2005), 
indicating that this response may be mediated by PTX-sensitive Gi/o proteins.  
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The objective of this experiment was to use PTX to functionally inactivate Gαi/o 
proteins (as previously demonstrated in adult rats, Garcia et al., 2006) to 
determine if this subset of proteins plays a role in 5-HT1A receptor-mediated 
increases of pAkt at Ser473 in the peripubertal PVN.  Intra-PVN injection with 
PTX decreased levels of Gαi1 and Gαi2, increased levels of Gαo, and had no 
effect on levels of Gαi3 and Gαz in the peripubertal hypothalamus (Chapter 4).   
 5-HT1A receptor-mediated phosphorylation at Ser473 was the focus of this 
experiment, as there is some evidence that the phosphorylation of Akt at Ser473 
by the mTOR complex occurs prior to the recruitment of Akt to the plasma 
membrane and subsequent phosphorylation at Thr308 by its upstream kinase 
PDK1 (Sarbossov et al., 2005). 
A.  Effects of PTX treatment on basal and 5-HT1A receptor-mediated increases in 
levels of pAkt (Ser473) in PVN.  As shown in figure 43, (+)8-OH-DPAT increased 
pAkt (Ser473) in the PVN by about 50% over basal in vehicle-treated rats.  In rats 
treated with PTX, however, 5-HT1A receptor-mediated increases in pAkt (Ser473) 
were not significantly elevated over its respective basal (↑24%).  However, PTX 
also produced an increase in the basal levels of pAkt (Ser473) (↑23%) in the PVN 
that precludes any further increase by 5-HT1A receptor stimulation.   
The two-way ANOVA for levels of pAkt (Ser473) in the PVN indicated no 
main effect of PTX treatment [F1,37 = 0.28, p = 0.5998] but a significant main effect 
of challenge injection [F1,37 = 11.27, p = 0.0020].  There was no significant 
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interaction between treatment and challenge injection [F1,37 = 1.55, p = 0.2220].  
Although the basal levels of phosphorylated Akt (Ser473) in the PVN increased 
by about 23% with PTX treatment, this did not reach statistical significance, nor 
did 5-HT1A receptor-stimulated elevations of pAkt in the PTX-treated group 
(↑24% over its respective basal and 45% over the vehicle-treated/saline-
challenged group).  The Newman-Keuls’ test indicated that vehicle 
treatment/(+)8-OH-DPAT challenge significantly elevated pAkt (Ser473) in the 
PVN over the vehicle-treated/saline-challenged group (p < 0.05) and that PTX 
treatment/(+)8-OH-DPAT challenge significantly elevated pAkt (Ser473) in the 
PVN over the vehicle-treated/saline-challenged group (p < 0.05).   
5.  Experiment 5:  Determination of chronic FLX-induced effects on (A) basal and  
5-HT1A receptor-mediated increases of pAkt (Thr308) and (B) basal and  5-HT1A 
receptor-mediated increases of pGSK3β in the peripubertal PVN.  Acute injection 
with fluoxetine has been shown to increase levels of pGSK3β in the mouse 
prefrontal cortex, hippocampus, and striatum, most likely due to the activation 
of 5-HT1A receptors (Li et al., 2004).  The objective of this experiment was to 
determine if chronic FLX injections (once per day for 7 or 14 days) have any 
effects on basal or 5-HT1A receptor-mediated pAkt and basal or 5-HT1A receptor-
mediated pGSK3β responses in the peripubertal PVN.  The activation of Akt via 
phosphorylation at Thr308 was measured, as (+)8-OH-DPAT induced a 
phosphorylation of Akt at Thr308 that was greater compared to Ser473 (see dose-
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response experiment, experiment 2 of this chapter), and thus may be more 
sensitive to detect changes induced by chronic FLX.   
A.  Effects of FLX treatment on basal and 5-HT1A receptor-mediated increases in 
levels of pAkt (Thr308) in PVN.  As shown in figure 44, in the rats treated for 7 
days with saline (PD 35-41), (+)8-OH-DPAT increased pAkt (Thr308) in the PVN 
(↑313%), consistent with data from experiment 1 of this chapter.  (+)8-OH-DPAT 
challenge after treatment for 14 days with saline (PD 28-41) increased pAkt 
(Thr308) in the PVN, although this response was not as robust (↑109%).  For both 
7D and 14D chronic treatments, FLX had no significant effect on (+)8-OH-DPAT-
induced increases in pAkt (Thr308).  There was also a non-significant increase 
(↑70%) in basal levels of pAkt (Thr308) with 7D FLX.  
The two-way ANOVA for levels of pAkt (Thr308) in the PVN indicated no 
main effect of 7 days of FLX treatment [F1,22 = 0.02, p = 0.8993] but a significant 
main effect of challenge injection [F1,22 = 48.25, p < 0.0001].  There was a 
significant interaction between treatment and challenge injection [F1,22 = 4.68, p = 
0.0435].  The Newman-Keuls’ test indicated that saline treatment/(+)8-OH-DPAT 
challenge significantly elevated pAkt (Thr308) in the PVN over the saline-
treated/saline-challenged group (p < 0.01) and also that 7D FLX treatment/(+)8-
OH-DPAT challenge significantly elevated pAkt (Thr308) in the PVN over the 7D 
FLX-treated/saline-challenged group.  Although the basal levels of 
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phosphorylated Akt (Thr308) in the PVN increased by about 70% with 7 days of 
FLX treatment, this did not reach statistical significance.  
The two-way ANOVA for levels of pAkt (Thr308) in the PVN indicated no 
main effect of 14 days of FLX treatment [F1,23 = 0.04, p = 0.8389] but a significant 
main effect of challenge injection [F1,23 = 9.25, p = 0.0064].  There was no 
significant interaction between treatment and challenge injection [F1,23 = 0.06, p = 
0.8101].  Although the (+)8-OH-DPAT increased levels of phosphorylated Akt 
(Thr308) in the PVN in both 14D saline-treated (↑109%) and 14D FLX-treated 
(↑92%), this did not reach statistical significance in the Neuman-Keuls post-hoc 
test.  
B.  Effects of FLX treatment on basal and 5-HT1A receptor-mediated increases in 
levels of pGSK3β in PVN.  As shown in figure 45, (+)8-OH-DPAT increased 
pGSK3β in the PVN of rats treated for 7 days with saline (↑114%) and in rats 
treated for 14 days with saline (↑150%).  Seven days of chronic FLX significantly 
attenuated (+)8-OH-DPAT-induced increases (to only 30% over basal) in pGSK3β, 
and 14D FLX partially attenuated (+)8-OH-DPAT-induced increases (to 80% over 
basal) in pGSK3β.  
The two-way ANOVA for levels of pGSK3β in the PVN indicated no main 
effect of 7 days of FLX treatment [F1,23 = 2.26, p = 0.1480] but a significant main 
effect of challenge injection [F1,23 = 10.35, p = 0.0043].  There was a trend towards 
a significant interaction between treatment and challenge injection [F1,23 = 3.29, p 
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= 0.0846].  The Newman-Keuls’ test indicated that saline treatment/(+)8-OH-
DPAT challenge significantly elevated pGSK3β in the PVN over the saline-
treated/saline-challenged group (p < 0.01).  Seven days FLX treatment 
significantly attenuated increases in pGSK3β induced by (+)8-OH-DPAT 
challenge compared to chronic saline treatment (p < 0.05).  
The two-way ANOVA for levels of pGSK3β in the PVN indicated no main 
effect of 14 days of FLX treatment [F1,23 = 1.48, p = 0.2384] but a significant main 
effect of challenge injection [F1,23 = 20.68, p = 0.0002].  There was no significant 
interaction between treatment and challenge injection [F1,23 = 1.77, p = 0.1984].  
The Newman-Keuls’ test indicated that (+)8-OH-DPAT challenge significantly 
elevated pGSK3β in the PVN over the saline challenge in both the 14D saline-
treated (p < 0.01) and 14D FLX-treated (p < 0.05) groups.   
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Figure 34. (A) Time-course of (+)8-OH-DPAT-induced elevations of pAkt at Thr308 in 
peripubertal rat hypothalamic PVN.  *, ** indicates significant difference (p < 0.05 and p < 0.01, 
respectively) from the saline-challenged group (two-way ANOVA and Newman-Keuls multiple-
range test). N = 7-8 per group.  (B) Representative western blot of pAkt (Thr308) (above) and Akt 
(below) from the PVN of rats treated with either saline or (+)8-OH-DPAT. 
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Figure 35. (A) Time-course of tandospirone-induced elevations of pAkt at Thr308 in peripubertal 
rat hypothalamic PVN.  * indicates significant difference (p < 0.05) from the saline-challenged 
group (two-way ANOVA and Newman-Keuls multiple-range test). N = 7-8 per group.  (B) 
Representative western blot of pAkt (Thr308) (above) and Akt (below) from the PVN of rats 
treated with either saline or tandospirone.  
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Figure 36. (A) Time-course of (+)8-OH-DPAT-induced increases in phosphorylated Akt at Ser473 
in the peripubertal rat hypothalamic PVN.  *, ** indicates significant difference (p < 0.05 and p < 
0.01, respectively) from the saline-challenged group; + indicates significant difference (p < 0.05) 
from 5 minute (+)8-OH-DPAT-challenged group (two-way ANOVA and Newman-Keuls 
multiple-range test). N = 8 per group. (B) Representative western blot of pAkt (Ser473) (above) 
and Akt (below) from the PVN of rats treated with either saline or (+)8-OH-DPAT. 
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Figure 37. (A) Time-course of tandospirone-induced increases in phosphorylated Akt at Ser473 in 
the peripubertal rat hypothalamic PVN.  ** indicates significant difference (p < 0.01) from the 
saline-challenged group (two-way ANOVA and Newman-Keuls multiple-range test).  N = 7-8 
per group. (B) Representative western blot of pAkt (Ser473) (above) and Akt (below) from the 
PVN of rats treated with either saline or tandospirone.  
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Figure 38. (A) Effects of different doses of (+)8-OH-DPAT on phosphorylation of Akt at Thr308 in 
the peripubertal rat hypothalamic PVN at 10 minutes post-injection.  ** indicates significant 
difference (p < 0.01) from the saline-challenged group; +,++ indicates significant difference (p < 
0.05 and p < 0.01, respectively) from the 0.04 mg/kg (+)8-OH-DPAT-challenged group; ## 
indicates significant difference (p < 0.01) from the 0.10 mg/kg (+)8-OH-DPAT-challenged group 
(two-way ANOVA and Newman-Keuls multiple-range test). N = 6-12 per group. (B) 
Representative western blot of pAkt (Thr308) (above) and Akt (below) from the PVN of rats 
treated with either saline or (+)8-OH-DPAT. 
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Figure 39. (A) Effects of different doses of tandospirone on phosphorylation of Akt at Thr308 in 
the peripubertal rat hypothalamic PVN at 10 minutes post-injection.  *, ** indicates significant 
difference (p < 0.05 and p < 0.01, respectively) from the saline-challenged group; +, ++ indicates 
significant difference (p < 0.05 and p < 0.01, respectively) from the 1 mg/kg tandospirone-
challenged group (two-way ANOVA and Newman-Keuls multiple-range test). N = 6-12 per 
group. (B) Representative western blot of pAkt (Thr308) (above) and Akt (below) from the PVN 
of rats treated with either saline or tandospirone. 
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Figure 40. (A) Effects of different doses of (+)8-OH-DPAT on the phosphorylation of Akt at 
Ser473 in the peripubertal rat hypothalamic PVN at 10 minutes post-injection.  ** indicates 
significant difference (p < 0.01) from the saline-challenged group; ++ indicates significant 
difference (p < 0.01) from the 0.04 mg/kg (+)8-OH-DPAT-challenged group; ## indicates 
significant difference (p < 0.01) from the 0.10 mg/kg (+)8-OH-DPAT-challenged group (two-way 
ANOVA and Newman-Keuls multiple-range test). N = 6-12 per group. (B) Representative 
western blot of pAkt (Ser473) (above) and Akt (below) from the PVN of rats treated with either 
saline or (+)8-OH-DPAT. 
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Figure 41. (A) Effects of different doses of tandospirone on the phosphorylation of Akt at Ser473 
in the peripubertal rat hypothalamic PVN at 10 minutes post-injection.  * indicates significant 
difference (p < 0.05) from the saline-challenged group (two-way ANOVA and Newman-Keuls 
multiple-range test). N = 6-12 per group. (B) Representative western blot of pAkt (Ser473) (above) 
and Akt (below) from the PVN of rats treated with either saline or tandospirone. 
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Figure 42. (A) The effects of either saline or the 5-HT1A receptor antagonist WAY100635 on basal 
and 5-HT1A receptor-mediated increases in pAkt (Ser473) in the peripubertal rat hypothalamic 
PVN. * indicates significant difference (p < 0.05) from the respective saline-challenged group; # 
indicates significant difference (p < 0.05 from the saline treated/(+)8-OH-DPAT challenged 
group (two-way ANOVA and Newman-Keuls multiple-range test). N = 6-8 per group. (B) 
Representative western blot of pAkt (Ser473) (above) and Akt (below) from the PVN of rats 
treated with saline or WAY100635 and subsequently challenged with either saline or (+)8-OH-
DPAT. 
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Figure 43. (A) The effects of intra-PVN injection with either vehicle or pertussis toxin (PTX) on 
basal and 5-HT1A receptor-mediated increases in pAkt (Ser473) in the peripubertal rat 
hypothalamic PVN. * indicates significant difference (p < 0.05) from the respective saline-
challenged group (two-way ANOVA and Newman-Keuls multiple-range test). N = 6-12 per 
group.  (B) Representative western blot of pAkt (Ser473) (above) and Akt (below) from the PVN 
of rats treated with vehicle or PTX and subsequently challenged with either saline or (+)8-OH-
DPAT. 
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Figure 44. The effects of (A) 7 days and (B) 14 days of chronic FLX injections on basal and 5-HT1A 
receptor-mediated increases in pAkt (Thr308) in the peripubertal rat hypothalamic PVN. ** 
indicates significant difference (p < 0.01) from the respective saline-challenged group (two-way 
ANOVA and Newman-Keuls multiple-range test). N = 5-6 per group. (C) Representative western 
blot of pAkt (Thr308) (above) and Akt (below) from the PVN of rats treated with sal or FLX and 
subsequently challenged with either saline or (+)8-OH-DPAT.  7D treatment is on the left and 
14D treatment is on the right. 
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Figure 45. The effects of (A) 7 days and (B) 14 days of chronic FLX injections on basal and 5-HT1A 
receptor-mediated increases in pGSK3β in the peripubertal rat hypothalamic PVN. *, ** indicates 
significant difference (p < 0.05 and p < 0.01, respectively) from the respective saline-challenged 
group; # indicates significant difference (p < 0.05) from the respective vehicle-treated group (two-
way ANOVA and Newman-Keuls multiple-range test). N = 6 per group. (C) Representative 
western blot of pGSK3β (above) and GSK3β (below) from the PVN of rats treated with sal or FLX 
and subsequently challenged with either saline or (+)8-OH-DPAT.  7D treatment is on the left 
and 14D treatment is on the right. 
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DISCUSSION 
 
Stressors suffered during childhood and adolescence (e.g., bullying, home 
displacement as with Hurricane Katrina, and abuse) and mental disorders such 
as depression have all been linked to hypothalamic dysfunction (Vaillancourt et 
al., 2007; Lopez-Duran et al., 2009; Vigil et al., 2010; Hankin et al., 2010).  
Preclinical studies have determined that, in a rat model of chronic stress, levels of 
pAkt were increased in the hypothalamus, hippocampus, and striatum, with the 
largest increases observed in the hypothalamus (Lee et al., 2006).  5-HT1A 
receptor agonists have been shown to increase levels of phosphorylated Akt and 
its downstream effectors in vitro (Adayev et al., 1999; Cowen et al., 2005; Hsiung 
et al., 2005) and in vivo (Polter et al., 2010).  The studies described in this chapter 
provide the first demonstration that 5-HT1A receptors can activate Akt via 
phosphorylation of Thr308 and Ser473 in the rat hypothalamus, and the first to 
characterize this signal transduction pathway and its regulation by fluoxetine in 
the peripubertal PVN. 
Our data reveal that the agonist (+)8-OH-DPAT mediates phosphorylation of 
Akt specifically via 5-HT1A receptors in the peripubertal PVN.  (+)8-OH-DPAT 
elevated levels of pAkt at Ser473 in the PVN, which was completely blocked by 
pretreatment with the 5-HT1A receptor antagonist WAY100635.  Recent evidence 
reveals that phosphorylation of Akt at Ser473 (within the hydrophobic motif of 
the protein) may promote recruitment of Akt to the plasma membrane and 
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enhances the interaction between Akt and PDK1, leading to the subsequent 
phosphorylation of Akt at Thr308 (Sarbossov et al., 2005).  Therefore, we did not 
measure levels of pAkt Thr308 in this experiment but, considering that 
phosphorylation of Akt at Ser473 most likely precedes that of Thr308, we would 
expect that (+)8-OH-DPAT-mediated increases in pAkt at Thr308 (as measured in 
other experiments in this chapter) is primarily by 5-HT1A receptors.  
Both Thr308 and Ser473 must be phosphorylated in order to fully activate Akt 
(Alessi et al., 1996).  Each of these sites is phosphorylated by different (and most 
likely independently regulated) upstream kinases:  PDK1 phosphorylates Thr308 
(Alessi et al., 1997; Anderson et al., 1998; Stephens et al., 1998), and the 
rictor/mTOR complex has recently been identified as the kinase for Ser473 
(Sarbassov et al., 2005).  We have shown that injection with two different 5-HT1A 
receptor agonists, (+)8-OH-DPAT and tandospirone, resulted in a rapid 
phosphorylation of Akt at both Thr308 and Ser473, although the magnitude of 
phosphorylation varied with agonist.  (+)8-OH-DPAT induced a higher maximal 
effect and was more potent than tandospirone in phosphorylating Akt at both 
Thr308 and Ser473.  These data indicate that (+)8-OH-DPAT is a “full” agonist 
and tandospirone a “partial” agonist in 5-HT1A receptor-mediated 
phosphorylation of Akt in the peripubertal PVN.  Therefore, (+)8-OH-DPAT may 
more effectively couple to the pathway initiating PDK1 phosphorylation of Akt 
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at Thr308 and the raptor/mTOR-mediated phosphorylation of Akt at Ser473 than 
tandospirone.   
A previous study had shown that 5-HT1A receptor-mediated activation of Akt 
in hippocampal cell cultures can be blocked with pertussis toxin (PTX) treatment 
(Cowen et al., 2005), indicating that 5-HT1A receptor-mediated activation of Akt 
could be dependent on PTX-sensitive Gi/o proteins.  In experiment 4 of this 
chapter, we determined that intra-PVN injection with PTX prevented significant 
elevations of 5-HT1A receptor-mediated phosphorylation of Akt at Ser473.  
Therefore, since Gαi1 and Gα2 proteins were the only Gα proteins reduced with 
PTX treatment (Chapter 4), these proteins may be playing a role in 5-HT1A 
receptor-mediated phosphorylation of Akt.  However, considering that   PTX 
treatment also increased basal levels of phosphorylated Akt at Ser473, this could 
have precluded obtaining a significant (+)8-OH-DPAT-induced increase above 
basal.  Therefore, we cannot rule out the possibility that 5-HT1A receptors may be 
signaling via Gαi3, Gαo, or Gαz to mediate the phosphorylation and activation 
of Akt in the peripubertal PVN.  Additionally, the PTX-induced increase in 
hypothalamic Gαo proteins may produce the elevations in basal pAkt (Ser473).  
Alternatively, 5-HT1A receptor-mediated Akt activation could be mediated by a 
mechanism other than one mediated by G proteins.  Akt can directly associate 
with Gβγ subunits in rat brain extracts (Konishi et al., 1995).  Akt can also be 
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activated in a G protein-independent, β-arrestin dependent manner, as has been 
demonstrated in fibroblast cell lines (Goel et al., 2002; Povsic et al., 2003).         
Akt activation leads to an increase in phosphorylated GSK3β, which 
inactivates this constitutively active protein kinase (Cross et al., 1995).  In mice, 
acute injection with fluoxetine increases levels of pGSK3β in the mouse 
prefrontal cortex, hippocampus, and striatum, which is most likely due to a 
synaptic increase in 5-HT and subsequent activation of 5-HT1A receptors (Li et al., 
2004).  However, it was not known if the 5-HT1A receptor-mediated activation of 
the Akt pathway in the peripubertal PVN was subject to regulation upon chronic 
treatment with FLX.  We determined that 5-HT1A receptor-mediated 
phosphorylation of Akt is generally not affected with either 7 or 14 days of FLX.  
However, 14 days of injections with either saline or FLX rendered the animals 
hyporesponsive to the effects of (+)8-OH-DPAT on 5-HT1A receptor-mediated 
phosphorylation of Akt.  This effect was also observed with the 5-HT1A receptor-
mediated activation of ERK (Chapter 4).  There may be stress-related effects upon 
an additional 7 days of injection.  Alternatively, starting injections at PD 28 (as 
with the 14 day treatment paradigm used) as opposed to PD 35 (as with the 7 day 
treatment paradigm used) may have exposed the animals to injection stress at a 
critical point in postnatal development.  Although we did not observe any 
specific FLX-induced effects on 5-HT1A receptor-mediated activation of Akt, its 
downstream target GSK3β was differentially affected by the 7 and 14 day chronic 
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treatments.  There was no hyporesponsive effect of 14 days of injection (as 
observed with (+)8-OH-DPAT challenge on pERK and pAkt) in either saline or 
FLX-treated animals on phosphorylated levels of GSK3β.  We observed almost a 
complete desensitization of (+)8-OH-DPAT-induced increases in pGSK3β with 7 
days FLX treatment.  With 14 days of FLX treatment, this desensitization is not as 
marked.  Either the levels of pGSK3β elicited by (+)8-OH-DPAT were starting to 
recover or, alternatively, starting treatment earlier in postnatal development was 
not having a robust effect on (+)8-OH-DPAT-stimulated pGSK3β.  FLX could 
possibly be modulating the protein levels or activity of a pGSK3β-specific 
phosphatase, which may account for the differential effects on GSK3β but not 
Akt phosphorylation.  Duric et al. determined that chronic stress increases 
hippocampal levels of a phosphatase specific for MAPK, and that 
antidepressants normalize the levels of this phosphatase (Duric et al., 2010).  
More closely linked with the Akt/GSK3β signaling pathway, protein levels of 
PP1 phosphatase, the primary phosphatase for GSK3β in COS-7 cell cultures 
(Hernandez et al., 2010), were increased in the frontal cortex and hippocampus of 
adult rats subjected to a model of depression compared to sham rats (Feng et al., 
2003).  Therefore, chronic FLX may be regulating the protein levels or activity of 
phosphatases specific to GSK3β.   
Together, these data provide the first in vivo demonstration that 5-HT1A 
receptors can activate Akt in the peripubertal PVN.  Given the previous studies 
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demonstrating that 5-HT1A receptors can stimulate hormone responses and 
activate ERK activation in the peripubertal PVN, these findings are the first to 
show that 5-HT1A receptors can mediate the concomitant activation of three 
signaling pathways in peripubertal hypothalamic PVN and that chronic FLX can 
regulate downstream targets of 5-HT1A receptor-mediated Akt pathways in the 
peripubertal PVN in vivo.  
 
 184 
CHAPTER 7 
DETAILED METHODS 
 
ANIMALS  
Male Sprague-Dawley rats were purchased from Harlan (Indianapolis, IN).  
The determination of post-natal day zero (day of birth) was carried out by the 
supplier.  All animals had 2-3 days to acclimate to their home cage and were 
housed two per cage in a room controlled for temperature (20-22°C), humidity 
(50-55%), and illumination (12h: 12h light/dark cycle; lights on at 07:00 h).  Food 
and water were available ad libitum.  All procedures were conducted in 
accordance with the National Institutes of Health Guide for the Care and Use of 
Laboratory Animals as approved by Loyola University Institutional Animal Care 
and Use Committee (IACUC).  Every effort was made to minimize suffering and 
discomfort to the animals. The number of rats per group was the minimum 
needed to obtain statistically meaningful evaluation of the data.  Our power 
analysis and past experience indicate that a minimum of 8 rats per group is 
needed to obtain hormone data that can be analyzed statistically because ACTH 
and oxytocin are “stress hormones” (Jezova et al., 1993; Jezova et al., 1996) and 
some rats may be more sensitive to stress effects of handling and injection.   
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HORMONE DETERMINATIONS 
Blood collection and centrifugation.  After sacrifice, trunk blood was 
collected in centrifuge tubes containing 0.3 M ethylenediamine tetraacetic acid 
solution (EDTA, pH 7.4; 0.25 ml for peripubertal or prepubertal rats and 0.50 ml 
for adult rats).  The blood was centrifuged at 3000 x g for 40 minutes at 4°C and 
the plasma was divided into aliquots.  Plasma aliquots were stored at -80°C until 
the respective hormones were determined by radioimmunoassay.   
Plasma oxytocin radioimmunoassay.  Plasma levels of oxytocin were 
determined by a double antibody assay using methods modified from Li et al. 
(1997).  First, plasma was extracted the day before the start of the assay.  Rat 
plasma (0.80 ml) was mixed with 1.6 ml ice cold acetone and centrifuged at 
1600xg, at 4°C for 30 min.  Then, the supernatant was added to 4 ml ice cold 
petroleum ether and thoroughly mixed by inverting the tube several times.  This 
mixture was centrifuged at 1600xg, at 4°C for 15 min.  The top layer was 
aspirated and discarded and the remaining solution was dried by blowing air 
into the tubes at 4°C.  A known quantity of oxytocin standard was added to 
several tubes of normal rat plasma; these tubes were used to determine the 
efficiency of the extraction.  The tubes containing the dried extract were stored 
overnight at 4°C. 
On the day of the assay, the dried extract was reconstituted in 0.80 ml of 
assay buffer (0.05 M phosphate buffer, pH 7.4, containing 0.125% bovine serum 
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albumin, 0.01% sodium azide and 0.001 M EDTA).  The reconstituted plasma 
extract (100 μl or 200 μl, each in duplicate) and oxytocin standards (Bachem Fine 
Chemicals, Torrance, CA) were incubated with 0.1 ml of rabbit anti-oxytocin 
serum (1:5,000 dilution) in a total volume of 0.4 ml for 24 hr at 4°C. 125I-oxytocin 
(Du Pont-NEN, Boston, MA, 3000 cpm, 0.1 ml) was then added to the tubes and 
incubated for 72 hr at 4°C.  Next, 0.1 ml goat anti-rabbit γ-globulin (1:20 dilution) 
was added to each of the tubes, followed by 0.1 ml of normal rabbit serum (1:120 
dilution). After incubation for 24 hr, the tubes were centrifuged at 2300xg, at 4°C 
for 20 min. The supernatant was decanted, and the radioactivity in the pellet was 
counted for 5 min by a Micromedic 4/200 plus γ counter and analyzed from the 
standard curve using the RIA-AID computer program (Robert Maciel Associates, 
Arlington, MA). The concentration of plasma oxytocin was calculated with a 
correction factor based on the recovery of the extraction. The sensitivity limit of 
this assay is 1 pg/tube, and the intra- and interassay variabilities are 8.1% and 
8.6%, respectively. 
Plasma ACTH radioimmunoassay.  This assay is a double-antibody assay 
and was performed as previously described (Van de Kar et al., 1989).  Briefly, 
plasma from each rat (unextracted plasma samples, 10 μl and 50 μl each in 
duplicate) and ACTH standards (Calbiochem, Los Angeles, CA) were incubated 
with 0.1 ml of rabbit anti-ACTH antibody (IgG Corp, Nashville, TN) in a total 
volume of 0.2 ml for 24 hr at 4°C. 125I-ACTH tracer (DiaSorin, Inc., Stillwater, MN) 
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was then added to the tubes and incubated for 48 hr at 4°C.  Next, 0.1 ml goat 
anti-rabbit γ-globulin (1:20 dilution) was added to each of the tubes. After 
incubation for 24 hr, 1.5 ml cold PBS buffer (0.01 M phosphate buffer + 0.15 M 
NaCl, pH 7.6) were added to each of the tubes.  The tubes were then centrifuged 
at 2300xg, at 4°C for 40 min. The supernatant was decanted, and the radioactivity 
in the pellet was counted for 5 min by a Micromedic 4/200 plus γ counter and 
analyzed from the standard curve using the RIA-AID computer program (Robert 
Maciel Associates, Arlington, MA).  The sensitivity limit of this assay is 0.25 
pg/tube, and the intra- and inter-assay variability is 4.2% and 14.6%, respectively 
(Van de Kar et al., 1989). 
 Plasma testosterone radioimmunoassay.  This assay is a solid-phase 
radioimmunoassay, based on testosterone-specific antibody immobilized to the 
wall of a polypropylene tube.  The Coat-A-Count® Total Testosterone kit was 
purchased from Siemens (Los Angeles, CA).  Briefly, plasma from each rat (50 μl, 
in duplicate) was placed in an antibody-coated tube and incubated with 1.0 ml of 
125I-testosterone for 3 hours at 37°C with light shaking.  After this incubation, the 
supernatant was decanted, and the radioactivity in the pellet was counted for 3 
min by a Micromedic 4/200 plus γ counter and analyzed from the standard curve 
using Microsoft Excel. The sensitivity limit of this assay is 4 ng/dl, and the intra- 
and inter-assay variability is 7.3% and 11.0%, respectively. 
 
188 
 
WESTERN BLOTTING  
 Microdissection of brain areas of interest.  Brains were placed in a cryostat 
at -12°C.  A 650 μm coronal section including the PVN was cut from each brain.  
This section was placed on a glass slide and adhered onto slides with Tissue Tek.  
The slides were then placed on a large deep Petri dish on an ice/salt mixture (to 
maintain the temperature at -5°C).  The hypothalamic PVN was dissected from 
its slice as a triangular “punch” (Crane et al., 2007; Serres et al., 2000a).   
 In the pertussis toxin experiment (Chapter 4), brains from each of the 
treatment groups (vehicle and PTX) had the whole hypothalamus dissected 
immediately after the brain was removed from the skull.  Each whole 
hypothalamus was placed in a tube and immediately frozen in liquid nitrogen.  
 In the developmental G protein study (Chapter 4), the frontal cortex was 
removed from each frozen brain, and the olfactory bulbs were separated from 
cortical tissue and discarded.  An additional 1100 μm coronal section including 
the hippocampus was also cut after the PVN section.  The hippocampus was 
removed from its respective coronal section with the use of a small angular 
blade.  Each of these respective brain regions were placed in individual 1.5 ml 
eppendorf tubes and stored at -80°C until prepared for western analysis. 
 Tissue preparation for the determination of pERK/ERK, pAkt/Akt, and 
pGSK3β/GSK3β.  The tissue preparation was performed using methods 
modified from Crane et al. (2007), and all procedures were conducted at 4°C 
189 
 
unless otherwise noted.  Briefly, the PVN was homogenized in 10 mM Tris buffer 
(pH 7.6) containing 100 mM NaCl, 1 mM EDTA, 2 mM activated sodium 
orthovanadate, and 50 mM NaF with additional protease inhibitors purchased in 
a cocktail (1 μg/10 mg of tissue; Sigma, St. Louis, MO).  This homogenate was 
stored at -80°C until ready for Western blot analysis.  A bicinchoninic acid (BCA) 
assay (Pierce Chemical, Rockford, IL) was performed to quantify total protein as 
per the manufacturer’s microplate procedure.  
 Tissue preparation for the determination of the levels of G proteins.  All 
procedures were conducted at 4°C unless otherwise indicated.  The tissues (PVN, 
hippocampus, frontal cortex, or whole hypothalamus) were homogenized in 50 
mM Tris buffer (pH 7.7) containing 150 mM NaCl, 10% sucrose, 0.5 mM 
phenylmethanesulfonyl fluoride (PMSF) and additional protease inhibitors 
purchased as a cocktail (1 μl/30 mg of tissue; Sigma, St. Louis, MO).  After 
centrifugation at 20,000 x g for 60 min, the supernatant was collected, aliquoted, 
and stored at -80°C for Western blot analyses of cytosol-associated protein levels. 
The pellets (containing the membrane-associated proteins) were solubilized and 
resuspended in 20 mM Tris buffer (pH 8), containing 1 mM EDTA, 100 mM 
NaCl, 1% sodium cholate, and 1 mM dithiothreitol, plus the protease inhibitory 
cocktail (1 μl/30 mg of tissue). The resuspended homogenates were placed on a 
shaker for 1 h at 4°C, followed by centrifugation at 40,000 x g for 60 min. The 
supernatant was collected, aliquoted, and stored at -80°C for Western blot 
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analyses of membrane-associated protein levels. Protein concentrations were 
measured using a bicinchoninic acid (BCA) protein assay kit (Pierce Chemical, 
Rockford, IL) (Li et al., 1996). 
 Separation of proteins using electrophoresis.  This assay was performed 
using methods modified from Li et al. (1996) and Crane et al. (2007).  Protein (1-7 
μg per lane) was loaded on 12.5% polyacrylamide gel and separated by 
electrophoresis (200 constant volts, 60-70 minutes).  Proteins were subsequently 
electrophoretically transferred onto a nitrocellulose membrane (100 constant 
volts, 50-60 minutes).  After transfer, the nitrocellulose membranes were 
incubated for 1 hour at room temperature on a shaker in a blocking solution of 
0.1 M phosphate-buffered saline (PBS) containing 5% bovine serum albumin and 
0.1% Tween-20 when probing for phosphorylated proteins or 0.1 M PBS 
containing 0.2% I-block (Tropix, Inc.) and 0.05% Tween-20 when probing for 
non-phosphorylated proteins.  The blot was then incubated in primary antibody 
overnight at 4°C on a shaker (with an intermediate washing step of 2 x 2 minutes 
with 0.1 M PBS with 0.1% Tween-20 for phosphorylated proteins). Primary 
antibodies (from Cell Signaling: pERK, ERK, pAkt (Ser473), pAkt (Thr308), Akt, 
pGSK3β, and GSK3β; from Santa Cruz: Gαz and Gαi1; from Upstate: Gαi3/o; from 
Chemicon: Gαi2; and from ICN Biomedicals: actin) were diluted in the same 
blocking solution used.  The blots were then washed (2 x 5 minutes, 1 x 10 
minutes) in 0.1 M PBS with 0.1% Tween-20 and subsequently incubated in goat 
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anti-rabbit-HRP-conjugated (for pERK, ERK, Gαi3/o, and Gαz) or goat anti-
mouse-HRP-conjugated (for Gαi1, Gαi2, and actin) for 1 hour at room temperature 
on a shaker.  HRP-labeled protein bands were detected with ECL (Amersham 
Chemical Co.) and captured on film as per the manufacturer’s protocol (Crane et 
al., 2007; Li et al., 1996).   
 Immunoblot film analysis.  Films were analyzed densitometrically using 
Scion Image software (Scion Corporation, Frederick, MD).  The gray-scale 
density readings were calibrated using a transmission step-wedge standard.  The 
integrated optical density (IOD) of each band was calculated as the sum of 
optical densities of all the pixels within the area of the band outlined.  An area 
adjacent to the outlined protein band was used to calculate the background 
optical density of the film and was subtracted from the IOD for each band.  To 
control for inter-gel variability, the resulting IOD for each protein band was then 
divided by the average IOD from the control group (i.e., saline-challenged) 
protein bands contained in the same blot. Since tissue samples were measured on 
three independent gels, the mean “% of control” obtained from the three gels 
represent the data for each rat.  The mean % of control for phosphorylated ERK, 
Akt, GSK3β, or G for each animal was divided by the mean % of control for the 
respective non-phosphorylated or actin protein level to control for differences in 
gel loading (modified from Crane et al., 2007).   
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STEREOTAXIC SURGERY AND PERTUSSIS TOXIN INJECTION 
 For the pertussis toxin experiment, rats were anesthetized with a mixture of 
ketamine and xylazine (100 mg ketamine plus 7 mg xylazine per ml, 1.4 ml/kg, 
i.p.) and a double-barreled guide cannula (26 gauge, 1.2 mm center-to-center 
distance, Plastics One, Roanoke, VA) with its corresponding dummy cannula 
inserted inside was implanted into the brain above both sides of the 
paraventricular nucleus at the following stereotaxic coordinates: 1.6 mm caudal 
with respect to bregma, -0.6 mm lateral with respect to lambda, and 6.0 mm 
ventral from the skull surface.  All cannula implantations were performed on rats 
that were at least PD 31.  Rats were allowed to recover for several days before 
further treatment.  Administration of PTX was performed according to 
procedures previously established in adult rats (Garcia et al., 2006).  An injection 
cannula was inserted through the implanted guide cannula above the PVN, and 
rats received an intracerebral injection of vehicle (100 mM sodium phosphate + 
500 mM NaCl, 0.5 μl/side) or PTX (1 μg/μl, 0.5 μl/side) over 1 minute.  The 
injection cannula was left in situ for an additional 1 minute before removal.  The 
brains were visually inspected during dissection to ensure proper implantation 
of the cannula.   
IMMUNOHISTOCHEMISTRY 
 Immersion Fixation of Brain Tissue.  This protocol was adapted from Khan 
and Watts, 2004.  Immediately after harvest, brains were placed in ice-cold 
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sodium acetate-buffered 4% paraformaldehyde (pH 6.5) and were then stored at 
4°C.  After 24 hours, each brain was removed from the fixative, gently blotted 
dry, and placed in sodium borate-buffered 4% paraformaldehyde (pH 9.5) at 4°C 
for 48 hours.  Brains were then transferred to 0.1 M sodium phosphate buffered 
4% paraformaldehyde (pH 7.4) and 20% glycerol at 4°C for 1-2 days (until brains 
had sunk to the bottom of the container).  Sections were cut on a sliding 
microtome in the coronal plane at 30 μm and stored as serial sets of one section in 
every twelve in ethylene-glycol based cryoprotectant solution and stored at -20°C 
until processed.   
 Colocalization of Oxytocin and pERK.  For double-labeling for oxytocin and 
pERK, labeling protocols with immunofluorescence detection were adapted from 
Garcia-Ovejero et al., 2002; Khan and Watts et al., 2004; Khan et al., 2007; Lorenz 
et al., 2005.  All washes and incubations were performed on free floating sections 
with shaking at room temperature unless otherwise indicated.  First, brain 
sections were rinsed 3 times for 10 minutes each with Tris-buffered saline (TBS) 
(50 mM Tris and 150 mM NaCl, pH 7.4). The slices were then transferred to TBS 
containing 0.3% Triton X-100 for 50 minutes to permeabilize the sections. 
Sections were then incubated for 72 h at 4°C with anti-oxytocin rabbit polyclonal 
antiserum (Calbiochem) at a concentration of 1:1000 and mouse anti-phospho-
p44/42 MAPK (ERK1/2) monoclonal antiserum (Cell Signaling) at a 
concentration of 1:800 in antibody solution (TBS + 2% normal goat serum).  
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Sections were then rinsed three times for 5 min each in TBS.  Next, the slices were 
incubated with a combination of secondary antibodies for 2 hours at RT: 
Invitrogen goat anti-rabbit conjugated to Alexa568 (1:200) and Vector 
biotinylated goat anti-mouse (1:250) in secondary solution (TBS + 2% normal 
goat serum + 1% Triton X-100). After three washes of 10 min each (TBS), the 
slices were incubated with streptavidin conjugated to Alexa488 (Invitrogen; 1:200 
in TBS) for 2 hours at RT.  Lastly, the slides were washed again with TBS for 
three times 10 min each and two times 15 min each.  Sections were mounted on 
gelatin-coated slides, allowed to dry for 30-40 minutes and then coverslipped 
with Fluoro-gel (Electron Microscopy Science #17985) and subsequently stored in 
a foil-wrapped box at 4°C.  The sections were allowed to dry thoroughly and 
were later analyzed using an Olympus IX-81 fluorescent microscope.  
Additionally, some slides were analyzed with a confocal microscope (Zeiss 
LSM510) at a higher magnification to confirm localization of fluorescent markers.  
DATA ANALYSIS 
 The data are represented as group means and the standard errors of the 
means (S.E.M.).  GB-STAT software (Dynamic Microsystems, Inc.) was used for 
all statistical analyses.   
For the immunohistochemistry experiment, to quantify the number of PVN 
neurons labeled for oxytocin or 5-HT1A receptor-stimulated pERK, two sections 
from each rat were selected for analysis. These sections corresponded in plane 
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and rostrocaudal position most closely to that represented in plate 26 of Paxinos 
and Watson, 1998.   For each fluorophore (Alexa488 and Alexa568), a stack of 30 
images (1 μm per image) was obtained for each half of the PVN using an 
Olympus IX-81 fluorescent microscope.  Each 1 μm-thick image was 
deconvolved using MicroTome Deconvolution 7.0 (VayTek, Fairfield, IA) and 
compressed into one composite image by ImagePro v6.3 (Scitech, Preston, 
Victoria, Australia).  Therefore, 4 composite images were obtained for each rat 
for each fluorophore.  Using Image J (NIH), each composite image was inverted 
so that the cell labeling for either oxytocin or pERK appeared as shades of gray 
on a white background.  Then, optical density for each image was determined by 
first calculating the density of the shaded pixels in an 850 pixel by 950 pixel area 
(encompassing either the left or right half of the PVN), which was then compared 
to a calibrated optical density step tablet.  The integrated density is defined as the 
product of the pixel area and the optical density.  Also, the total cell count for 
each composite image was obtained using particle analysis in the ImageJ 
program.  Therefore, the cell density is defined as the number of particles within 
the 850 x 950 pixel area for each composite image.  The average of the integrated 
density and cell density was calculated from the values for each composite image 
(4 per rat).  Confocal images were processed using Zeiss LSM Image Browser and 
ImageJ.   
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CHAPTER 8 
GENERAL DISCUSSION 
The serotonin 1A (5-HT1A) receptor was one of the first serotonin receptor 
subtypes to be investigated with respect to its pharmacological functions and 
regional distribution in brain.  Although the somatodentritic 5-HT1A autoreceptor 
population has received much attention due to its involvement in the therapeutic 
efficacy of various drugs used to treat mood disorders, postsynaptic 5-HT1A 
receptors on non-serotonergic cells may also be involved with antidepressant-
induced neuroadaptations.  Post-synaptic 5-HT1A receptors are localized in 
various brain regions such as the hippocampus, frontal cortex, and 
hypothalamus (Kia et al., 1996a; Kia et al., 1996b; Blier and Ward 2003; Marvin et 
al., 2010), where they can initiate a variety of signal transduction cascades 
(Raymond et al., 2001).  5-HT1A receptors in the hypothalamus are involved in 
the serotonergic stimulation of various hormones and regulation of the 
hypothalamic-pituitary-adrenal (HPA) axis.  Recent studies have also shown that 
hypothalamic 5-HT1A receptors can activate extracellular signal regulated kinase 
(ERK) (Sullivan et al., 2005; Crane et al., 2007), a protein kinase involved with 
many functions including gene expression, mitosis, differentiation, cell 
survival/apoptosis, learning, memory, neuroplasticity, and receptor
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desensitization (Marshall 1995; Pouysségur and Lenormand 2003; Trincavelli et 
al., 2002).  However, the majority of information on 5-HT1A receptor signaling 
has been obtained from in vitro studies in cells or in vivo studies in adult animal 
models.  Similarly, studies on the mechanisms of 5-HT1A receptor signaling in 
vivo in hypothalamic paraventricular nucleus (PVN) have also utilized adult 
animal models.  Prior to these dissertation studies, there have been no 
comparable studies on 5-HT1A receptor signaling in the peripubertal 
hypothalamic PVN.  Considering the significant contribution of the serotonergic 
system over brain development around the time of sexual maturation (Whitaker-
Azmitia 2001), the role of serotonin in regulating neuroendocrine function, and 
that serotonergic modulation (e.g. with antidepressant treatment) produces 
responses that are distinct and more long-lasting than those produced in adults 
(Maciag et al., 2006; Ansorge et al., 2004; Taravosh-Lahn et al., 2006; Oh et al., 
2009), this dissertation investigated 5-HT1A receptor-mediated signaling 
pathways in the hypothalamic PVN of peripubertal rats.    
 Previous studies demonstrated, in the adult rat hypothalamic PVN, 5-HT1A 
receptors activate independent signaling pathways (utilizing different Gα 
protein subtypes):  Gαz proteins exclusively mediate the 5-HT1A receptor-
induced increase in plasma levels of oxytocin and adrenocorticotropin hormone 
(ACTH) (Serres et al., 2000a) and concomitantly activate the mitogen-activated 
protein kinase (MAPK) ERK via pertussis toxin-sensitive Gαi/o proteins (Crane 
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et al., 2007; Garcia et al., 2006; Sullivan et al., 2005).  These pathways are 
independent, as blockade of ERK signaling does not alter 5-HT1A signaling of 
hormone responses (Jia et al., 2007).   
 The present studies provide the first in vivo evidence that 5-HT1A receptors in 
the peripubertal PVN mediate the concomitant activation of multiple hormone 
and kinase signaling responses.  More specifically, these dissertation studies 
demonstrated that 5-HT1A receptors stimulate increases in plasma levels of 
oxytocin and ACTH, phosphorylation of ERK, and phosphorylation of protein 
kinase B (Akt).  We have also determined that Gα proteins may be uniquely 
regulated in the peripubertal PVN and that these proteins may be playing a 
broader or different role in 5-HT1A receptor-mediated signaling and 
desensitization in the peripubertal PVN than previously established in the adult 
PVN.  The data also demonstrate that 5-HT1A receptor-mediated pathways may 
be differentially responsive to different classes of 5-HT1A agonists.  (+)8-OH-
DPAT (an aminotetralin), acted as a “full” agonist on the 5-HT1A receptor-
mediated neuroendocrine and kinase responses.  In contrast, tandospirone (an 
azapirone) exhibited “partial” agonist activity with regards to Akt activation 
despite “full” agonist activity in stimulating increases in both oxytocin and 
ACTH and in the activation of ERK.  5-HT1A receptor-mediated activation of ERK 
in the peripubertal PVN is a rapid and prolonged response, unlike the rapid but 
transient nature of this response observed in the adult PVN.  These studies also 
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suggest that ERK activation may be expressed only in certain populations of 
neuroendocrine cells in the peripubertal PVN.  We have also determined that 5-
HT1A receptor-mediated increases in the phosphorylation of GSK3β were 
attenuated in fluoxetine-treated peripubertal rats in the absence of changes in 
Akt activation.  These data suggest that fluoxetine may be altering phosphatase 
activity or that Akt may not be the kinase responsible for GSK3β 
phosphorylation in PVN or at this developmental age. 
 These unique aspects of 5-HT1A receptor signaling in the peripubertal brain 
may be involved with differences in therapeutic and/or side effects of SSRIs in 
adult vs. young patients or may represent novel drug targets to treat mood 
disorders in children and adolescents. 
5-HT1A receptor signaling in the peripubertal PVN 
In the peripubertal PVN, activation of 5-HT1A receptors leads to increases in 
plasma levels of both oxytocin and ACTH hormones and increases the levels of 
activated (phosphorylated) ERK (pERK) in the PVN (Chapter 3).  Furthermore, 
we determined that 5-HT1A receptor activation increases activated 
(phosphorylated) Akt (pAkt) in the peripubertal PVN (Chapter 6).   
 5-HT1A receptors activate the mitogen activated protein kinase (MAPK) ERK in the 
peripubertal PVN.  In the adult PVN, activation of ERK is a rapid but transient 
response, as the aminotetralin “full” agonist (+)8-OH-DPAT significantly 
elevates levels of activated ERK at 5 minutes which returns to basal levels by 15 
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minutes post-injection (Crane et al., 2007).  Tandospirone, an azapirone “partial” 
agonist at postsynaptic 5-HT1A receptors, also increases pERK in the adult rat 
PVN (Sullivan et al., 2005) although the time- and dose-dependence of 
tandospirone on 5-HT1A receptor-mediated pERK responses has not been 
determined in the adult PVN.  In the peripubertal PVN, (+)8-OH-DPAT and 
tandospirone also produced rapid (≤ 5 minutes) increases in pERK.  However, in 
contrast to adult PVN, 5-HT1A receptor-mediated activation of ERK in the 
peripubertal PVN was prolonged, remaining elevated over basal at least 30 
minutes after injection.  These data demonstrate that (+)8-OH-DPAT produced a 
more prolonged 5-HT1A receptor-mediated increase in pERK in the PVN of 
peripubertal rats as compared to that previously published in adult PVN.  Age-
dependent effects on ERK signaling have also been demonstrated in response to 
peptide-induced activation of NMDA receptors in the spinal cord of rats (Chiu et 
al., 2010).  Prolonged ERK activation in the PVN of peripubertal rats could 
impact a variety of cellular functions under the control of ERK.  In a variety of 
mammalian cell lines, the duration of ERK signaling is associated with distinct 
cell behavior (Traverse et al., 1992; Nguyen et al., 1993; Mansour et al., 1994; 
Sharp et al., 1997; Whalen et al., 1997; Murphy et al., 2002; Murphy et al., 2004; 
Sinnett-Smith et al., 2004).  For example, prolonged but not transient ERK 
activation was associated with (1) neuronal differentiation in PC-12 cells 
(Traverse et al., 1992), (2) nuclear translocation of ERK in PC12 cells (Nguyen et 
201 
 
al., 1993), and (3) c-fos accumulation and DNA synthesis in Swiss 3T3 cells 
(Sinnett-Smith et al., 2004).  In consideration of our previous findings that ERK is 
required for SSRI-induced desensitization of 5-HT1A receptor-mediated 
neuroendocrine responses in the adult PVN, a more prolonged ERK signaling in 
the immature brain could potentially induce a more rapid desensitization of 5-
HT1A receptor-mediated hormone responses upon administration of SSRIs.   
 In Chapter 5, we demonstrated that cells in the peripubertal PVN that were 
immunoreactive for oxytocin were localized distinct from cells displaying 
immunoreactivity for 5-HT1A receptor-mediated pERK.  Our preliminary data 
suggested that these markers were localized in distinct cell populations in the 
adult PVN as well.  These data are consistent with the literature suggesting that 
little to no receptor-stimulated ERK is observed in oxytocin-containing cells 
(Wang et al., 2006; Blume et al., 2009; Jankord et al., 2010).  In the adult PVN, 
intact ERK signaling is necessary for SSRI-induced desensitization of 5-HT1A 
receptor-mediated oxytocin neuroendocrine responses (Jia et al., 2007).  The 
findings of the current study suggest that the effects of ERK on SSRI-induced 
desensitization of 5-HT1A receptor-mediated oxytocin responses in the adult PVN 
may be induced via a cell-to-cell mechanism rather than via a more direct 
intracellular communication between signaling pathways.  Nevertheless, the 
present immunohistochemical studies indicate that 5-HT1A receptors mediating 
oxytocin responses exhibit a different localization than those 5-HT1A receptors 
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responsible for the activation of ERK.  It is currently unknown if ERK is 
necessary for SSRI-induced desensitization of 5-HT1A receptor-mediated oxytocin 
responses in the peripubertal PVN.  If so, the current data suggest that similar 
cell-to-cell mechanisms are likely operative in the immature brain.  In contrast, 
receptor-stimulated pERK localizes with corticotrophin releasing hormone 
(CRH)-immunoreactive cells in the PVN (Khan et al., 2007).  Consistent with 
these findings, we have preliminary data that suggest, in the peripubertal PVN, 
5-HT1A receptor-mediated pERK immunoreactivity localized with cells 
immunoreactive for CRH.  Since CRH-containing cells can project to other areas 
of the PVN (Sakanaka et al., 1987), and that 5-HT1A receptor-mediated activation 
may occur in CRH containing cells, it is possible that CRH-containing could exert 
a wide range of control over multiple cell subtypes within the PVN and in other 
areas of the hypothalamus.  
5-HT1A receptors activate protein kinase B (Akt) in the peripubertal PVN.  Due to 
recent evidence linking the PI3K/Akt/GSK3 pathway to the pathology of 
psychological disorders including chronic stress, depression, and schizophrenia 
(Beaulieu et al., 2009) and actions of psychoactive drugs (Beaulieu et al., 2004; Li 
et al., 2004), 5-HT1A receptor signaling of Akt was investigated in the 
peripubertal PVN (Chapter 6).  These studies are among the first to identify that 
activation of a G protein coupled receptor results in the phosphorylation of Akt 
in the hypothalamus in vivo.  The PI3K/Akt pathway had been classically 
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characterized as being activated via growth factor receptors such as tyrosine 
kinase receptors.  However, recent studies show that GPCRs (e.g. D2 dopamine 
and 5-HT1A receptors) also can activate this pathway (Beaulieu et al., 2005; 
Adayev et al., 1999; Cowen et al., 2005; Hsiung et al., 2005).  For full activation, 
Akt must be phosphorylated at two residues, Thr308 and Ser473.  Each of these 
sites is phosphorylated by different upstream kinases:  PDK1 phosphorylates 
Thr308 (Alessi et al., 1997; Stephens et al., 1998) and mTOR has been identified as 
the kinase for Ser473 (Sarbassov et al., 2005).  Phosphorylation at Ser473 by 
mTOR appears to occur in the cytoplasm and subsequently assists in the 
recruitment of Akt to the plasma membrane and so that it can be phosphorylated 
at Thr308 by PDK1 (Andjelkovic et al., 1997; Scheid and Woodgett, 2003).   
Activation of 5-HT1A receptors in vivo resulted in increases in phosphorylated 
Akt in the peripubertal PVN.  In the current studies, injection with two different 
structural classes of 5-HT1A receptor agonists, (+)8-OH-DPAT and tandospirone, 
resulted in a rapid phosphorylation of Akt at both Thr308 and Ser473, although 
(+)8-OH-DPAT appeared to induce a higher magnitude of phosphorylation at 
both Akt phosphorylation sites.  Considering that Akt may be first 
phosphorylated at Ser473 by mTOR, it is conceivable that (+)8-OH-DPAT (at 0.20 
mg/kg) may induce more effective coupling of 5-HT1A receptors to the activation 
of mTOR than tandospirone.  Alternatively, (+)8-OH-DPAT may be more 
efficacious than tandospirone in activating 5-HT1A receptors responsible for the 
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phosphorylation of Akt.  This will be discussed further in another section of this 
chapter. 
5-HT1A receptor-mediated activation of Akt in peripubertal vs. adult PVN 
was examined in a separate study (data not shown).  Both adult and peripubertal 
(PD 42) rats were given a challenge injection of 0.20 mg/kg (+)8-OH-DPAT and 
sacrificed 10 minutes later.  5-HT1A receptor-mediated phosphorylation of Akt 
was significantly less in the adult PVN than peripubertal PVN at both Thr308 
(75% over basal in adult PVN compared to 100% over basal in peripubertal PVN) 
and Ser473 sites (40% over basal in adult PVN compared to 79% over basal in 
peripubertal PVN) (Petrunich-Rutherford et al., unpublished data).  5-HT1A 
receptors in the adult PVN could potentially be less effective in activating the 
PI3K/Akt pathway than in young rats.  However, considering that 5-HT1A 
receptor-mediated increases in pERK are rapid and transient in the adult PVN 
(Crane et al., 2007), it is more likely that 5-HT1A receptor-mediated increases in 
pAkt may display a more transient time course of activation in the adult PVN 
than that observed in peripubertal PVN.  In either case, a more prolonged 5-HT1A 
receptor-mediated activation of Akt in the peripubertal PVN could potentially 
impact a wide variety of cellular functions.  
Together, these data provide the first in vivo demonstration that 5-HT1A 
receptors can activate Akt in the peripubertal PVN.  Given the previous studies 
demonstrating that 5-HT1A receptors can stimulate hormone responses and 
205 
 
activate ERK in the peripubertal PVN (Chapter 3), these findings are the first to 
show that 5-HT1A receptors can mediate the concomitant activation of multiple 
downstream kinase effectors in peripubertal hypothalamic PVN.  
5-HT1A receptor-mediated neuroendocrine responses and activation of ERK in the 
peripubertal PVN:  independent pathways?  In the adult rat hypothalamic PVN, 5-
HT1A receptors mediate neuroendocrine and ERK kinase responses via separate 
and independent pathways mediated by separate subsets of Gα proteins.  The 
data from the current studies suggest that 5-HT1A receptor-mediated signaling of 
neuroendocrine responses and ERK activation may also be independent in the 
peripubertal PVN, although the role of G proteins in these signaling pathways 
were harder to discern.  As previously mentioned, the immunohistochemical 
study indicated that 5-HT1A receptor-mediated activation of ERK does not occur 
on oxytocin-containing cells in the peripubertal PVN, indicating that increases in 
plasma levels of oxytocin and increases in PVN levels of pERK are activated in 
separate cell groups and therefore via independent pathways (Chapter 5).  
Furthermore, it seems unlikely that 5-HT1A receptor-mediated pERK contributes 
to the increases observed in plasma concentrations of oxytocin and ACTH, 
considering that 0.10 mg/kg (+)8-OH-DPAT significantly increased plasma 
levels of oxytocin and ACTH but did not significantly increase pERK levels in the 
peripubertal PVN (Chapter 3).  However, these studies did not directly 
determine the independence of 5-HT1A receptor-mediated pathways and merely 
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suggest a possible independence of 5-HT1A receptor-mediated neuroendocrine 
responses and activation of ERK in the peripubertal PVN.  The specific roles of 
Gα proteins in 5-HT1A receptor-mediated signaling in the peripubertal PVN were 
also investigated; these findings are discussed further in another section of this 
chapter.   
In the literature, it is not clear whether or not Akt and ERK protein kinase 
pathways are activated as a result of one shared pathway or multiple 
independent pathways.  In a transfected Chinese hamster ovary (CHO) cell line, 
both the 5-HT1A receptor-mediated activation of ERK and Akt were reported to 
be pertussis toxin-sensitive and PI3K-dependent (Hsiung et al., 2005).  However, 
the 5-HT1A receptor-mediated activation of Akt, but not 5-HT1A receptor-
mediated ERK, is PI3K-dependent in the hippocampal neuron-derived cell line 
HN2-5 (Adayev et al., 1999).  At this point, it appears that the 
dependence/independence of ERK and Akt phosphorylation depends on the cell 
type.  The current studies indicated that ERK and Akt phosphorylation follow a 
similar time course (i.e. elevated within 5 minutes of agonist injection, remained 
elevated until around 15 minutes post-injection, and slowly returned to basal 
levels).  Therefore, we are unable to say with certainty if ERK activation leads to 
Akt phosphorylation or vice versa, or if these pathways are independently 
stimulated in the peripubertal PVN. 
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“Full” vs. “partial” agonism at 5-HT1A receptor-mediated responses in the 
peripubertal PVN.   
In the literature, (+)8-OH-DPAT is considered a “full” agonist and 
tandospirone is considered a “partial” agonist at post-synaptic 5-HT1A receptors.  
However, most studies have examined the 5-HT1A receptor mediated-responses 
induced by these agonists in cell cultures or in brain regions other than the 
hypothalamus.  The studies from Chapter 3 indicated that both (+)8-OH-DPAT 
and tandospirone had comparable maximal efficacies in stimulating oxytocin, 
with (+)8-OH-DPAT being a more potent agonist than tandospirone.  The 
maximal efficacies of (+)8-OH-DPAT and tandospirone on ACTH responses 
were also comparable, and maximally effective doses of the aminotetralin or 
azapirone agonists appear to produce comparable increases in pERK in PVN.  
Therefore, both (+)8-OH-DPAT and tandospirone act as “full” agonists on 5-
HT1A receptor-mediated neuroendocrine responses and ERK activation in the 
peripubertal PVN.  However, in Chapter 6, it appeared that the maximal 
increases of pAkt at both Thr308 and Ser473 induced by (+)8-OH-DPAT are 
greater than that induced by tandospirone.  Therefore, with respect to Akt 
activation, (+)8-OH-DPAT may be considered a “full” agonist and tandospirone 
a “partial” agonist in contrast with the data demonstrating that both drugs are 
“full” agonists on 5-HT1A receptor-mediated neuroendocrine and ERK responses 
(as reported in Chapter 3).  These data demonstrated that the classification of 
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agonists as “full” or “partial” are dependent on the respective receptor-mediated 
response, despite the fact that multiple responses can be stimulated by the same 
receptor in the same brain region.    
Effects of chronic fluoxetine on 5-HT1A receptor signaling in the peripubertal 
PVN 
In the adult rat PVN, 5-HT1A receptor-mediated neuroendocrine and kinase 
pathways are differentially regulated by selective serotonin reuptake inhibitors 
(SSRIs).  Chronic treatment with SSRIs decreases levels of Gαz proteins and 
desensitizes 5-HT1A receptor-mediated oxytocin and ACTH hormone responses 
(Raap et al., 1999) but has no effect on levels of Gαi/o proteins and does not 
desensitize the 5-HT1A receptor-mediated increase in pERK in the PVN (Jia et al., 
2006).  Furthermore, intact ERK signaling is necessary for SSRI-induced 
desensitization of 5-HT1A receptor-mediated neuroendocrine responses, since 
pharmacological blockade of MAPK kinase (the activating kinase for ERK) 
during SSRI treatment abolishes both the SSRI-induced desensitization of 5-HT1A 
receptor signaling of hormone responses and reductions in associated Gαz 
proteins (Jia et al., 2007).  In the peripubertal brain, chronic fluoxetine also 
desensitizes 5-HT1A receptor-mediated oxytocin and ACTH responses (Chen et 
al., 2006); however, neither 7 nor 14 days of fluoxetine treatment had any effect 
on either membrane- or cytosol-associated Gαz protein levels in the peripubertal 
hypothalamus (Chapter 4).  Gz is the exclusive Gα protein mediator of increases 
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in plasma hormone concentrations stimulated by 5-HT1A receptor activation in 
the adult and the only Gα protein reduced by SSRIs in the adult brain (Serres et 
al., 2000a; Jia et al., 2006).  Therefore, the data from the current fluoxetine study 
described in Chapter 4 suggest that either 5-HT1A receptor-mediated 
neuroendocrine responses are mediated via a different subset of Gα protein(s) in 
the peripubertal PVN or that SSRIs desensitize 5-HT1A receptor-mediated 
neuroendocrine responses in the peripubertal PVN via a different mechanism—
one not dependent on the downregulation or reductions in the levels of Gz 
proteins.  Differences in the roles and regulation of G proteins will be discussed 
further in the section on the unique regulation of Gα proteins in the peripubertal 
brain.   
We also determined that chronic fluoxetine (7 and 14 days) had differential 
effects on the ERK and Akt kinase pathways.  5-HT1A receptor-mediated 
phosphorylation of ERK and phosphorylation of Akt is generally not affected 
with either 7 or 14 days of fluoxetine.  However, 14 days of injections with either 
saline or fluoxetine rendered the animals hyporesponsive to the effects of (+)8-
OH-DPAT on 5-HT1A receptor-mediated activation of ERK (Chapter 4) and on 5-
HT1A receptor-mediated phosphorylation of Akt (Chapter 6).  Given the blunted 
response in chronic saline-treated rats, there may be stress-related effects due to 
the additional 7 days of injection in the peripubertal period.  Alternatively, 
starting injections at PD 28 (as with the 14 day treatment paradigm used) as 
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opposed to PD 35 (as with the 7 day treatment paradigm used) may have 
exposed the animals to injection stress at a critical point in postnatal 
development.  Although we did not observe any specific fluoxetine-induced 
effects at the level of Akt, its downstream target GSK3β was differentially 
affected by the 7 and 14 day chronic treatments.  There was no hyporesponsive 
effect of 14 days of injection (as observed with (+)8-OH-DPAT challenge on 
pERK and pAkt) in either saline or fluoxetine-treated animals on phosphorylated 
levels of GSK3β.  We did observe almost a complete desensitization of (+)8-OH-
DPAT-induced increases in pGSK3β with 7 days fluoxetine treatment.  With 14 
days of fluoxetine treatment, this desensitization is not as marked, suggesting 
some neuroadaptive response to fluoxetine in the developing peripubertal brain.  
Alternatively, starting treatment earlier in postnatal development may not be 
having a robust effect on (+)8-OH-DPAT-stimulated pGSK3β, or fluoxetine could 
possibly be modulating the protein levels or activity of a pGSK3β-specific 
phosphatase, which may account for the differential effects on GSK3β but not 
Akt phosphorylation.   
Unique regulation of Gα proteins in the peripubertal PVN. 
 Developmental differences in the regulation of 5-HT1A receptor-associated Gα 
proteins in the PVN.  With regards to protein levels of 5-HT1A receptor-associated 
Gα proteins, we determined that Gαo proteins, but none of the other Gα protein 
subtypes tested, exhibit age-dependent increases.  Gαi1, Gαi2, Gαi3, and Gαz 
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proteins (but not Gαo proteins) are present in the PVN, hippocampus, and 
frontal cortex at their adult levels in both prepubertal (PD 28) and peripubertal 
(PD 42) rats, whereas Gαo proteins steadily increase with age.  This is consistent 
with a previously published study that determined that levels of Gα proteins 
change throughout several brain regions during early postnatal development.  
Gαi1, Gαi2, and Gα3 proteins reach adult levels around postnatal day 18 in the 
cortex, thalamus, and hippocampus, whereas Gαo proteins continue to increase 
past early postnatal development in these regions (Ihnatovych et al., 2002).  
Together, these data indicate that, besides Gαo, all other Gα proteins with the 
capacity to couple to 5-HT1A receptors are present in the peripubertal PVN at 
levels similar to that in the adult PVN.  The developmental increase in Gαo 
proteins may impact 5-HT1A receptor signaling if the lower density of Gαo 
proteins in peripubertal vs. adult PVN alters the effective coupling of the 5-HT1A 
receptor to the respective signaling pathways in the brain of younger vs. adult 
rats.  For example, if the relative abundance of other proteins (like Gαi3 and Gαz) 
makes it less likely for the 5-HT1A receptor to couple to Gαo, then Gαo proteins 
may be precluded from signaling in a manner similar to that in the adult brain.  
Unfortunately, the limitation of western blotting is that comparisons cannot be 
made between the relative levels of Gα proteins to one another.  The results from 
other experiments, however, indicate that there may be some other difference in 
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the Gα proteins (and not just the physical availability) that may explain 
differences in 5-HT1A receptor signaling in the peripubertal vs. adult PVN. 
 In Chapters 4 and 6, we intended to thoroughly investigate the specific roles 
of Gα proteins in 5-HT1A receptor signaling in the peripubertal PVN.  However, 
we discovered some key differences in the regulation of Gα proteins that 
prevented the determination of the specific roles that these Gα proteins play in 5-
HT1A receptor-mediated signaling in the peripubertal PVN.  These differences in 
regulation are described in the next few paragraphs, and the conclusions that we 
made regarding the specific roles of Gα proteins in 5-HT1A receptor-mediated 
signaling pathways are discussed in the next section in this chapter. 
 Pertussis toxin (PTX) is a bacterial toxin that catalyzes the addition of an 
ADP-ribose group to a c-terminal cysteine residue on Gαi1, Gαi2, Gαi3, and Gαo 
proteins, which functionally inactivates these respective proteins.  PTX-
insensitive Gαz proteins lack this critical cysteine residue necessary for PTX-
induced ADP ribosylation.  In the adult rat in vivo, an intra-PVN injection with 
PTX induces a significant decrease (~50%) in the amount of each of the PTX-
sensitive Gα proteins in the hypothalamus at 72 hours post-injection (Garcia et 
al., 2006).  This reduction is not due to an alteration in the antibody recognition 
of the ADP-ribosylated Gα proteins, since in vitro incubation of adult 
hypothalamic membranes with PTX has no effect on the levels of Gα proteins 
measured with western blotting (Petrunich-Rutherford et al., unpublished data).  
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In contrast to the effects of PTX in adults, in peripubertal rats, an intra-PVN 
injection of PTX did not reduce all subsets of Gαi/o proteins in the 
hypothalamus (as in the adult) but only reduced Gαi1 and Gαi2.  Gαi3 protein 
levels in the hypothalamus remained unchanged and Gαo protein levels in the 
hypothalamus increased two-fold.  It is important to note that there may have 
been changes in specific Gα proteins at the level at the PVN that were masked by 
changes in the whole hypothalamus.  However, considering the same Gα 
proteins were measured in the whole hypothalamus with a comparable 
incubation time of drug (72 hours) in this study as the one previously published 
in adults (Garcia et al., 2006), these data indicate that there may be a 
developmental difference in the PTX-sensitivity of Gα proteins in the 
hypothalamus.  Although unlikely, a difference in the Gαi3/Gαo protein 
structure may be preventing ADP ribosylation in the peripubertal rat brain.  It is 
more likely that there is a difference in post-translational modifications of the 
proteins that may be preventing ADP ribosylation and subsequent reduction in 
membrane-associated levels of these proteins.  There is also a possibility that a 
72-hour incubation time is not sufficient (or is perhaps too short) to functionally 
inactivate Gαi3 and Gαo proteins.  It could be that Gαi3 and Gαo proteins are 
more resilient to ADP-ribosylation and begin to recover from the effect of the 
toxin or are replenished by transcription and translation of their respective genes 
before the end of the three-day time period.  Indeed, the increased levels of Gαo 
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may be due to a robust compensatory increase to the initial effects of PTX.  There 
has been one other study comparing the effects of PTX in peripubertal vs. adult 
brain:  using adult rat brain membranes, GABAB receptor/G protein binding was 
reduced upon incubation with PTX in cortex, hippocampus, and cerebellum but 
not the striatum.  However, when PTX was incubated with peripubertal rat brain 
membranes, GABAB receptor/G protein binding was reduced in striatum and 
hippocampus but not cortex or cerebellum (Knott et al., 1993).  In either case, in 
vivo or in vitro, it seems as if certain Gα proteins (namely Gαi3 and Gαo) have not 
functionally matured in the peripubertal brain and may possibly impact the 
signaling of the 5-HT1A receptor in the PVN and other regions in the brain. 
 We also observed developmental differences in the PVN upon chronic 
treatment with fluoxetine in the peripubertal rat.  Chronic fluoxetine reduces 
levels of Gαz proteins in the PVN of adult rats.  Our preliminary studies 
indicated that, in the peripubertal PVN, chronic fluoxetine did not reduce Gαz 
proteins but did reduce Gαi3 and Gαo (Chen et al., 2006).  However, upon 
replicating the treatment paradigm for both 7 and 14 days, we determined that 
chronic fluoxetine did not reduce Gαz proteins but also did not reduce any of the 
other Gα proteins (cytosol-associated or membrane-associated) in the 
peripubertal PVN (Chapter 4).  Therefore, SSRIs may be desensitizing 5-HT1A 
receptor-mediated neuroendocrine responses in the peripubertal PVN via a 
different mechanism as opposed to reducing levels of Gαz proteins in the 
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hypothalamus, as in the adult.  For example, SSRI treatment in peripubertal rats 
may be affecting the function of regulators of G protein signaling (RGS) proteins.  
The RGSZ protein functions to deactivate Gαz subunits and is present in the 
hypothalamus.  Members of the RGSZ protein family have been shown to 
influence mu receptor signaling in the central nervous system by sequestering 
Gα proteins (Garzon et al., 2005).  SSRIs may be causing RGSZ proteins to 
inactivate or sequester, but not cause a reduction in the levels of Gαz proteins in 
the peripubertal hypothalamus.  Alternatively, chronic fluoxetine may be 
altering the balance of G proteins in lipid rafts, and subsequently the signaling 
activity of these proteins, as has been observed with chronic escitalopram (an 
SSRI) on Gs proteins in vitro (Zhang and Rasenick, 2010). 
Roles of 5-HT1A receptor-associated Gα proteins in the PVN.  Intra-PVN injection 
with PTX caused a reduction of hypothalamic levels of Gαi1 and Gαi2 proteins 
and increased Gαo proteins (Chapter 4, figure 13).  We found no significant 
reductions in 5-HT1A receptor-mediated neuroendocrine responses; therefore, 
this data suggests that Gαi3, Gαo, and/or Gαz could potentially mediate 5-HT1A 
receptor stimulation of hormone responses in the PVN of peripubertal rats.  It is 
likely that Gαi3, Gαo, and/or Gαz proteins may mediate 5-HT1A receptor 
activation of ERK considering that there were also no significant reductions of 5-
HT1A receptor-mediated phosphorylation of ERK in the PVN.  However, the 
PTX-induced increases in Gαo may be responsible for the elevations observed in 
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basal levels of activated ERK in the PVN.  Similarly, we observed slightly 
elevated basal levels of phosphorylated Akt at Ser473, although this increase did 
not reach statistical significance.  This increase in basal levels of pAkt may have 
precluded any further increase in pAkt at Ser473 by 5-HT1A receptor activation.  
Therefore, 5-HT1A receptors may be signaling via Gαi1 or Gαi2 proteins to 
mediate Akt activation, although we cannot completely rule out any potential 
contribution of Gαi3, Gαo, or Gαz in mediating the phosphorylation and 
activation of Akt in the peripubertal PVN. 
 To determine the specific Gα protein contribution to 5-HT1A receptor-
mediated signaling pathways in the peripubertal PVN, a more selective method 
is necessary, like adenoviral-delivered siRNA for Gαi3 and Gαo proteins.  This 
will be discussed further in the last section of this chapter. 
Alternate signaling mediators of 5-HT1A receptor-mediated responses in peripubertal 
PVN.  Although the studies in this dissertation have focused on the contributions 
of Gα proteins to 5-HT1A receptor-mediated signaling in the peripubertal PVN, 
many studies have revealed that GPCRs can mediate the signaling of ERK and 
Akt via Gβγ subunits or even via β-arrestin.  Gβγ subunits have been shown to 
activate ERK (Goubaeva et al., 2003; Mukhin et al., 2000) and Akt (Konishi et al., 
1995; Guzmán-Hernández et al., 2009); therefore, Gβγ could potentially mediate 
5-HT1A receptor-mediated responses rather than G proteins in the peripubertal 
PVN.  Although β-arrestin has been classically involved with receptor 
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desensitization, uptake, and degradation, in certain situations it can serve as a 
signaling mediator for GPCR/G protein-independent signaling.  For example, β-
arrestin has been shown to activate ERK in response to activation by (1) β2 
adrenergic receptors (Shenoy et al., 2006), (2) GPR54 receptors (Pampillo et al., 
2009), and (3) angiotensin II receptors (Ahn et al., 2004).  Either Gβγ subunits or 
β-arrestin could be potential second messengers for G protein-independent 
signaling of the respective 5-HT1A receptor-mediated responses in the 
peripubertal PVN.  
It is also possible that 5-HT1A receptor-mediated activation of protein kinase 
pathways could be due to transactivation of growth factor receptors by the 5-
HT1A receptor in the PVN.  One potential growth factor receptor is insulin-like 
growth factor 1 receptor (IGF-1R).  IGF-1R has been localized to the PVN (Saeed 
et al., 2007) and can be transactivated by another GPCR, the GABAB receptor.  
Transactivation of IGF-1R by GABAB results in increased levels of 
phosphorylated Akt in primary cerebellar granule neurons (Tu et al., 2010).  
Although the interaction of 5-HT1A receptor with IGF-1R pathways has not been 
examined in the hypothalamus in vivo, 5-HT1A receptors have been shown to 
regulate IGF-1R mRNA and protein levels in the spinal cord (Bonnefont et al., 
2007). 
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Clinical significance:  some implications for therapeutic strategies for children 
and adolescents. 
 Differences observed in hypothalamic 5-HT1A receptor signaling and the 
properties of Gα proteins and their signaling may only make up a fraction of 
developmental differences in brain function between a developing animal and an 
adult animal.  For example, there are differences observed between the 
peripubertal and adult groups in: (1) cocaine-induced behavior (Laviola et al., 
1995; Schramm-Sapyta et al., 2004); (2) nicotine-induced sensitization of cocaine 
responses (Collins and Izenwasser 2004); (3) motor activity and cortex activation 
in response to an NMDA receptor modulator (Pesic et al., 2010); and (4) receptor 
regulation induced by treatment with a tricyclic antidepressant (Deupree et al., 
2007).  One study observed that there was no overall differences in the 
magnitude of behavior induced by bupropion (an antidepressant used in treating 
nicotine addiction) in the peripubertal and adult animals, but that the developing 
animals may be more sensitive to lower doses of the drug.  Furthermore, in 
neuroendocrine neurons, a balance between GABA and glutamate (NMDA and 
AMPA) receptor subtypes controls intracellular levels of calcium.  One group has 
observed a developmental shift in the levels of AMPA receptors controlling this 
as the animal matures (Constantin et al., 2010).  These studies along with the 
studies described in this dissertation have serious implications for the use and 
abuse of drugs by children and adolescents.  Even a developmental difference 
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that seems inconsequential (such as a more prolonged activation of ERK) may 
have far-reaching consequences, such as with the effectiveness of antidepressant 
drugs used in children and adolescents, the side effect profile of psychotropic 
drugs in younger populations, and the permanence of brain changes upon 
maturation.  Some observations of young animals treated with a variety of drugs 
reveal later alterations of adult behavior and brain function:  (1) ethanol 
treatment alters locomotor behavior as an adult (Roskam and Koch, 2009) and (2) 
nicotine increases anxiety behavior and alters CRH and neuropeptide Y systems 
(Slawecki et al., 2005).   
Future directions for the present studies 
 There are several courses of action that could be pursued to further clarify the 
mechanisms of 5-HT1A receptor-mediated signaling and desensitization in the 
peripubertal PVN.   
 First of all, a few of the pharmacological tools employed in these studies 
(namely PTX and fluoxetine) did not produce the anticipated effects on Gα 
proteins.  To completely clarify the role of specific Gα proteins in 5-HT1A 
receptor-mediated neuroendocrine responses and kinase activation, a more 
specific tool such as adenoviral-delivered siRNA or antisense oligonucleotides 
for the specific Gα proteins must be utilized.  This will also assist in determining 
if 5-HT1A receptor-mediated pathways in the peripubertal PVN are independent 
and, if so, if these pathways are mediated by separate subsets of Gα proteins.   
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 It may also be important to determine if ERK or Akt protein kinase pathways 
contribute to the respective 5-HT1A receptor-mediated responses.  In a separate 
experiment, we gave peripubertal rats an intra-PVN injection of the PI3K 
inhibitor LY294002 to assess the role of Akt’s upstream kinase PI3K in 5-HT1A 
receptor-mediated signaling of neuroendocrine, ERK, and Akt responses in the 
peripubertal PVN.  Although 5-HT1A receptor-mediated oxytocin and ACTH 
responses, but not pERK responses, were partially reduced, there were no 
significant effects of the PI3K inhibitor on the phosphorylation of Akt at either 
Thr308 or Ser473 (Petrunich-Rutherford et al., unpublished data).  Therefore, it 
may be possible that PI3K may contribute to 5-HT1A receptor-mediated 
neuroendocrine responses in the peripubertal PVN.  An alternative explanation 
for the lack of PI3K inhibition on 5-HT1A receptor-mediated ERK and Akt kinase 
responses could be that 5-HT1A receptors may be activating ERK and Akt via a 
PI3K-independent mechanism, which has been observed in other systems (Alessi 
et al., 1996; Sable et al., 1997; Yano et al., 1998).  
 Further research is necessary to determine specifically which cells contain 5-
HT1A receptor-mediated pERK in peripubertal PVN.  Currently, a protocol for 
immunohistochemical double labeling of CRH and 5-HT1A receptor-stimulated 
pERK is in progress to optimize colocalization of these markers in both 
peripubertal and adult PVN using perfused rather than post-fixed brain tissue.  
Thus far, it appears that some of the factors involved with perfusion (anesthesia, 
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stress, perfusion itself) increases basal levels of ERK such that further stimulation 
of 5-HT1A receptors by (+)8-OH-DPAT can not be clearly discerned.  More 
studies are necessary to determine the impact of these factors on ERK stimulation 
in the PVN. 
 As mentioned previously, in the adult PVN (Petrunich-Rutherford et al., 
unpublished data), 5-HT1A receptors increase the phosphorylation of Akt; 
however, the full time course and dose-responsiveness has not been investigated 
in this age group with either (+)8-OH-DPAT or tandospirone.  Also, it is 
unknown at this time whether tandospirone acts as a “full” or “partial” agonist 
at 5-HT1A receptor-mediated oxytocin, ACTH, pERK, and pAkt responses in the 
adult PVN.  It would be interesting to determine if the actions of tandospirone in 
the adult PVN are different compared with the “full” agonist actions on 
neuroendocrine responses and pERK yet “partial” agonist on pAkt responses in 
the peripubertal PVN. 
Another key piece of information would be to determine if intact ERK or Akt 
signaling pathways are necessary for SSRI-induced desensitization of 5-HT1A 
receptor-mediated neuroendocrine responses in the peripubertal PVN.  
Furthermore, considering that 5-HT1A receptor-mediated phosphorylation of 
GSK3β (but not 5-HT1A receptor-mediated activation of its upstream kinase Akt) 
was desensitized following chronic fluoxetine, another potential area for study is 
the regulation of phosphatases responsible for dephosphorylating ERK and Akt 
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upon chronic antidepressant or acute 5-HT1A receptor stimulation.  Phosphatases 
have been implicated in stress and the effects of chronic antidepressants in other 
models.  In the hippocampus, chronic stress increases hippocampal levels of a 
phosphatase specific for MAPK, and antidepressants normalize the levels of this 
phosphatase (Duric et al., 2010).  The protein level of PP1 phosphatase (the 
primary phosphatase for GSK3β in COS-7 cell cultures, Hernandez et al., 2010), 
was increased in the adult frontal cortex and hippocampus in a rat model of 
depression (Feng et al., 2003).  Therefore, pursuing the regulation of 
phosphatases in the peripubertal and adult PVN may represent a new and 
exciting research area.   
In conclusion, although several facets of 5-HT1A receptor-mediated signaling 
in the peripubertal PVN have been determined, it seems that even more 
questions have been generated about the signaling and regulation of this 
receptor in the immature brain, and much more research is needed to fully 
elucidate the role of this receptor in mood disorders and the effects of 
antidepressants. 
 
 223 
REFERENCE LIST 
 
Abumaria N, Rygula R, Hiemke C, Fuchs E, Havemann-Reinecke U, Rüther E, 
Flügge G.  Effect of chronic citalopram on serotonin-related and stress-
regulated genes in the dorsal raphe nucleus of the rat.  Eur 
Neuropsychopharmacol 2007. 17: 417-29.  
 
Adamec RE. Does kindling model anything clinically relevant? Biol Psychiatry 
1990. 27: 249-79. 
 
Adayev T, El-Sherif Y, Barua M, Penington NJ, Banerjee P. Agonist stimulation of 
the serotonin1A receptor causes suppression of anoxia-induced apoptosis 
via mitogen-activated protein kinase in neuronal HN2-5 cells. J Neurochem 
1999. 72: 1489-96. 
 
Agid O, Kohn Y, Lerer B Environmental stress and psychiatric illness.  Biomed 
Pharmacother 2000. 54: 135-41. 
Ahn S, Shenoy SK, Wei H, Lefkowitz RJ.  Differential kinetic and spatial patterns 
of beta-arrestin and G protein-mediated ERK activation by the angiotensin 
II receptor.  J Biol Chem 2004. 279: 35518-25. 
Albert PR, Lembo P, Storring JM, Charest A, Saucier C.  The 5-HT1A receptor: 
signaling, desensitization, and gene transcription.  
Neuropsychopharmacology 1996. 14: 19-25.  
 
Albert PR, Zhou QY, Van Tol HH, Bunzow JR, Civelli O.  Cloning, functional 
expression, and mRNA tissue distribution of the rat 5-
hydroxytryptamine1A receptor gene. Biol Chem 1990. 265: 5825-32. 
Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P, Hemmings 
BA.  Mechanism of activation of protein kinase B by insulin and IGF-1.  
EMBO J 1996. 15: 6541-51. 
 
 
 
224 
 
Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB, Cohen P.  
Characterization of a 3-phosphoinositide-dependent protein kinase which 
phosphorylates and activates protein kinase Balpha.  Curr Biol 1997. 7: 261-
9. 
 
Almeida M, Lee R, Coccaro EF.  Cortisol responses to ipsapirone challenge 
correlate with aggression, while basal cortisol levels correlate with 
impulsivity, in personality disorder and healthy volunteer subjects.  J 
Psychiatr Res 2010. 44: 874-80.  
 
Amar S, Shaltiel G, Mann L, Shamir A, Dean B, Scarr E, Bersudsky Y, Belmaker 
RH, Agam G.  Possible involvement of post-dopamine D2 receptor 
signalling components in the pathophysiology of schizophrenia.  Int J 
Neuropsychopharmacol 2008. 11: 197-205. 
 
Andersen SL. Trajectories of brain development: point of vulnerability or 
window of opportunity? Neurosci Biobehav Rev 2003. 27: 3-18. 
 
Andersen SL, Navalta CP. Altering the course of neurodevelopment: a 
framework for understanding the enduring effects of psychotropic drugs. 
Int J Dev Neurosci 2004. 22: 423-40. 
 
Anderson KE, Coadwell J, Stephens LR, Hawkins PT.  Translocation of PDK-1 to 
the plasma membrane is important in allowing PDK-1 to activate protein 
kinase B.  Curr Biol 1998. 8: 684-91. 
 
Andjelkovic M, Alessi DR, Meier R, Fernandez A, Lamb NJ, Frech M, Cron P, 
Cohen P, Lucocq JM, Hemmings BA.  Role of translocation in the 
activation and function of protein kinase B.  J Biol Chem 1997. 272: 31515-
24. 
 
Ansorge MS, Zhou M, Lira A, Hen R, Gingrich JA. Early-life blockade of the 5-
HT transporter alters emotional behavior in adult mice. Science 2004. 306: 
879-81. 
 
Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB.  The role of corticotropin-
releasing factor in depression and anxiety disorders.  J Endocrinol 1999. 
160:1-12.  
 
 
 
225 
Armstrong WE.  “Hypothalamic Supraoptic and Paraventricular Nuclei.”  The 
Rat Nervous System.  Ed. G Paxinos.  Amsterdam:  Elsevier Academic 
Press, 2004.  369-388. 
 
Armstrong WE, Warach S, Hatton GI, McNeill TH.  Subnuclei in the rat 
hypothalamic paraventricular nucleus: a cytoarchitectural, horseradish 
peroxidase and immunocytochemical analysis.  Neuroscience 1980.  5: 1931-
58. 
 
Avissar S, Roitman G, Schreiber G.  Differential effects of the antipsychotics 
haloperidol and clozapine on G protein measures in mononuclear 
leukocytes of patients with schizophrenia.  Cell Mol Neurobiol 2001. 21: 799-
811.  
 
Azmitia EC, Gannon PJ, Kheck NM, Whitaker-Azmitia PM.  Cellular localization 
of the 5-HT1A receptor in primate brain neurons and glial cells.  
Neuropsychopharmacology 1996. 14: 35-46. 
 
Aznar S, Qian Z, Shah R, Rahbek B, Knudsen GM.  The 5-HT1A serotonin 
receptor is located on calbindin- and parvalbumin-containing neurons in 
the rat brain.  Brain Res 2003. 959: 58-67. 
 
Bagdy G, Kalogeras KT. Stimulation of 5-HT1A and 5-HT2/5-HT1C receptors 
induce oxytocin release in the male rat. Brain Res 1993. 611: 330-2. 
Bagdy G, Sved AF, Murphy DL, Szemeredi K.  Pharmacological characterization 
of serotonin receptor subtypes involved in vasopressin and plasma renin 
activity responses to serotonin agonists.  Eur J Pharmacol 1992. 210: 285-9.  
Bale TL, Vale WW.  CRF and CRF receptors: role in stress responsivity and other 
behaviors.  Annu Rev Pharmacol Toxicol 2004. 44: 525-57. 
 
Bao AM, Meynen G, Swaab DF. The stress system in depression and 
neurodegeneration: Focus on the human hypothalamus. Brain Res Rev 
2008. 57: 531-53.  
 
Barnes NM, Sharp T.  A review of central 5-HT receptors and their function. 
Neuropharmacology 1999. 38: 1083-152. 
 
Barrett EJ.  “The Adrenal Gland.”  Chapter 49 in Medical physiology: a cellular and 
molecular approach. Edited by Boron WF and Boulpaep WF. Philadelphia: 
W.B. Saunders, 2003. 
226 
Basta-Kaim A, Budziszewska B, Jaworska-Feil L, Tetich M, Kubera M, 
Leśkiewicz M, Lasoń W.  Inhibitory effect of imipramine on the human 
corticotropin-releasing-hormone gene promoter activity operates through 
a PI3-K/AKT mediated pathway.  Neuropharmacology 2005. 49: 156-64. 
 
Basura GJ, Walker PD.  Serotonin 2A and 2C receptor biosynthesis in the rodent 
striatum during postnatal development: mRNA expression and functional 
linkage to neuropeptide gene regulation.  Synapse 2000. 38: 216-25. 
 
Battaglia G, Petrunich-Rutherford ML, Garcia F. In vivo 5-HT1A receptor 
activation of MAP kinase in the peripubertal rat hypothalamic PVN: 
Temporal differences in agonist-dependent activation.  Program No. 
516.5/C18. 2009 Neuroscience Meeting Planner. Chicago, IL: Society for 
Neuroscience, 2009. Online. 
 
Battaglia G, Shankaran M, Van de Kar LD, Tetzlaff J, D’Souza DN, Garcia F, 
Zhang Y. 5-HT1A receptor-mediated neuroendocrine responses in 
immature and adult male rats by the isomers of 8-OH-DPAT.  Program 
No. 741.15. 2002 Abstract Viewer/Itinerary Planner. Washington, DC: 
Society for Neuroscience, 2002. Online. 
 
Beaulieu JM, Gainetdinov RR, Caron MG.  Akt/GSK3 signaling in the action of 
psychotropic drugs.  Annu Rev Pharmacol Toxicol 2009. 49: 327-47. 
 
Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG.  
An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic 
neurotransmission and behavior.  Cell 2005. 122: 261-73. 
 
Beaulieu JM, Sotnikova TD, Yao WD, Kockeritz L, Woodgett JR, Gainetdinov RR, 
Caron MG.  Lithium antagonizes dopamine-dependent behaviors 
mediated by an AKT/glycogen synthase kinase 3 signaling cascade.  Proc 
Natl Acad Sci U S A 2004. 101: 5099-104. 
 
Bellacosa A, Testa JR, Staal SP, Tsichlis PN.  A retroviral oncogene, akt, encoding 
a serine-threonine kinase containing an SH2-like region.  Science 1991. 254: 
274-7. 
 
Berg KA, Maayani S, Goldfarb J, Scaramellini C, Leff P, Clarke WP.  Effector 
pathway-dependent relative efficacy at serotonin type 2A and 2C 
receptors: evidence for agonist-directed trafficking of receptor stimulus.  
Mol Pharmacol 1998. 54: 94-104. 
 
227 
Berger M, Gray JA, Roth BL.  The expanded biology of serotonin.  Annu Rev Med 
2009. 60: 355-66. 
 
Blier P, Ward NM.  Is there a role for 5-HT1A agonists in the treatment of 
depression?  Biol Psychiatry 2003. 53: 193-203.  
 
Blume A, Torner L, Liu Y, Subburaju S, Aguilera G, Neumann ID.  Prolactin 
activates mitogen-activated protein kinase signaling and corticotropin 
releasing hormone transcription in rat hypothalamic neurons.  
Endocrinology 2009. 150: 1841-9.  
 
Boado RJ, Li JY, Nagaya M, Zhang C, Pardridge WM.  Selective expression of the 
large neutral amino acid transporter at the blood-brain barrier.  Proc Natl 
Acad Sci U S A 1999. 96: 12079-84. 
Bonnefont J, Daulhac L, Etienne M, Chapuy E, Mallet C, Ouchchane L, Deval C, 
Courade JP, Ferrara M, Eschalier A, Clottes E.  Acetaminophen recruits 
spinal p42/p44 MAPKs and GH/IGF-1 receptors to produce analgesia via 
the serotonergic system. Mol Pharmacol 2007. 71: 407-15. 
Bonnin A, Peng W, Hewlett W, Levitt P.  Expression mapping of 5-HT1 serotonin 
receptor subtypes during fetal and early postnatal mouse forebrain 
development. Neuroscience 2006. 141: 781-94. 
Borsini F. Balance between cortical 5-HT1A and 5-HT2 receptor function: 
hypothesis for a faster antidepressant action. Pharmacol Res 1994. 30: 1-11. 
 
Bostic JQ, Rubin DH, Prince J, Schlozman S.  Treatment of depression in children 
and adolescents.  J Psychiatr Pract 2005. 11: 141-54.  
 
Bouma EM, Ormel J, Verhulst FC, Oldehinkel AJ.  Stressful life events and 
depressive problems in early adolescent boys and girls: the influence of 
parental depression, temperament and family environment.  J Affect 
Disord 2008. 105: 185-93. 
 
Bourne HR, von Zastro M.  “Drug Receptors and Pharmacodynamics.”  Chapter 
2 in Basic and Clinical Pharmacology, Ninth Edition. Edited by Katzung BG.  
New York:  Lange Medical Books/McGraw-Hill, 2004. 
 
 
 
228 
Budziszewska B, Szymanska M, Leskiewicz M, Basta-Kaim A, Jaworska-Feil L, 
Kubera M, Jantas D, Lason W.  The decrease in JNK- and p38-MAP kinase 
activity is accompanied by the enhancement of PP2A phosphate level in 
the brain of prenatally stressed rats.  J Physiol Pharmacol 2010. 61: 207-15. 
 
Buritova J, Berrichon G, Cathala C, Colpaert F, Cussac D.  Region-specific 
changes in 5-HT1A agonist-induced Extracellular signal-Regulated Kinases 
1/2 phosphorylation in rat brain: a quantitative ELISA study.  
Neuropharmacology 2009. 56:350-61.  
Carlson KE, Brass LF, Manning DR.  Thrombin and phorbol esters cause the 
selective phosphorylation of a G protein other than Gi in human platelets.  
J Biol Chem 1989. 264: 13298-305. 
Carrasco GA, Van de Kar LD.  Neuroendocrine pharmacology of stress.  Eur J 
Pharmacol 2003. 463: 235-72.  
 
Celada P, Puig M, Amargos-Bosch M, Adell A, Artigas F. The therapeutic role of 
5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci 2004. 29: 
252-65. 
 
Chalecka-Franaszek E, Chuang DM.  Lithium activates the serine/threonine 
kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 
activity in neurons.  Proc Natl Acad Sci U S A 1999. 96: 8745-50. 
Chen C, Ishikawa Y, Amano I, Eguchi T, Ishida H.  Age-dependent changes in 
response of rat prostatic tissues to isoproterenol and forskolin: changes 
with sexual maturation in function of G proteins.  Mech Ageing Dev 1995. 
81: 1-13. 
Chen J, Shen C, Meller E. 5-HT1A receptor-mediated regulation of mitogen-
activated protein kinase phosphorylation in rat brain. Eur J Pharmacol 
2002. 452: 155-62. 
 
Chen S, Owens GC, Crossin KL, Edelman DB.  Serotonin stimulates 
mitochondrial transport in hippocampal neurons.  Mol Cell Neurosci 2007. 
36: 472-83. 
  
 
 
 
229 
Chen Z, Shankaran M, Garcia F, Van de Kar LD, D'Souza DN, Battaglia G. 
Chronic fluoxetine treatment of immature rats desensitizes 5-HT1A 
receptor-mediated neuroendocrine responses in the absence of reductions 
in Gαz proteins.  Program No. 33.24/C16. 2006 Neuroscience Meeting 
Planner. Atlanta, GA: Society for Neuroscience, 2006. Online. 
Chiu HY, Lin HH, Lai CC.  Cocaine- and amphetamine-regulated transcript 
(CART) peptide activates ERK pathways via NMDA receptors in rat 
spinal cord dorsal horn in an age-dependent manner.  Regul Pept 2010. 164: 
90-6. 
Coffer PJ, Jin J, Woodgett JR.  Protein kinase B (c-Akt): a multifunctional 
mediator of phosphatidylinositol 3-kinase activation.  Biochem J 1998. 335: 
1-13. 
Coffer PJ, Woodgett JR.  Molecular cloning and characterisation of a novel 
putative protein-serine kinase related to the cAMP-dependent and protein 
kinase C families.  Eur J Biochem 1991. 201: 475-81. 
Cohen D. Should the use of selective serotonin reuptake inhibitors in child and 
adolescent depression be banned? Psychother Psychosom 2007. 76: 5-14. 
Collin M, Bäckberg M, Onnestam K, Meister B.  5-HT1A receptor 
immunoreactivity in hypothalamic neurons involved in body weight 
control. Neuroreport 2002. 13: 945-51. 
Collins SL, Izenwasser S.  Chronic nicotine differentially alters cocaine-induced 
locomotor activity in adolescent vs. adult male and female rats.  
Neuropharmacology 2004. 46: 349-62. 
Constantin S, Jasoni CL, Wadas B, Herbison AE.  Gamma-aminobutyric acid and 
glutamate differentially regulate intracellular calcium concentrations in 
mouse gonadotropin-releasing hormone neurons.  Endocrinology 2010. 151: 
262-70.  
Conti B, Maier R, Barr AM, Morale MC, Lu X, Sanna PP, Bilbe G, Hoyer G and 
Bartfai T. Region-specific transcriptional changes following the three 
antidepressant treatments electro convulsive therapy, sleep deprivation 
and fluoxetine. Mol Psychiatry 2007. 12: 167-89. 
 
Cowen DS, Johnson-Farley NN, Travkina T.  5-HT receptors couple to activation 
of Akt, but not extracellular-regulated kinase (ERK), in cultured 
hippocampal neurons.  J Neurochem 2005. 93: 910-7. 
230 
Cowen PJ.  “Neuroendocrine Challenge Tests:  What Can We Learn from Them?” 
Methods in Neuroendocrinology. Ed. LD Van de Kar.  Boca Raton: CDC 
Press, 1998. 205-223. 
 
Crane JW, Shimizu K, Carrasco GA, Garcia F, Jia C, Sullivan NR, D'Souza DN, 
Zhang Y, Van de Kar LD, Muma NA, Battaglia G. 5-HT(1A) receptors 
mediate (+)8-OH-DPAT-stimulation of extracellular signal-regulated 
kinase (MAP kinase) in vivo in rat hypothalamus: Time dependence and 
regional differences. Brain Res 2007. 1183: 51-9. 
 
Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA.  Inhibition of 
glycogen synthase kinase-3 by insulin mediated by protein kinase B.  
Nature 1995.378: 785-9. 
 
Czachura JF, Rasmussen K.  Effects of acute and chronic administration of 
fluoxetine on the activity of serotonergic neurons in the dorsal raphe 
nucleus of the rat.  Naunyn Schmiedebergs Arch Pharmacol 2000. 362: 266-75. 
 
Dahlstrom A, Fuxe K  Evidence for the existence of monoamine-containing 
neurons in the central nervous system.  I.  Demonstration of monoamines 
in the cell bodies of brain stem neurons. Acta Physiol Scand Suppl 1964.  
232:1-55.  
 
Delcommenne M, Tan C, Gray V, Rue L, Woodgett J, Dedhar S.  
Phosphoinositide-3-OH kinase-dependent regulation of glycogen 
synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase.  
Proc Natl Acad Sci U S A 1998. 95: 11211-6. 
De Sarno P, Li X, Jope RS.  Regulation of Akt and glycogen synthase kinase-3 
beta phosphorylation by sodium valproate and lithium.  
Neuropharmacology 2002. 43: 1158-64. 
Deupree JD, Reed AL, Bylund DB.  Differential effects of the tricyclic 
antidepressant desipramine on the density of adrenergic receptors in 
juvenile and adult rats.  J Pharmacol Exp Ther 2007. 321: 770-6.  
De Vivo M, Maayani S.  Characterization of the 5-hydroxytryptamine1a receptor-
mediated inhibition of forskolin-stimulated adenylate cyclase activity in 
guinea pig and rat hippocampal membranes. J Pharmacol Exp Ther 1986. 
238: 248-53. 
 
231 
Di Sciullo A, Bluet-Pajot MT, Mounier F, Oliver C, Schmidt B, Kordon C.  
Changes in anterior pituitary hormone levels after serotonin 1A receptor 
stimulation.  Endocrinology 1990. 127: 567-72. 
 
Dowlatshahi D, MacQueen GM, Wang JF, Reiach JS, Young LT.  G Protein-
coupled cyclic AMP signaling in postmortem brain of subjects with mood 
disorders: effects of diagnosis, suicide, and treatment at the time of death.  
J Neurochem 1999.  73: 1121-6. 
 
Duman CH, Schlesinger L, Kodama M, Russell DS, Duman RS. A role for MAP 
kinase signaling in behavioral models of depression and antidepressant 
treatment. Biol Psychiatry 2007. 61: 661-70. 
 
Dumuis A, Sebben M, Bockaert J.  Pharmacology of 5-hydroxytryptamine-1A 
receptors which inhibit cAMP production in hippocampal and cortical 
neurons in primary culture.  Mol Pharmacol 1988. 33: 178-86. 
 
Duric V, Banasr M, Licznerski P, Schmidt HD, Stockmeier CA, Simen AA, 
Newton SS, Duman RS.  A negative regulator of MAP kinase causes 
depressive behavior.  Nat Med 2010. 16: 1328-32. 
 
Du Vigneaud V, Ressler C, Trippett S. The sequence of amino acids in oxytocin, 
with a proposal for the structure of oxytocin.  J Biol Chem 1953. 205: 949-57. 
 
Dwivedi Y, Rizavi HS, Conley RR, Pandey GN.  ERK MAP kinase signaling in 
post-mortem brain of suicide subjects: differential regulation of upstream 
Raf kinases Raf-1 and B-Raf.  Mol Psychiatry 2006. 11: 86-98. 
 
Dwivedi Y, Rizavi HS, Roberts RC, Conley RC, Tamminga CA, Pandey GN.  
Reduced activation and expression of ERK1/2 MAP kinase in the post-
mortem brain of depressed suicide subjects.  J Neurochem 2001. 77: 916-28. 
 
Dwivedi Y, Rizavi HS, Zhang H, Roberts RC, Conley RR, Pandey GN.  Aberrant 
extracellular signal-regulated kinase (ERK)1/2 signalling in suicide brain: 
role of ERK kinase 1 (MEK1). Int J Neuropsychopharmacol 2009. 12: 1337-
1354. 
 
D'Souza DN, Zhang Y, Damjanoska KJ, Carrasco GA, Sullivan NR, Garcia F, 
Battaglia G, Doncarlos LL, Muma NA, Van de Kar LD.  Estrogen reduces 
serotonin-1A receptor-mediated oxytocin release and Galpha(i/o/z) 
proteins in the hypothalamus of ovariectomized rats.  Neuroendocrinology 
2004.  80: 31-41. 
232 
Emamghoreishi M, Li PP, Schlichter L, Parikh SV, Cooke R, Warsh JJ.  Associated 
disturbances in calcium homeostasis and G protein-mediated cAMP 
signaling in bipolar I disorder.  Biol Psychiatry 2000. 48: 665-73. 
 
Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA.  Convergent 
evidence for impaired AKT1-GSK3beta signaling in schizophrenia.  Nat 
Genet 2004. 36: 131-7. 
 
European Medicines Agency. CHMP meeting on Paroxetine and other SSRIs.  
2004. Online [Available] http://www.emea.europa.eu/pdfs/human/ 
press/pr/19257004en.pdf. 
 
Fatemi SH, Reutiman TJ, Folsom TD.  Chronic psychotropic drug treatment 
causes differential expression of Reelin signaling system in frontal cortex 
of rats.  Schizophr Res 2009.  111: 138-52. 
 
Feng P, Guan Z, Yang X, Fang J.  Impairments of ERK signal transduction in the 
brain in a rat model of depression induced by neonatal exposure of 
clomipramine.  Brain Res 2003. 991: 195-205. 
 
Ferrari PF, Lowther S, Tidbury H, Greengrass P, Wilson CA, Horton RW.  The 
influence of gender and age on neonatal rat hypothalamic 5-HT1A and 5-
HT2A receptors.  Cell Mol Neurobiol 1999. 19: 775-84. 
Fields TA, Casey PJ. Phosphorylation of Gz alpha by protein kinase C blocks 
interaction with the beta gamma complex. J Biol Chem 1995. 270: 23119-25. 
Filip M, Bader M.  Overview on 5-HT receptors and their role in physiology and 
pathology of the central nervous system. Pharmacol Rep 2009. 61: 761-77. 
 
Franke TF, Hornik CP, Segev L, Shostak GA, Sugimoto C. PI3K/Akt and 
apoptosis: size matters. Oncogene 2003. 22: 8983-98.  
 
Frasch A, Zetzsche T, Steiger A, Jirikowski GF.  Reduction of plasma oxytocin 
levels in patients suffering from major depression.  Adv Exp Med Biol 1995. 
395: 257-8. 
 
Friedman E, Wang HY.  Receptor-mediated activation of G proteins is increased 
in postmortem brains of bipolar affective disorder subjects.  J Neurochem 
1996. 67: 1145-52. 
 
 
233 
Galandrin S, Bouvier M.  Distinct signaling profiles of beta1 and beta2 adrenergic 
receptor ligands toward adenylyl cyclase and mitogen-activated protein 
kinase reveals the pluridimensionality of efficacy.  Mol Pharmacol 2006.  70: 
1575-84. 
 
Garcia F, Jia C, Carrasco GA, Chadda R, Chen Z, Yu Z, Muma NA, Battaglia G.  
Hypothalamic 5-HT1A receptors mediate the phosphorylation of ERK and 
neuroendocrine responses via distinct signaling pathways in rats.  
Program No. 33.22/C14. 2006 Neuroscience Meeting Planner. Atlanta, GA: 
Society for Neuroscience, 2006. Online. 
 
Garcia-Ovejero D, Veiga S, Garcia-Segura LM, Doncarlos LL. Glial expression of 
estrogen and androgen receptors after rat brain injury. J Comp Neurol 2002. 
450: 256-71. 
 
Garnovskaya MN, Van Biesen T, Hawes B, Casañas Ramos S, Lefkowitz RJ, 
Raymond JR.  Ras-dependent activation of fibroblast mitogen-activated 
protein kinase by 5-HT1A receptor via a G protein beta gamma-subunit-
initiated pathway. Biochemistry 1996. 35: 13716-22. 
Garzón J, Rodríguez-Muñoz M, López-Fando A, Sánchez-Blázquez P. The 
RGSZ2 protein exists in a complex with mu-opioid receptors and 
regulates the desensitizing capacity of Gz proteins. 
Neuropsychopharmacology 2005. 30: 1632-48. 
Gibbons RD, Brown CH, Hur K, Marcus SM, Bhaumik DK, Erkens JA, Herings 
RMC, Mann JJ.  Early evidence on the effects of regulators' suicidality 
warnings on SSRI prescriptions and suicide in children and adolescents. 
Am J Psychiatry 2007. 164: 1356-63. 
 
Gibbs DM, Vale W.  Effect of the serotonin reuptake inhibitor fluoxetine on 
corticotropin-releasing factor and vasopressin secretion into hypophysial 
portal blood.  Brain Res 1983. 280: 176-9. 
Giedd JN, Blumenthal J, Jeffries NO, Castellanos FX, Liu H, Zijdenbos A, Paus T, 
Evans AC, Rapoport JL.  Brain development during childhood and 
adolescence: a longitudinal MRI study.  Nat Neurosci 1999. 2: 861-3. 
Gilbert F, Brazell C, Tricklebank MD, Stahl SM. Activation of the 5-HT1A receptor 
subtype increases rat plasma ACTH concentration. Eur J Pharmacol 1988. 
147: 431-9. 
234 
Goel N, Plyler KS, Daniels D, Bale TL.  Androgenic Influence on Serotonergic 
Activation of the HPA Stress Axis.  Endocrinology 2011. 
doi:10.1210/en.2010-0964 
Goel R, Phillips-Mason PJ, Raben DM, Baldassare JJ.  alpha-Thrombin induces 
rapid and sustained Akt phosphorylation by beta-arrestin1-dependent 
and -independent mechanisms, and only the sustained Akt 
phosphorylation is essential for G1 phase progression.  J Biol Chem 2002. 
277: 18640-8. 
Goubaeva F, Ghosh M, Malik S, Yang J, Hinkle PM, Griendling KK, Neubig RR, 
Smrcka AV.  Stimulation of cellular signaling and G protein subunit 
dissociation by G protein betagamma subunit-binding peptides. J Biol 
Chem 2003. 278: 19634-41. 
Gould TD, Einat H, Bhat R, Manji HK.  AR-A014418, a selective GSK-3 inhibitor, 
produces antidepressant-like effects in the forced swim test.  Int J 
Neuropsychopharmacol 2004. 7: 387-90. 
Gourley SL, Wu FJ, Kiraly DD, Ploski JE, Kedves AT, Duman RS, Taylor JR. 
Regionally Specific Regulation of ERK MAP Kinase in a Model of 
Antidepressant-Sensitive Chronic Depression. Biol Psychiatry 2008. 63: 353-
359. 
Guzmán-Hernández ML, Vázquez-Macías A, Carretero-Ortega J, Hernández-
García R, García-Regalado A, Hernández-Negrete I, Reyes-Cruz G, 
Gutkind JS, Vázquez-Prado J.  Differential inhibitor of Gbetagamma 
signaling to AKT and ERK derived from phosducin-like protein: effect on 
sphingosine 1-phosphate-induced endothelial cell migration and in vitro 
angiogenesis.  J Biol Chem 2009. 284: 18334-46. 
Grimes CA, Jope RS.  The multifaceted roles of glycogen synthase kinase 3beta in 
cellular signaling.  Prog Neurobiol 2001. 65: 391-426. 
 
Gross C, Zhuang X, Stark K Ramboz S, Oosting R, Kirby L, Santarelli L, Beck S, 
Hen R.  Serotonin1A receptor acts during development to establish normal 
anxiety-like behaviour in the adult. Nature 2002. 416: 396-400. 
 
Hamik A, Oksenberg D, Fischette C, Peroutka SJ.  Analysis of tandospirone (SM-
3997) interactions with neurotransmitter receptor binding sites. Biol 
Psychiatry 1990. 28: 99-109. 
 
235 
Hankin BL, Badanes LS, Abela JR, Watamura SE.  Hypothalamic-pituitary-
adrenal axis dysregulation in dysphoric children and adolescents: cortisol 
reactivity to psychosocial stress from preschool through middle 
adolescence. Biol Psychiatry 2010. 68: 484-90. 
Hatton GI.  Emerging concepts of structure-function dynamics in adult brain: the 
hypothalamo-neurohypophysial system.  Prog Neurobiol 1990. 34: 437-504. 
 
Heim C, Mletzko T, Purselle D, Musselman DL, Nemeroff CB.  The 
dexamethasone/corticotropin-releasing factor test in men with major 
depression: role of childhood trauma.  Biol Psychiatry 2008.  63: 398-405.  
 
Heim C, Plotsky PM, Nemeroff CB.  Importance of studying the contributions of 
early adverse experience to neurobiological findings in depression.  
Neuropsychopharmacology 2004. 29: 641-8.  
 
Heinrichs M, Gaab J.  Neuroendocrine mechanisms of stress and social 
interaction: implications for mental disorders.  Curr Opin Psychiatry 2007. 
20: 158-62. 
 
Hensler JG.  Serotonergic modulation of the limbic system.  Neurosci Biobehav Rev 
2006. 30: 203-14. 
 
Hensler JG.  “Serotonin.”  Chapter 13 in Basic Neurochemistry, 7th edition. Edited 
by Siegel GJ.  Massachusetts:  Elsevier, 2006. 
 
Hernández F, Langa E, Cuadros R, Avila J, Villanueva N.  Regulation of GSK3 
isoforms by phosphatases PP1 and PP2A. Mol Cell Biochem 2010. 344: 211-
5. 
 
Hirschfeld RM.  Efficacy of SSRIs and newer antidepressants in severe 
depression: comparison with TCAs.  J Clin Psychiatry 1999. 60: 326-35.  
 
Hiroi N, Wong ML, Licinio J, Park C, Young M, Gold PW, Chrousos GP, 
Bornstein SR.  Expression of corticotropin releasing hormone receptors 
type I and type II mRNA in suicide victims and controls.  Mol Psychiatry 
2001. 6: 540-6. 
 
Holford NHG.  “Pharmacokinetics and Pharmacodynamics:  Rational Dosing 
and the Time Course of Drug Action.”  Chapter 3 in Basic and Clinical 
Pharmacology, Ninth Edition. Edited by Katzung BG.  New York:  Lange 
Medical Books/McGraw-Hill, 2004. 
 
236 
Holsboer F.  The rationale for corticotropin-releasing hormone receptor (CRH-R) 
antagonists to treat depression and anxiety.  J Psychiatr Res 1999. 33: 181-
214.  
 
Holsboer F.  The corticosteroid receptor hypothesis of depression.  
Neuropsychopharmacology 2000. 23: 477-501.  
 
Holsboer F, Ising M.  Stress hormone regulation: biological role and translation 
into therapy.  Annu Rev Psychol 2010. 61: 81-109, C1-11. 
Homberg JR, Olivier JD, Blom T, Arentsen T, van Brunschot C, Schipper P, Korte-
Bouws G, van Luijtelaar G, Reneman L.  Fluoxetine exerts age-dependent 
effects on behavior and amygdala neuroplasticity in the rat.  PLoS One 
2011. 6: e16646. 
Hsiung SC, Adlersberg M, Arango V, Mann JJ, Tamir H, Liu KP.  Attenuated 5-
HT1A receptor signaling in brains of suicide victims: involvement of 
adenylyl cyclase, phosphatidylinositol 3-kinase, Akt and mitogen-
activated protein kinase. J Neurochem 2003. 87: 182-94. 
 
Hsiung SC, Tamir H, Franke TF, Liu KP. Roles of extracellular signal-regulated 
kinase and Akt signaling in coordinating nuclear transcription factor-
kappaB-dependent cell survival after serotonin 1A receptor activation. J 
Neurochem 2005. 95: 1653-66. 
 
Ihnatovych I, Novotny J, Haugvicova R, Bourova L, Mares P, Svoboda P.  
Opposing changes of trimeric G protein levels during ontogenetic 
development of rat brain.  Brain Res Dev Brain Res 2002. 133: 57-67. 
Iniguez SD, Warren BL, Bolaños-Guzman CA.  Short- and long-term functional 
consequences of fluoxetine exposure during adolescence in male rats.  Biol 
Psychiatry 2010. 67: 1057-66. 
Jankord R, Zhang R, Flak JN, Solomon MB, Albertz J, Herman JP.  Stress 
activation of IL-6 neurons in the hypothalamus.  Am J Physiol Regul Integr 
Comp Physiol 2010. 299: R343-51.  
 
Jezova D, Juránková E, Mosnárová A, Kriska M, Skultétyová I.  Neuroendocrine 
response during stress with relation to gender differences.  Acta Neurobiol 
Exp (Wars) 1996. 56: 779-85.  
 
237 
Jezova D, Michajlovskij N, Kvetnanský R, Makara GB. Paraventricular and 
supraoptic nuclei of the hypothalamus are not equally important for 
oxytocin release during stress. Neuroendocrinology 1993. 57: 776-81. 
 
Jia C, Carrasco GA, Garcia F, Chadda R, Chen Z, Xu H, Muma NA, Battaglia G. 
SSRI-induced desensitization of hypothalamic 5-HT1A receptor-mediated 
neuroendocrine reponses requires activation of MAP kinase (MEK/ERK) 
pathways.  Program No. 464.10/G45. 2007 Neuroscience Meeting Planner. 
San Diego, CA: Society for Neuroscience, 2007. Online. 
 
Jia C, Carrasco GA, Garcia F, Chadda R, Chen Z, Yu Z, Muma NA, Battaglia G.  
Treatment with SSRIs or 8-OH-DPAT differentially alters 5-HT1A receptor-
mediated phosphorylation of ERK and neuroendocrine responses in rats. 
Program No. 33.21/C13. 2006 Neuroscience Meeting Planner. Atlanta, GA: 
Society for Neuroscience, 2006. Online. 
 
Jones PF, Jakubowicz T, Hemmings BA.  Molecular cloning of a second form of 
rac protein kinase. Cell Regul 1991. 2:1001-9. 
 
Jope RS, Song L, Grimes CA, Pacheco MA, Dilley GE, Li X, Meltzer HY, 
Overholser JC, Stockmeier CA.  Selective increases in phosphoinositide 
signaling activity and G protein levels in postmortem brain from subjects 
with schizophrenia or alcohol dependence.  J Neurochem 1998.  70: 763-71. 
Jorgensen H, Knigge U, Kjaer A, Møller M, Warberg J.  Serotonergic stimulation 
of corticotropin-releasing hormone and pro-opiomelanocortin gene 
expression.  J Neuroendocrinol 2002. 14: 788-95. 
Jorgensen HS.  Studies on the neuroendocrine role of serotonin.  Dan Med Bull 
2007. 54: 266-88. 
 
Kenakin T.  Agonist-receptor efficacy. II. Agonist trafficking of receptor signals.  
Trends Pharmacol Sci 1995. 16: 232-8.  
 
Khan AM, Ponzio TA, Sanchez-Watts G, Stanley BG, Hatton GI, Watts AG.  
Catecholaminergic control of mitogen-activated protein kinase signaling 
in paraventricular neuroendocrine neurons in vivo and in vitro: a 
proposed role during glycemic challenges. J Neurosci 2007. 27: 7344-60. 
 
 
 
 
238 
Khan AM, Watts AG. Intravenous 2-deoxy-D-glucose injection rapidly elevates 
levels of the phosphorylated forms of p44/42 mitogen-activated protein 
kinases (extracellularly regulated kinases 1/2) in rat hypothalamic 
parvicellular paraventricular neurons. Endocrinology 2004. 145: 351-9. 
 
Kia HK, Miquel MC, Brisorgueil MJ, Daval G, Riad M, El Mestikawy S, Hamon 
M, Vergé D.  Immunocytochemical localization of serotonin1A receptors 
in the rat central nervous system.  J Comp Neurol 1996a. 365: 289-305. 
 
Kia HK, Brisorgueil MJ, Hamon M, Calas A, Vergé D.  Ultrastructural 
localization of 5-hydroxytryptamine1A receptors in the rat brain.  J 
Neurosci Res 1996b. 46: 697-708. 
Kiss JZ.  Dynamism of chemoarchitecture in the hypothalamic paraventricular 
nucleus.  Brain Res Bull 1988. 20: 699-708.  
Klein PS, Melton DA.  A molecular mechanism for the effect of lithium on 
development. Proc Natl Acad Sci U S A 1996. 93: 8455-9. 
Knott C, Maguire JJ, Bowery NG.  Age-related regional sensitivity to pertussis 
toxin-mediated reduction in GABAB receptor binding in rat brain.  Brain 
Res Mol Brain Res 1993. 18: 353-7. 
Konishi H, Kuroda S, Tanaka M, Matsuzaki H, Ono Y, Kameyama K, Haga T, 
Kikkawa U.  Molecular cloning and characterization of a new member of 
the RAC protein kinase family: association of the pleckstrin homology 
domain of three types of RAC protein kinase with protein kinase C 
subspecies and beta gamma subunits of G proteins. Biochem Biophys Res 
Commun 1995. 216: 526-34. 
Kruk MR. Ethology and pharmacology of hypothalamic aggression in the rat. 
Neurosci Biobehav Rev 1991. 15: 527-38. 
 
Lauder JM.  Ontogeny of the serotonergic system in the rat: serotonin as a 
developmental signal.  Ann N Y Acad Sci 1990. 600: 297-313. 
Laviola G, Wood RD, Kuhn C, Francis R, Spear LP.  Cocaine sensitization in 
periadolescent and adult rats.  J Pharmacol Exp Ther 1995. 275: 345-57. 
Lee R, Garcia F, van de Kar LD, Hauger RD, Coccaro EF.  Plasma oxytocin in 
response to pharmaco-challenge to D-fenfluramine and placebo in healthy 
men.  Psychiatry Res 2003. 118: 129-36. 
239 
Lee SY, Kang JS, Song GY, Myung CS. Stress induces the expression of 
heterotrimeric G protein beta subunits and the phosphorylation of 
PKB/Akt and ERK1/2 in rat brain. Neurosci Res 2006. 56: 180-92. 
Le Poul E, Boni C, Hanoun N, Laporte AM, Laaris N, Chauveau J, Hamon M, 
Lanfumey L.  Differential adaptation of brain 5-HT1A and 5-HT1B receptors 
and 5-HT transporter in rats treated chronically with fluoxetine.  
Neuropharmacology 2000. 39:110-22. 
Lerer B, Gelfin Y, Gorfine M, Allolio B, Lesch KP, Newman ME.  5-HT1A receptor 
function in normal subjects on clinical doses of fluoxetine: blunted 
temperature and hormone responses to ipsapirone challenge. 
Neuropsychopharmacology 1999. 20: 628-39. 
 
Li PP, Andreopoulos S, Wong CC, Vecil GG, Warsh JJ.  Effect of thyroid 
deficiency on Go alpha-subunit isoforms in developing rat cerebral cortex. 
Neurochem Res 1995. 20: 1249-55. 
 
Li Q, Brownfield MS, Levy AD, Battaglia G, Cabrera TM, Van de Kar LD.  
Attenuation of hormone responses to the 5-HT1A agonist ipsapirone by 
long-term treatment with fluoxetine, but not desipramine, in male rats. 
Biol Psychiatry 1994. 36: 300-8. 
 
Li Q, Levy AD, Cabrera TM, Brownfield MS, Battaglia G, Van de Kar LD. Long-
term fluoxetine, but not desipramine, inhibits the ACTH and oxytocin 
responses to the 5-HT1A agonist, 8-OH-DPAT, in male rats. Brain Res 1993. 
630: 148-56.  
 
Li Q, Muma NA, Battaglia G, Van De Kar LD. A desensitization of hypothalamic 
5-HT1A receptors by repeated injections of paroxetine: reduction in the 
levels of G(i) and G(o) proteins and neuroendocrine responses, but not in 
the density of 5-HT1A receptors. J Pharmacol Exp Ther 1997. 282: 1581-90. 
 
Li Q, Muma NA, Van De Kar LD. Chronic fluoxetine induces a gradual 
desensitization of 5-HT1A receptors: reductions in hypothalamic and 
midbrain Gi and G(o) proteins and in neuroendocrine responses to a 5-
HT1A agonist. J Pharmacol Exp Ther 1996. 279: 1035-42. 
Li X, Rosborough KM, Friedman AB, Zhu W, Roth KA. Regulation of mouse 
brain glycogen synthase kinase-3 by atypical antipsychotics. Int J 
Neuropsychopharmacol 2007. 10: 7-19.  
240 
Li X, Zhu W, Roh MS, Friedman AB, Rosborough K, Jope RS.  In vivo regulation 
of glycogen synthase kinase-3beta (GSK3beta) by serotonergic activity in 
mouse brain.  Neuropsychopharmacology 2004. 29: 1426-31. 
 
Lidow MS, Rakic P.  Scheduling of monoaminergic neurotransmitter receptor 
expression in the primate neocortex during postnatal development.  Cereb 
Cortex 1992. 2: 401-16. 
Liposits Z, Paull WK, Sétáló G, Vigh S. Evidence for local corticotropin releasing 
factor (CRF)-immunoreactive neuronal circuits in the paraventricular 
nucleus of the rat hypothalamus. An electron microscopic 
immunohistochemical analysis. Histochemistry 1985. 83: 5-16.  
Liposits Z, Phelix C, Paull WK.  Synaptic interaction of serotonergic axons and 
corticotropin releasing factor (CRF) synthesizing neurons in the 
hypothalamic paraventricular nucleus of the rat. A light and electron 
microscopic immunocytochemical study.  Histochemistry 1987. 86: 541-9. 
Liu Q, Wong-Riley MT.  Postnatal changes in tryptophan hydroxylase and 
serotonin transporter immunoreactivity in multiple brainstem nuclei of 
the rat: implications for a sensitive period.  J Comp Neurol 2010. 518: 1082-
97. 
Lopez-Duran NL, Kovacs M, George CJ. Hypothalamic-pituitary-adrenal axis 
dysregulation in depressed children and adolescents: a meta-analysis. 
Psychoneuroendocrinology 2009.  34: 1272-83.  
Lounsbury KM, Casey PJ, Brass LF, Manning DR.  Phosphorylation of Gz in 
human platelets. Selectivity and site of modification. J Biol Chem 1991. 266: 
22051-6. 
Lorenz B, Garcia-Segura LM, Doncarlos LL. Cellular phenotype of androgen 
receptor-immunoreactive nuclei in the developing and adult rat brain. J 
Comp Neurol 2005. 492: 456-68. 
 
Maciag D, Simpson KL, Coppinger D, Lu Y, Wang Y, Lin RC, Paul IA.  Neonatal 
antidepressant exposure has lasting effects on behavior and serotonin 
circuitry. Neuropsychopharmacology 2006. 31: 47-57. 
 
MacMaster FP, Leslie R, Rosenberg DR, Kusumakar V.  Pituitary gland volume 
in adolescent and young adult bipolar and unipolar depression.  Bipolar 
Disord 2008. 10: 101-4. 
241 
Madaan V, Wilson DR.Neuropeptides: relevance in treatment of depression and 
anxiety disorders. Drug News Perspect 2009. 22: 319-24. 
Mahmood I, Sahajwalla C.  Clinical pharmacokinetics and pharmacodynamics of 
buspirone, an anxiolytic drug.  Clin Pharmacokinet 1999. 36: 277-87. 
 
Mannoury la Cour C, El Mestikawy S, Hanoun N, Hamon M, Lanfumey L. 
Regional differences in the coupling of 5-hydroxytryptamine-1A receptors 
to G proteins in the rat brain. Mol Pharmacol 2006. 70: 1013-21. 
Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, Fukasawa K, Vande 
Woude GF, Ahn NG. Transformation of mammalian cells by 
constitutively active MAP kinase kinase. Science 1994. 265: 966-70. 
Marazziti D, Catena Dell'osso M.  The role of oxytocin in neuropsychiatric 
disorders.  Curr Med Chem 2008. 15: 698-704.  
 
Marshall CJ.  Specificity of receptor tyrosine kinase signaling: transient versus 
sustained extracellular signal-regulated kinase activation.  Cell 1995. 80: 
179-85. 
 
Marvin E, Scrogin K, Dudás B.  Morphology and distribution of neurons 
expressing serotonin 5-HT1A receptors in the rat hypothalamus and the 
surrounding diencephalic and telencephalic areas. J Chem Neuroanat 2010. 
39: 235-41. 
 
Meinlschmidt G, Heim C.  Decreased cortisol awakening response after early loss 
experience.  Psychoneuroendocrinology 2005. 30:568-76. 
 
Millan MJ, Rivet JM, Canton H, Le Marouille-Girardon S, Gobert A. Induction of 
hypothermia as a model of 5-hydroxytryptamine1A receptor-mediated 
activity in the rat: a pharmacological characterization of the actions of 
novel agonists and antagonists. J Pharmacol Exp Ther 1993. 264: 1364-76. 
Miller LG, Thompson ML, Byrnes JJ, Greenblatt DJ, Shemer A.  Kinetics, brain 
uptake, and receptor binding of tandospirone and its metabolite 1-(2-
pyrimidinyl)-piperazine. J Clin Psychopharmacol 1992. 12: 341-5. 
Modell S, Holsboer F.  “Depression and Effects of Antidepressant Drugs on the 
Stress Systems.”  Chapter 3.3 in Handbook of Stress and the Brain, Volume 15. 
Edited by Steckler T, Kalin NH, Reul JMHM.  Amsterdam:  Elsevier, 2005. 
242 
Mukhin YV, Garnovskaya MN, Collinsworth G, Grewal JS, Pendergrass D, Nagai 
T, Pinckney S, Greene EL, Raymond JR.  5-Hydroxytryptamine1A 
receptor/Gibetagamma stimulates mitogen-activated protein kinase via 
NAD(P)H oxidase and reactive oxygen species upstream of src in chinese 
hamster ovary fibroblasts. Biochem J 2000. 347 Pt 1:61-7. 
Muraki Y, Yamanaka A, Tsujino N, Kilduff TS, Goto K, Sakurai T.  Serotonergic 
regulation of the orexin/hypocretin neurons through the 5-HT1A receptor. 
J Neurosci 2004. 24: 7159-66. 
Murphy LO, MacKeigan JP, Blenis J. A network of immediate early gene 
products propagates subtle differences in mitogen-activated protein 
kinase signal amplitude and duration. Mol Cell Biol 2004. 24: 144-53. 
Murphy LO, Smith S, Chen RH, Fingar DC, Blenis J. Molecular interpretation of 
ERK signal duration by immediate early gene products. Nat Cell Biol 2002. 
4: 556-64. 
Musazzi L, Mallei A, Tardito D, Gruber SH, El Khoury A, Racagni G, Mathé AA, 
Popoli M.  Early-life stress and antidepressant treatment involve synaptic 
signaling and Erk kinases in a gene-environment model of depression.  J 
Psychiatr Res 2010. 44: 511-20.  
 
Nakano M, Osada K, Misonoo A, Fujiwara K, Takahashi M, Ogawa Y, Haga T, 
Kanai S, Tanaka D, Sasuga Y, Yanagida T, Asakura M, Yamaguchi N.  
Fluvoxamine and sigma-1 receptor agonists dehydroepiandrosterone 
(DHEA)-sulfate induces the Ser473-phosphorylation of Akt-1 in PC12 cells. 
Life Sci 2010. 86: 309-14. 
 
National Institutes of Health. Adolescent Depression.  2010/02/14. Online 
[Available] 
http://www.nlm.nih.gov/medlineplus/ency/article/001518.htm. 
 
Nemeroff CB. The corticotropin-releasing factor (CRF) hypothesis of depression: 
new findings and new directions.  Mol Psychiatry 1996. 1: 336-42.  
 
Neumann ID.  Brain oxytocin: a key regulator of emotional and social behaviours 
in both females and males.  J Neuroendocrinol 2008. 20:858-65. 
 
Newman ME, Shalom G, Ran A, Gur E, Van de Kar LD.  Chronic fluoxetine-
induced desensitization of 5-HT1A and 5-HT1B autoreceptors: regional 
differences and effects of WAY-100635.  Eur J Pharmacol 2004. 486: 25-30. 
243 
Nguyen TT, Scimeca JC, Filloux C, Peraldi P, Carpentier JL, Van Obberghen E. 
Co-regulation of the mitogen-activated protein kinase, extracellular 
signal-regulated kinase 1, and the 90-kDa ribosomal S6 kinase in PC12 
cells. Distinct effects of the neurotrophic factor, nerve growth factor, and 
the mitogenic factor, epidermal growth factor. J Biol Chem 1993. 268: 9803-
10. 
 
Nobile M, Cataldo GM, Marino C, Molteni M. Diagnosis and treatment of 
dysthymia in children and adolescents. CNS Drugs 2003.  17: 927-46. 
O'Brien WT, Harper AD, Jové F, Woodgett JR, Maretto S, Piccolo S, Klein PS. 
Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral 
and molecular effects of lithium. J Neurosci 2004. 24: 6791-8. 
Oh JE, Zupan B, Gross S, Toth M. Paradoxical anxiogenic response of juvenile 
mice to fluoxetine. Neuropsychopharmacology 2009. 34: 2197-207. 
 
Osei-Owusu P, James A, Crane J, Scrogin KE.  5-Hydroxytryptamine 1A 
receptors in the paraventricular nucleus of the hypothalamus mediate 
oxytocin and adrenocorticotropin hormone release and some behavioral 
components of the serotonin syndrome.  J Pharmacol Exp Ther 2005. 313: 
1324-30.  
 
Ozsoy S, Esel E, Kula M.  Serum oxytocin levels in patients with depression and 
the effects of gender and antidepressant treatment. Psychiatry Res 2009.  
169: 249-52. 
 
Pace TW, Mletzko TC, Alagbe O, Musselman DL, Nemeroff CB, Miller AH, Heim 
CM.  Increased stress-induced inflammatory responses in male patients 
with major depression and increased early life stress.  Am J Psychiatry 2006. 
163: 1630-3. 
 
Pak TF and Handa RJ.  “Steroid hormone receptors and sex differences in 
behavior.”  Chapter 7 in Sex Differences in the Brain:  From Genes to Behavior.  
Edited by Becker JB.  USA:  Oxford University Press, 2007.   
Pampillo M, Camuso N, Taylor JE, Szereszewski JM, Ahow MR, Zajac M, Millar 
RP, Bhattacharya M, Babwah AV.  Regulation of GPR54 signaling by 
GRK2 and {beta}-arrestin. Mol Endocrinol 2009. 23: 2060-74. 
Papadimitriou A, Priftis KN.  Regulation of the hypothalamic-pituitary-adrenal 
axis.  Neuroimmunomodulation 2009.  16: 265-71.  
244 
Papakostas GI, Fava M. A metaanalysis of clinical trials comparing moclobemide 
with selective serotonin reuptake inhibitors for the treatment of major 
depressive disorder.  Can J Psychiatry 2006. 51: 783-90. 
 
Papiol S, Arias B, Gastó C, Gutiérrez B, Catalán R, Fañanás L. Genetic variability 
at HPA axis in major depression and clinical response to antidepressant 
treatment.  J Affect Disord 2007.  104: 83-90. 
Paterson DS, Belliveau RA, Trachtenberg F, Kinney HC. Differential 
development of 5-HT receptor and the serotonin transporter binding in 
the human infant medulla. J Comp Neurol 2004. 472: 221-31. 
Paxinos G and Watson C.  The rat brain in stereotaxic coordinates.  1998.  San Diego: 
Academic Press. 
Pesić V, Popić J, Milanović D, Loncarević-Vasiljković N, Rakić L, Kanazir S, 
Ruzdijić S.  The effect of MK-801 on motor activity and c-Fos protein 
expression in the brain of adolescent Wistar rats.  Brain Res 2010. 1321: 96-
104.  
Petrunich ML, Garcia F, Quaka M, Losada A, Battaglia G.  Gαi3, Gαo, and Gαz 
proteins are pertussis toxin insensitive in the adolescent hypothalamus:  
effects on 5-HT1A receptor activation.  Program No. 825.3/D8. 2008 
Neuroscience Meeting Planner. Washington, DC: Society for Neuroscience, 
2008. Online. 
Pfeffer CR, Altemus M, Heo M, Jiang H.  Salivary cortisol and psychopathology 
in children bereaved by the September 11, 2001 terror attacks. Biol 
Psychiatry 2007. 61: 957-65.  
Pittman QJ, Blume HW, Renaud LP.  Connections of the hypothalamic 
paraventricular nucleus with the neurohypophysis, median eminence, 
amygdala, lateral septum and midbrain periaqueductal gray: an 
electrophysiological study in the rat. Brain Res 1981. 215: 15-28. 
Pompili M, Serafini G, Innamorati M, Möller-Leimkühler AM, Giupponi G, 
Girardi P, Tatarelli R, Lester D.  The hypothalamic-pituitary-adrenal axis 
and serotonin abnormalities: a selective overview for the implications of 
suicide prevention. Eur Arch Psychiatry Clin Neurosci 2010. 260: 583-600.  
Polter AM, Li X.  5-HT1A receptor-regulated signal transduction pathways in 
brain.  Cell Signal 2010. 22: 1406-12.  
245 
Polter AM, Yang S, Jope RS, Li X.  Regulation of GSK3 by 5-HT1A receptors in the 
hippocampus.  Program No. 741.17/D35. 2010 Neuroscience Meeting 
Planner. San Diego, CA: Society for Neuroscience, 2010. Online. 
Pouysségur J, Lenormand P.  Fidelity and spatio-temporal control in MAP kinase 
(ERKs) signalling.  Eur J Biochem 2003.  270: 3291-9. 
Povsic TJ, Kohout TA, Lefkowitz RJ. Beta-arrestin1 mediates insulin-like growth 
factor 1 (IGF-1) activation of phosphatidylinositol 3-kinase (PI3K) and 
anti-apoptosis. J Biol Chem 2003. 278: 51334-9. 
Qi X, Lin W, Li J, Pan Y, Wang W. The depressive-like behaviors are correlated 
with decreased phosphorylation of mitogen-activated protein kinases in 
rat brain following chronic forced swim stress. Behav Brain Res 2006. 175: 
233-40.  
 
Qi X, Lin W, Li J, Li H, Wang W, Wang D, Sun M.  Fluoxetine increases the 
activity of the ERK-CREB signal system and alleviates the depressive-like 
behavior in rats exposed to chronic forced swim stress.  Neurobiol Dis 2008. 
31: 278-85.  
 
Qi X, Lin W, Wang D, Pan Y, Wang W, Sun M.  A role for the extracellular signal-
regulated kinase signal pathway in depressive-like behavior. Behav Brain 
Res 2009. 199: 203-9. 
 
Raap DK, Evans S, Garcia F, Li Q, Muma NA, Wolf WA, Battaglia G, Van De Kar 
LD.  Daily injections of fluoxetine induce dose-dependent desensitization 
of hypothalamic 5-HT1A receptors: reductions in neuroendocrine 
responses to 8-OH-DPAT and in levels of Gz and Gi proteins. J Pharmacol 
Exp Ther 1999. 288: 98-106. 
Rabin RA, Winter JC.  Studies of the biochemical basis for the discriminative 
properties of 8-hydroxy-2-(di-n-propylamino)tetralin. Eur J Pharmacol 1993. 
235: 237-43. 
Rajagopal S, Rajagopal K, Lefkowitz RJ.  Teaching old receptors new tricks: 
biasing seven-transmembrane receptors.  Nat Rev Drug Discov 2010. 9: 373-
86. 
 
246 
Rapoport JL, Giedd JN, Blumenthal J, Hamburger S, Jeffries N, Fernandez T, 
Nicolson R, Bedwell J, Lenane M, Zijdenbos A, Paus T, Evans A.  
Progressive cortical change during adolescence in childhood-onset 
schizophrenia. A longitudinal magnetic resonance imaging study. Arch 
Gen Psychiatry 1999. 56: 649-54. 
Raymond JR.  Protein kinase C induces phosphorylation and desensitization of 
the human 5-HT1A receptor.  J Biol Chem 1991. 266: 14747-53. 
Raymond JR, El Mestikawy S, Fargin A. The 5-HT1A receptor: From molecular 
characteristics to Clinical correlates. In Brann, MR, ed. Molecular biology of 
G-protein-coupled Receptors. Boston: Birkhauser, 1992: 113-41. 
 
Raymond JR, Mukhin YV, Gelasco A, Turner J, Collinsworth G, Gettys TW, 
Grewal JS, Garnovskaya MN.  Multiplicity of mechanisms of serotonin 
receptor signal transduction.  Pharmacol Ther 2001. 92: 179-212.  
 
Raymond JR, Olsen CL, Gettys TW. Cell-specific physical and functional 
coupling of human 5-HT1A receptors to inhibitory G protein alpha-
subunits and lack of coupling to Gs alpha. Biochemistry (Mosc) 1993. 32:  
11064-73. 
Reddy KK, Lefkove B, Chen LB, Govindarajan B, Carracedo A, Velasco G, 
Carrillo CO, Bhandarkar SS, Owens MJ, Mechta-Grigoriou F, Arbiser JL. 
The antidepressant sertraline downregulates Akt and has activity against 
melanoma cells. Pigment Cell Melanoma Res 2008. 21: 451-6. 
Reeves RR, Ladner ME. Antidepressant-induced suicidality: an update. CNS 
Neurosci Ther 2010. 16: 227-34.  
Roh MS, Eom TY, Zmijewska AA, De Sarno P, Roth KA, Jope RS. Hypoxia 
activates glycogen synthase kinase-3 in mouse brain in vivo: protection by 
mood stabilizers and imipramine. Biol Psychiatry 2005. 57: 278-86. 
Romeo RD.  Pubertal maturation and programming of hypothalamic-pituitary-
adrenal reactivity.  Front Neuroendocrinol 2010. 31: 232-40.  
Romeo RD, Bellani R, Karatsoreos IN, Chhua N, Vernov M, Conrad CD, McEwen 
BS.  Stress history and pubertal development interact to shape 
hypothalamic-pituitary-adrenal axis plasticity.  Endocrinology 2006. 147: 
1664-74. 
 
247 
Röskam S, Koch M.  Effects of neonatal and peripubertal ethanol treatment on 
various aspects of adult rat behavior and brain anatomy. Int J Dev Neurosci 
2009. 27: 249-56. 
Rozengurt E. Mitogenic signaling pathways induced by G protein-coupled 
receptors. J Cell Physiol 2007. 213: 589-602. 
Rubenstein JL.  Development of serotonergic neurons and their projections.  Biol 
Psychiatry 1998. 44: 145-50.  
 
Rushton JL, Whitmire JT. Pediatric stimulant and selective serotonin reuptake 
inhibitor prescription trends: 1992 to 1998. Arch Pediatr Adolesc Med 2001. 
155: 560-5. 
Ryan ND. Child and adolescent depression: short-term treatment effectiveness 
and long-term opportunities. Int J Methods Psychiatr Res 2003. 12: 44-53. 
Sable CL, Filippa N, Hemmings B, Van Obberghen E.  cAMP stimulates protein 
kinase B in a Wortmannin-insensitive manner. FEBS Lett 1997. 409: 253-7. 
Saeed O, Yaghmaie F, Garan SA, Gouw AM, Voelker MA, Sternberg H, Timiras 
PS.  Insulin-like growth factor-1 receptor immunoreactive cells are 
selectively maintained in the paraventricular hypothalamus of calorically 
restricted mice. Int J Dev Neurosci 2007. 25: 23-8.  
Saitoh A, Yamaguchi K, Tatsumi Y, Murasawa H, Nakatani A, Hirose N, Yamada 
M, Yamada M, Kamei J.  Effects of milnacipran and fluvoxamine on 
hyperemotional behaviors and the loss of tryptophan hydroxylase-
positive cells in olfactory bulbectomized rats.  Psychopharmacology (Berl) 
2007. 191:857-65. 
Sakanaka M, Shibasaki T, Lederis K. Corticotropin releasing factor-like 
immunoreactivity in the rat brain as revealed by a modified cobalt-glucose 
oxidase-diaminobenzidine method.  J Comp Neurol 1987. 260: 256-98. 
Saphier D, Feldman S.  Effects of neural stimuli on paraventricular nucleus 
neurones.  Brain Res Bull 1985. 14: 401-7. 
 
Sarbassov DD, Guertin DA, Ali SM, Sabatini DM.  Phosphorylation and 
regulation of Akt/PKB by the rictor-mTOR complex.  Science 2005. 307: 
1098-101. 
 
248 
Sawchenko PE, Swanson LW.  The organization and biochemical specificity of 
afferent projections to the paraventricular and supraoptic nuclei.  Prog 
Brain Res 1983. 60: 19-29.  
 
Sawchenko PE, Swanson LW, Steinbusch HW, Verhofstad AA. The distribution 
and cells of origin of serotonergic inputs to the paraventricular and 
supraoptic nuclei of the rat.  Brain Res 1983. 277: 355-60. 
 
Sawchenko PE, Swanson LW, Vale WW.  Co-expression of corticotropin-
releasing factor and vasopressin immunoreactivity in parvocellular 
neurosecretory neurons of the adrenalectomized rat.  Proc Natl Acad Sci 
USA 1984a. 81: 1883-7. 
 
Sawchenko PE, Swanson LW, Vale WW.  Corticotropin-releasing factor: co-
expression within distinct subsets of oxytocin-, vasopressin-, and 
neurotensin-immunoreactive neurons in the hypothalamus of the male rat.  
J Neurosci 1984b. 4: 1118-29. 
 
Scantamburlo G, Ansseau M, Geenen V, Legros JJ. Oxytocin: From milk ejection 
to maladaptation in stress response and psychiatric disorders. A 
psychoneuroendocrine perspective. Ann Endocrinol (Paris) 2009. 70: 449-54. 
 
Scheid MP, Woodgett JR.  Unravelling the activation mechanisms of protein 
kinase B/Akt. FEBS Lett 2003. 546: 108-12. 
 
Schmidt MV, Czisch M, Sterlemann V, Reinel C, Sämann P, Müller MB.  Chronic 
social stress during adolescence in mice alters fat distribution in late life: 
prevention by antidepressant treatment.  Stress 2009. 12: 89-94. 
Schramm-Sapyta NL, Pratt AR, Winder DG.  Effects of periadolescent versus 
adult cocaine exposure on cocaine conditioned place preference and 
motor sensitization in mice. Psychopharmacology (Berl) 2004. 173: 41-8. 
Serres F, Li Q, Garcia F, Raap DK, Battaglia G, Muma NA, Van de Kar LD. 
Evidence That Gz-Proteins Couple to Hypothalamic 5-HT1A Receptors In 
Vivo.  J Neurosci 2000a. 20: 3095-3103.  
 
Serres F, Muma NA, Raap DK, Garcia F, Battaglia G, Van de Kar LD. 
Coadministration of 5-hydroxytryptamine(1A) antagonist WAY-100635 
prevents fluoxetine-induced desensitization of postsynaptic 5-
hydroxytryptamine(1A) receptors in hypothalamus. J Pharmacol Exp Ther 
2000b. 294: 296-301. 
249 
Seymour PA, Mena EE, McLean S, Heym J.  Pharmacology of the serotonergic 
anxiolytic tandospirone (SM-3997).  Prog Clin Biol Res 1990. 361: 453-60.  
Sharp LL, Schwarz DA, Bott CM, Marshall CJ, Hedrick SM. The influence of the 
MAPK pathway on T cell lineage commitment. Immunity 1997. 7: 609-18.  
Shen CP, Tsimberg Y, Salvadore C, Meller E. Activation of Erk and JNK MAPK 
pathways by acute swim stress in rat brain regions. BMC Neurosci 2004. 5: 
36. 
Shenoy SK, Drake MT, Nelson CD, Houtz DA, Xiao K, Madabushi S, Reiter E, 
Premont RT, Lichtarge O, Lefkowitz RJ.  Beta-arrestin-dependent, G 
protein-independent ERK1/2 activation by the beta2 adrenergic receptor. J 
Biol Chem 2006. 281: 1261-73. 
Silverman AJ, Hoffman DL, Zimmerman EA.  The descending afferent 
connections of the paraventricular nucleus of the hypothalamus (PVN). 
Brain Res Bull 1981. 6: 47-61. 
Sinnett-Smith J, Zhukova E, Hsieh N, Jiang X, Rozengurt E. Protein kinase D 
potentiates DNA synthesis induced by Gq-coupled receptors by 
increasing the duration of ERK signaling in swiss 3T3 cells. J Biol Chem 
2004. 279: 16883-93. 
Slattery DA, Neumann ID.  Chronic icv oxytocin attenuates the pathological high 
anxiety state of selectively bred Wistar rats. Neuropharmacology 2010. 58: 
56-61. 
Slawecki CJ, Thorsell AK, El Khoury A, Mathé AA, Ehlers CL.  Increased CRF-
like and NPY-like immunoreactivity in adult rats exposed to nicotine 
during adolescence: relation to anxiety-like and depressive-like behavior.  
Neuropeptides 2005. 39: 369-77. 
Sowell ER, Peterson BS, Thompson PM, Welcome SE, Henkenius AL, Toga AW.  
Mapping cortical change across the human life span.  Nat Neurosci 2003. 6: 
309-15. 
Spear L.  “The Developing Brain and Adolescent-Typical Behavior Patterns:  An 
Evolutionary Approach.”  Adolescent Psychopathology and the Developing 
Brain. Eds. Romer D and Walker EF.  New York:  Oxford University Press, 
2007.  9-30. 
 
250 
Spear LP.  The adolescent brain and age-related behavioral manifestations.  
Neurosci Biobehav Rev 2000.  24: 417-63. 
 
Spleiss O, van Calker D, Schärer L, Adamovic K, Berger M, Gebicke-Haerter PJ.  
Abnormal G protein alpha(s) - and alpha(i2)-subunit mRNA expression in 
bipolar affective disorder.  Mol Psychiatry 1998. 3: 512-20. 
 
Stephens L, Anderson K, Stokoe D, Erdjument-Bromage H, Painter GF, Holmes 
AB, Gaffney PR, Reese CB, McCormick F, Tempst P, Coadwell J, Hawkins 
PT.  Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-
trisphosphate-dependent activation of protein kinase B.  Science 1998. 279: 
710-4. 
 
Sullivan NR, Crane JW, Damjanoska KJ, Carrasco GA, D'Souza DN, Garcia F, 
Van de Kar LD.  Tandospirone activates neuroendocrine and ERK (MAP 
kinase) signaling pathways specifically through 5-HT1A receptor 
mechanisms in vivo. Naunyn Schmiedebergs Arch Pharmacol 2005. 371: 18-26. 
 
Sullivan Hanley NR, Van de Kar LD.  Serotonin and the neuroendocrine 
regulation of the hypothalamic--pituitary-adrenal axis in health and 
disease. Vitam Horm 2003.  66: 189-255. 
 
Sutherland C, Leighton IA, Cohen P.  Inactivation of glycogen synthase kinase-3 
beta by phosphorylation: new kinase connections in insulin and growth-
factor signalling. Biochem J 1993. 296: 15-9. 
 
Swanson LW, Kuypers HG.  The paraventricular nucleus of the hypothalamus: 
cytoarchitectonic subdivisions and organization of projections to the 
pituitary, dorsal vagal complex, and spinal cord as demonstrated by 
retrograde fluorescence double-labeling methods.  J Comp Neurol 1980. 194: 
555-70. 
 
Swanson LW, Sawchenko PE.  Paraventricular nucleus: a site for the integration 
of neuroendocrine and autonomic mechanisms.  Neuroendocrinology 1980. 
31: 410-7.  
Swanson LW, Sawchenko PE, Rivier J, Vale WW. Organization of ovine 
corticotropin-releasing factor immunoreactive cells and fibers in the rat 
brain: an immunohistochemical study. Neuroendocrinology 1983. 36: 165-86. 
Swiergiel AH, Leskov IL, Dunn AJ.  Effects of chronic and acute stressors and 
CRF on depression-like behavior in mice.  Behav Brain Res 2008. 186: 32-40. 
251 
Szymańska M, Suska A, Budziszewska B, Jaworska-Feil L, Basta-Kaim A, 
Leśkiewicz M, Kubera M, Gergont A, Kroczka S, Kaciński M, Lasoń W. 
Prenatal stress decreases glycogen synthase kinase-3 phosphorylation in 
the rat frontal cortex. Pharmacol Rep 2009. 61: 612-20. 
Taber E, Brodal A, Walberg F.  The raphe nuclei of the brain stem in the cat. I. 
Normal topography and cytoarchitecture and general discussion.  J Comp 
Neurol 1960.  114: 161-87. 
 
Taravosh-Lahn K, Bastida C, Delville Y. Differential responsiveness to fluoxetine 
during puberty. Behav Neurosci 2006. 120: 1084-92. 
Thomson F, Craighead M. Innovative approaches for the treatment of depression: 
targeting the HPA axis. Neurochem Res 2008. 33: 691-707. 
Törk I.  Anatomy of the serotonergic system.  Ann N Y Acad Sci 1990.  600: 9-35. 
Traverse S, Gomez N, Paterson H, Marshall C, Cohen P. Sustained activation of 
the mitogen-activated protein (MAP) kinase cascade may be required for 
differentiation of PC12 cells. Comparison of the effects of nerve growth 
factor and epidermal growth factor. Biochem J 1992. 288: 351-5. 
Trickett PK, Noll JG, Susman EJ, Shenk CE, Putnam FW. Attenuation of cortisol 
across development for victims of sexual abuse. Dev Psychopathol 2010. 22: 
165-75. 
Trincavelli ML, Tuscano D, Marroni M, Klotz KN, Lucacchini A, Martini C.  
Involvement of mitogen protein kinase cascade in agonist-mediated 
human A(3) adenosine receptor regulation.  Biochim Biophys Acta 2002.  
1591: 55-62. 
Tu H, Xu C, Zhang W, Liu Q, Rondard P, Pin JP, Liu J.  GABAB receptor 
activation protects neurons from apoptosis via IGF-1 receptor 
transactivation. J Neurosci 2010. 30: 749-59. 
Turner JH, Gelasco AK, Raymond JR. Calmodulin interacts with the third 
intracellular loop of the serotonin 5-hydroxytryptamine1A receptor at two 
distinct sites: putative role in receptor phosphorylation by protein kinase 
C. J Biol Chem 2004.  279: 17027-37. 
United States Food and Drug Administration. FDA updates its review of 
antidepressant drugs in children.  2004. Online [Available] 
http://www.fda.gov/bbs/topics/ANSWERS/2004/ANS01306.html. 
252 
Uvnäs-Moberg K, Bjökstrand E, Hillegaart V, Ahlenius S.  Oxytocin as a possible 
mediator of SSRI-induced antidepressant effects.  Psychopharmacology (Berl) 
1999. 142: 95-101. 
 
Vaillancourt T, Duku E, Decatanzaro D, Macmillan H, Muir C, Schmidt LA.  
Variation in hypothalamic-pituitary-adrenal axis activity among bullied 
and non-bullied children.  Aggress Behav 2008. 34: 294-305. 
 
Vale W, Spiess J, Rivier C, Rivier J.  Characterization of a 41-residue ovine 
hypothalamic peptide that stimulates secretion of corticotropin and beta-
endorphin.  Science 1981. 213: 1394-7.  
 
Van de Kar LD, Carnes M, Maslowski RJ, Bonadonna AM, Rittenhouse PA, 
Kunimoto K, Piechowski RA, Bethea CL. Neuroendocrine evidence for 
denervation supersensitivity of serotonin receptors: effects of the 5-HT 
agonist RU 24969 on corticotropin, corticosterone, prolactin and renin 
secretion. J Pharmacol Exp Ther 1989. 251: 428-34. 
Van den Hooff P, Galvan M. Actions of 5-hydroxytryptamine and 5-HT1A 
receptor ligands on rat dorso-lateral septal neurones in vitro. Br J 
Pharmacol 1992. 106: 893-9. 
Vicentic A, Li Q, Battaglia G, Van de Kar LD. WAY-100635 inhibits 8-OH-DPAT-
stimulated oxytocin, ACTH and corticosterone, but not prolactin 
secretion. Eur J Pharmacol 1998. 346: 261-6. 
Vigil JM, Geary DC, Granger DA, Flinn MV. Sex differences in salivary cortisol, 
alpha-amylase, and psychological functioning following Hurricane 
Katrina. Child Dev 2010. 81: 1228-40. 
Villablanca JR, Schmanke TD, Lekht V, Crutcher HA.  The growth of the feline 
brain from late fetal into adult life. I. A morphometric study of the 
neocortex and white matter.  Brain Res Dev Brain Res 2000. 122: 11-20. 
Volgin DV, Fay R, Kubin L.  Postnatal development of serotonin 1B, 2 A and 2C 
receptors in brainstem motoneurons.  Eur J Neurosci 2003. 17: 1179-88. 
Walther DJ, Bader M.  A unique central tryptophan hydroxylase isoform. Biochem 
Pharmacol 2003. 66: 1673-80. 
 
253 
Wang X, Zhang XJ, Tan QR, Ju G, Wang BR.  Different signaling molecules 
responsible for IL-1beta-induced oxytocinergic and vasopressinergic 
neuron activation in the hypothalamic paraventricular nucleus of the rat. 
Neurochem Int 2006. 48: 312-7. 
Whalen AM, Galasinski SC, Shapiro PS, Nahreini TS, Ahn NG. Megakaryocytic 
differentiation induced by constitutive activation of mitogen-activated 
protein kinase kinase. Mol Cell Biol 1997. 17: 1947-58. 
Whalen EJ, Rajagopal S, Lefkowitz RJ.  Therapeutic potential of β-arrestin- and G 
protein-biased agonists.  Trends Mol Med 2011. 17: 126-39. 
Whitaker-Azmitia PM.  Serotonin and brain development: role in human 
developmental diseases.  Brain Res Bull 2001. 56: 479-85. 
Whitaker-Azmitia PM, Clarke C, Azmitia EC. Localization of 5-HT1A receptors to 
astroglial cells in adult rats: implications for neuronal-glial interactions 
and psychoactive drug mechanism of action. Synapse 1993. 14: 201-5. 
Williamson M, Bingham B, Gray M, Innala L, Viau V.  The medial preoptic 
nucleus integrates the central influences of testosterone on the 
paraventricular nucleus of the hypothalamus and its extended circuitries. 
J Neurosci 2010. 30: 11762-70. 
 
Wong IC, Besag FM, Santosh PJ, Murray ML. Use of selective serotonin reuptake 
inhibitors in children and adolescents. Drug Saf 2004. 27:991-1000. 
Woodgett JR. Molecular cloning and expression of glycogen synthase kinase-
3/factor A. EMBO J 1990. 9: 2431-8. 
Yang CQ, Kitamura N, Nishino N, Shirakawa O, Nakai H.  Isotype-specific G 
protein abnormalities in the left superior temporal cortex and limbic 
structures of patients with chronic schizophrenia.  Biol Psychiatry 1998. 43: 
12-9. 
 
Yano S, Tokumitsu H, Soderling TR.  Calcium promotes cell survival through 
CaM-K kinase activation of the protein-kinase-B pathway.  Nature 1998.  
396: 584-7. 
 
Yoshida M, Takayanagi Y, Inoue K, Kimura T, Young LJ, Onaka T, Nishimori K.  
Evidence that oxytocin exerts anxiolytic effects via oxytocin receptor 
expressed in serotonergic neurons in mice.  J Neurosci 2009. 29: 2259-71. 
254 
Young EA, Altemus M, Lopez JF, Kocsis JH, Schatzberg AF, DeBattista C, 
Zubieta JK.  HPA axis activation in major depression and response to 
fluoxetine: a pilot study. Psychoneuroendocrinology 2004. 29: 1198-204. 
Yu H, Lewander T. Pharmacokinetic and pharmacodynamic studies of (R)-8-
hydroxy-2-(di-n-propylamino)tetralin in the rat. Eur Neuropsychopharmacol 
1997. 7: 165-72. 
Yuan P, Zhou R, Wang Y, Li X, Li J, Chen G, Guitart X, Manji HK.  Altered levels 
of extracellular signal-regulated kinase signaling proteins in postmortem 
frontal cortex of individuals with mood disorders and schizophrenia.  J 
Affect Disord 2010. 124: 164-169. 
Zhang F, Phiel CJ, Spece L, Gurvich N, Klein PS. Inhibitory phosphorylation of 
glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for 
autoregulation of GSK-3. J Biol Chem 2003. 278: 33067-77. 
Zhang L, Rasenick MM. Chronic treatment with escitalopram but not R-
citalopram translocates Galpha(s) from lipid raft domains and potentiates 
adenylyl cyclase: a 5-hydroxytryptamine transporter-independent action 
of this antidepressant compound. J Pharmacol Exp Ther 2010. 332: 977-84.  
Zhang Y, Gray TS, D'Souza DN, Carrasco GA, Damjanoska KJ, Dudas B, Garcia 
F, Zainelli GM, Sullivan Hanley NR, Battaglia G, Muma NA, Van de Kar 
LD. Desensitization of 5-HT1A receptors by 5-HT2A receptors in 
neuroendocrine neurons in vivo. J Pharmacol Exp Ther 2004. 310: 59-66. 
 
 255 
VITA 
Maureen Lynn Petrunich Rutherford was born April 14, 1983, in Hammond, 
Indiana and is the daughter of Michael Petrunich and Mary Kay Ader and 
stepfather Patrick Ader.  In 2001, she graduated as valedictorian from George 
Rogers Clark High School.  She then attended Indiana University Northwest in 
Gary, Indiana, where she earned Bachelor of Science degrees in Chemistry and 
Psychology in May 2005. During the course of her undergraduate studies, she 
carried out research projects in both chemistry and psychology under the 
guidance of Drs. Attila Tuncay and Mark Hoyert, respectively. Maureen’s 
interest in the neurochemical and biological basis of psychological disorders and 
the treatment of these disorders led her to pursue a graduate degree in the 
Neurosciences.     
Maureen entered the Neuroscience Graduate Program at Loyola University 
Chicago in August of 2005.  She joined the laboratory of Dr. George Battaglia in 
2006, where she began her work on serotonin 1A receptor signaling in the 
peripubertal hypothalamic paraventricular nucleus.  During her time at Loyola, 
Maureen has presented her research at the Society for Neuroscience conferences 
in San Diego and Washington DC, as well as at local Chicago Chapter meetings.  
She has served as treasurer and secretary for the LUMC Graduate Student 
256 
 
Council, and in 2009 received an Arthur J. Schmitt Predoctoral Fellowship to 
support her training.   
After completing her Ph.D., Maureen plans to pursue a career in teaching.  
One of her goals is to establish a program in Neuroscience at an undergraduate 
university in northwest Indiana that would foster research opportunities for 
undergraduate students.  Maureen married her husband Billy Rutherford in 2009.  
They currently reside in Portage, Indiana.   
 
  
